EAHP Congress Programme Book 2022

PROGRAMME BOOK #EAHP2022

• CONGRESS PROGRAMME • STUDENTS PROGRAMME • SATELLITE EVENTS

26TH CONGRESS OF THE EAHP – LEADERSHIP & STAFF

|5

GENERAL INFORMATION

|7

FOREWORD BY THE PRESIDENT

| 11

ABOUT EAHP

| 13

IMPLEMENTATION OF THE EUROPEAN STATEMENTS OF HOSPITAL PHARMACY

| 17

EAHP’S CURRENT POLICY AND ADVOCACY PRIORITIES

| 20

CALL FOR ABSTRACTS – 2023 LISBON

| 21

INFORMATION ABOUT ACPE ACCREDITATION

| 22

EAHP ACCREDITATION INITIATIVE

| 24

SCIENTIFIC PROGRAMME

| 31

PROGRAMME SCHEDULE: WEDNESDAY, 23 MARCH

| 35

PROGRAMME SCHEDULE: THURSDAY, 24 MARCH

| 38

PROGRAMME SCHEDULE: FRIDAY, 25 MARCH

| 40

POSTER AWARD NOMINEES - ORAL PRESENTATIONS

| 43

KEYNOTE PRESENTATIONS

| 45

SEMINARS

| 55

WORKSHOPS

| 79

INTERACTIVE SESSIONS

| 89

STUDENT PROGRAMME

| 93

PHARMACOTHERAPY SESSION

| 95

HAZARDOUS MEDICINAL PRODUCTS SESSION

| 97

SPEAKERS’ BIOGRAPHIES

| 99

INDUSTRY SPONSORED SATELLITES

| 157

GOOD PRACTICE INITIATIVES

| 169

EXHIBITOR STAND LISTING

| 170

EXHIBITION MAP

| 171

CONGRESS CENTRE FLOOR PLAN

| 173

General Information

INDEX

3

ORGANISING COMMITTEE

EAHP BOARD OF DIRECTORS

Chairman Dr. Nenad Miljković (Serbia) Director of Finance

President Dr. András Süle

Members Dr. András Süle (Hungary) President Prof. Dr. Thomas De Rijdt (Belgium) Chairman of the Scientific Committee Mrs. Jennie De Greef (United States) Managing Director

SCIENTIFIC COMMITTEE Chairman Prof. Dr. Thomas De Rijdt (Belgium) Members Dr. Kornelia Chrapkova (Czechia) Dr. Torsten Hoppe-Tichy (Germany) Ms. Beata Horoszko (Poland) Dr. Ulrika Gillespie (Sweden) Dr. Lene Juel Kjeldsen (Denmark) Prof. Dr. Raisa Laaksonen (Finland) Ms. Despoina Makridaki (Greece) Prof. Branislava Miljkovic (Serbia) Dr. Gunar Stemer (Austria) Dr. Inese Sviestiņa (Latvia) Dr. Juraj Sykora (Slovakia) Dr. Ana Valladolid Walsh (Spain) Dr. Francesca Venturini (Italy) Dr. Virginia Silvari (Ireland) Mr. Jonathan Underhill (United Kingdom) Mr. Armando Alcobia (Portugal) Dr. Fatma Karapinar (The Netherlands) Dr. Stefanie Deuster (Switzerland)

Immediate Past President Mr. Petr Horák Vice President Mrs. Aida Batista Director of Finance Dr. Nenad Miljković Director of Professional Development Mrs. Despoina Makridaki

General Information

26TH CONGRESS OF THE EAHP – LEADERSHIP & STAFF

Director of Professional Development Mr. Tjalling van der Schors Director of Professional Development Dr. Piera Polidori Director of Professional Development Mrs. Ana Lozano Director of Professional Development Ms. Claudia Plesan Director of Professional Development Mr. Louis Bertin Director of Professional Development Mrs. Darija Kuruc Poje

EAHP HEADQUARTERS Boulevard Brand Whitlock 87 Box 11 (4th floor) 1200 Brussels email: congress@eahp.eu website: www.eahp.eu

EAHP STAFF Management Jennie De Greef, Managing Director Policy & Advocacy Stephanie Kohl, Policy & Advocacy Officer Projects Gonzalo Marzal López, Project Specialist Events Chris Irons, Events Assistant Accounting Patricia Thonus, Senior Bookkeeper

5

The rest of your pharmacy is automated.

Why isn’t your cleanroom?

ARxIUM is enabling the digital transformation of sterile compounding in healthcare settings around the world.

Pharmacies have automated virtually all dispensing activities, from packagers to carousels to cabinets to inventory and workflow management software systems. But what about sterile compounding? That’s where accuracy and safety matter most. The RIVA automated compounding system reduces labour-intensive and risk-prone manual cleanroom processes, allowing you to focus your knowledge and expertise where it’s needed most – providing patient care.

As an integral part of the digital transformation of healthcare, ARxIUM is innovating pharmacy operations to maximize inventory and logistics efficiency, manage costs and improve the quality of patient care.

Let’s Talk.

Learn how ARxIUM can transform sterile compounding in your pharmacy.

888.537.3102 ARxIUM.com info@ARxIUM.com

CORONAVIRUS INFORMATION ENTRY REGULATIONS FOR AUSTRIA Find the latest Coronavirus information for Vienna on the following official online tour guide of the City of Vienna You can find more information for Austria on this on the website of the Austrian Federal Ministry of the Interior Travel to Austria Meeting related updates

COVID PROTOCOL FOR THE AUSTRIA CENTER VIENNA • FFP2 masks mandatory

General Information

GENERAL INFORMATION

• If a person is tested positive they will be requested to leave the venue immediately • Proof of vaccination or recovery certificate required Gel for hands can be found in the congress bags and around the congress centre.

CONGRESS SECRETARIAT AND REGISTRATION DESK* OPENING HOURS Tuesday 22 March, from 12.00 to 17.00 Wednesday 23 March, from 07.00 to 17.00 Thursday 24 March, from 08.00 to 17.00 Friday 25 March, from 08.00 to 11.00 *(individuals, groups and exhibitors’ registrations)

COFFEE BREAKS AND LUNCHES Coffee breaks and lunches will be available free of charge for all participants during the official congress days. Lunch will be served in the Exhibition Hall from 13.30 to 14.45 on Wednesday and from 13.30 to 15.00 on Thursday.

ADMISSION TO SESSIONS There will be no ticketing for sessions. The doors will be closed to the sessions on time and will re-open 10 minutes after the session begins, for latecomers. Please note that the entrance to sessions will not be permitted within the last 30 minutes of each session. Name badges will be scanned as participants exit the room at the end of each session. Badges must be scanned in order to obtain continuing education points.

No exception will be made.

Please note that badge switching/sharing during the event is strictly prohibited and will subject badges to confiscation by security. We thank you for your cooperation.

POSTER SESSIONS The deadline to deliver and hang your poster is Wednesday, 23 March from 10.15 to 17.00. Please note that there will be no access to the poster area to hang your posters before the indicated time. Please go to the poster area and check-in with the hostesses on duty to find out where and how to hang your poster.

7

General Information

The posters will be displayed in Hall X1 for the duration of the congress. Presenters are expected to be present at their poster during 2 coffee breaks (Thursday, 24 March from 10.30 to 11.00, and Friday, 25 March from 10.30 to 11.30). The presence of at least one of the poster authors is mandatory under disciplinary sanctions.

Abstract Award Nominees’ oral presentations will take place on Wednesday, 23 March from 10.30 to 12.00, in Hall G1, and the winners announced at the closing ceremony on Friday, 25 March from 11.30 to 13.00. Authors must be present during the closing ceremony to win the prize.

Good Practice Initiatives oral presentations by GPI Nominees will take place on Wednesday, 23 March from 10.30 to 12.00, in Hall G1, and the winners announced at the closing ceremony on Friday, 25 March from 11.30 to 13.00. Authors must be present during the closing ceremony to win the prize.

Posters can be removed on Friday, 25 March between 13.00 and 14.00. Posters not removed after the dismantling deadline will be removed and discarded.

EXHIBITION NOTE: Doors to the exhibition hall will have security as entry in not permitted until Wednesday, 23 March at 10.15.

Opening hours Wednesday, 23 March from 10.15 to 20.00 Thursday, 24 March from 08.00 to 17.00 Friday, 25 March from 09.00 to 12.00

CLOAKROOM The cloakroom is located at Hall X1 and will be available for use each day, free of charge.

The cloakroom hours are as follows: Wednesday, 23 March from 07.00 to 20.15 Thursday, 24 March from 06.30 to 18.15 Friday, 25 March from 08.00 to 14.00

WIFI ACCESS Free WiFi service will be available throughout the congress centre. The WiFi network name is ACV, with no password needed. Note that you will automatically be logged out after 15 min. should you remain inactive.

NEAREST PHARMACY Apotheke im Andromeda-Tomwer Address: Donau-City Strasse 6 - im Andromeda-Tower - Ebene UG-3 - 1220 Wien Email: info@apoandromeda.at

Phone: +43 (0)1 263 78 786

Website: https://www.apoandromeda.com Opening hours: 08.00 to 18.00 (Monday to Friday) and 08.00 to 12.00 (Saturday)

CONGRESS FIRST AID NUMBER +43 676 319 9561

EMERGENCY NUMBERS

8

European Emergency: 112

Ambulance service: 144

Fire brigade: 122

Police: 133

­

­

­

COMPOUNDING IN HOSPITAL PHARMACY SOLUTIONS FOR EFFICIENT PREPARATION OF DRUGS AND PARENTERAL NUTRITION

B. Braun Melsungen AG | www.bbraun.com

Dear Colleagues, It is a great pleasure and a humbling honour to invite you all to the 2022 EAHP Annual Congress, a year in which we will also celebrate our association’s 50th anniversary. While these unprecedented times have turned our world upside down, our profession has prevailed and hospital pharmacists have never ceased to proactively adapt to a changing world in order to continuously serve our patients’ best interests.

Our team at EAHP has resiliently continued to work hard for our upcoming 2022 Congress, so that the hospital pharmacist community of Europe and beyond could finally get together in person and join us in celebrating EAHP’s 50th anniversary. We are delighted to offer you an unforgettable experience along with a valuable learning and networking opportunity. On March 23rd 2022, when Spring will be already shining its heartwarming light on the Danube Valley, our congress will again open its gates for you in Vienna.

General Information

FOREWORD BY THE PRESIDENT

The capital of Austria is one of the most charming, elegant, history-rich and yet excitingly cosmopolitan cities in Europe. Embracing its historic roots, it offers everything one could expect for a modern cosy city life.

This gorgeous city of immense cultural heritage will be our host, providing an impressive background to our Anniversary Congress.

Spring, being the season of awakening, a period when nature applauds life with colourful diversity, I firmly believe that all of us will gather to celebrate the opportunity to meet up in person again and to commemorate all the losses the pandemic has made us endure. This new beginning will also bring about vast scientific novelties and practical knowledge upon which we can further develop and strengthen our services for our patients, in Europe and beyond. Therapeutic possibilities are growing rapidly in several disease groups, including those for which treatment options have been seriously limited for many decades. These emerging therapeutic modalities have brought about many challenges for hospital pharmacists and they keep changing the way pharmacy services are delivered. Hospital pharmacists have to acquire more knowledge related to immunology, infection control, the human genome, cell regulation and much more... Besides these novel therapeutic areas, our emerging competencies of frontline patient care in the clinical setting call for new and changing roles of our profession.

These “high tech” modalities, going hand-in-hand with the irreplaceable personal touch of pharmaceutical care are paving the way towards the future of our profession.

Besides the professional and methodological challenges, healthcare systems all over the world have to find a way to employ these new possibilities with the limited resources that are available. That rather complex issue calls for a deep involvement and input from hospital pharmacists as well. I am sure that the scientific programme at the Congress will help all of us to face these challenges and find valid answers.

Furthermore, your time with us in Vienna will also be an ideal opportunity to meet your fellow colleagues, exchange experiences and knowledge, and find new professional connections and friends.

50 years is a long time in the life of an association, as is in the life of a person. EAHP, during these tumultuous years, has been through thick and thin with challenges, accomplishments, losses and victories along its path. We have never ever forgotten our main mission and we never will: it is our duty to enable hospital pharmacists to make a difference in our patients’ lives with their safe medication as our top priority.

I am very much looking forward to meeting you in Vienna!

Dr. András Süle EAHP President

11

Your partner for patient safety and efficiency in your hospital Baxter’s broad range of products help to:

Enhance clinical outcomes

Improve workflow efficiency

Increase staff and patient safety

Reduce medication errors

We offer a broad portfolio of products and services to increase efficiency in daily medication delivery routines and help improve safety in patient care.

Come and visit Baxter at stand number 44 EMA-00-220001 v0.3 January 2022 Baxter is a trademark of Baxter International Inc.

Baxter Healthcare SA 8010 Zurich, Switzerland

The European Association of Hospital Pharmacists represents more than 23.000 hospital pharmacists in 35 European countries and is the only association of national organisations representing hospital pharmacists at European and international levels.

HOW HAS THE EAHP DEVELOPED? At a scientific congress in Strasbourg a number of hospital pharmacists from different European countries decided that they should establish a new European association to represent their common interests. Thus in 1969, the seeds of EAHP were sown. On 6 March 1972, the representatives of six European countries signed the first Statutes of the European Association of Hospital Pharmacists, in The Hague, The Netherlands. The first President of EAHP was Marcel Lebas from France.

General Information

ABOUT EAHP

The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands. In 1973, Ireland and Spain joined EAHP, soon followed by Norway, Greece, Austria, Sweden and Switzerland. In the 1990s, Italy, Portugal, Hungary, Luxembourg, Finland, Slovakia, Slovenia, Croatia and the Czech Republic became members. Estonia, Latvia, Lithuania, Poland, Serbia, Turkey, North Macedonia, Bulgaria and Bosnia Herzegovina followed.

More recently, Iceland, Malta, Romania and Montenegro became members of EAHP. Membership within EAHP is open to countries members of the Council of Europe.

On the 1st of August 2011, the EAHP officially became an International Not-for-Profit Organization, and adjusted its policy to better face modern challenges.

EAHP MISSION EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.

WHAT ARE THE GOALS OF THE EAHP? • In the interest of patients and public health, to promote and further develop hospital pharmacy and to obtain and maintain general joint pharmaceutical principles and a joint pharmaceutical policy; • to foster research and education activities on behalf of hospital pharmacy, in order to allow hospital pharmacists in all countries which are members of the Council of Europe from time to time (hereinafter “Countries • in the European Region”) to contribute optimally to public health and furthermore anything directly or indirectly related or beneficial thereto, all in the broadest sense of the word;

13

General Information

• to promote co-operation with other organisations in the domain of public health; • to promote the position and function of hospital pharmacists; • to support and uphold the interests of hospital pharmacists at the European Union authorities; to support and uphold the interests of hospital pharmacists at the Council of Europe authorities; • to support and undergo everything related to the above that may be conducive to carrying out the Association’s purpose.

EAHP SCIENTIFIC COMMITTEE – EDUCATIONAL MISSION The European Association of Hospital Pharmacists is committed to providing educational innovation and training of hospital pharmacists to a level of specialisation and maintain continuing professional development (CPD). We will facilitate and enhance the professional growth of European hospital pharmacists and develop hospital pharmacy in order to promote the best and safest use of medicines and medical devices for the benefit of patients in Europe.

EAHP SCIENTIFIC COMMITTEE – EDUCATIONAL GOALS • To identify the educational needs of EAHP members and prepare educational programmes to meet those needs; • to provide knowledge and application based educational programmes to assist pharmacists who practice in hospitals meet their patient care responsibilities and expand their professional roles and goals; • to share best practice, innovation and educational programmes that can be applied to daily practice; • to promote hospital pharmacy practice research. *EAHP defines Continuing Pharmacy Education (CPE) as per the ACPE definition which states that “Continuing education for the profession of pharmacy is a structured educational activity designed or intended to support the continuing development of pharmacists and/or pharmacy technicians to maintain and enhance their competence. Continuing pharmacy education (CPE) should promote problem-solving and critical thinking and be applicable to the practice of pharmacy.“

STRUCTURE OF THE EAHP The prime governing body is the General Assembly, which meets annually and elects the Board of the Association. The General Assembly is a delegate conference at which each member state may have up to three delegates. Every delegation has one vote regardless of size.

The Board of Directors is the Executive Body of the Association and is elected for a three-year term of office, with the possibility to be re-elected. The responsibility for the core activities of the association is shared between the different directors. The Board normally meets four times a year in addition to meetings during the Congress and the General Assembly.

14

Every year, at the General Assembly, the Director of Finances discloses all the expenses and revenues and explains them in detail. Members would have had the opportunity to study them before the General Assembly meeting as they receive the files at least 6 weeks prior the General Assembly meeting.

EAHP is funded by: • membership dues

General Information

The Board carries out the policies agreed at the General Assembly, and designs and coordinates the implementation of the strategic goals of the association, with the support of the EAHP staff.

In addition, the Board is closely involved in the control of the official journal of the Association, European Journal of Hospital Pharmacy (EJHP). The Board is also closely involved in the organisation of the annual EAHP Congress of Hospital Pharmacy, with one director chairing the congress organising committee and another chairing the scientific committee.

• revenues generated by the yearly congress • advertising revenue related to the annual congress • gifts • educational grants • subsidies and donations • all other income legally obtained.

All accounts are audited both by EAHP auditors, appointed by the General Assembly and external auditors.

Click HERE to view the EAHP Statutes.

Click HERE to view the EAHP Code of Conduct.

EAHP PARTNERS WITH CLIMATECARE EAHP join forces with climate and sustainable development experts from ClimateCare to offset the carbon emissions associated with the air travel of the Association’s Board members to and from Board meetings. Through projects which tackle global climate change.

By offsetting emissions through ClimateCare, EAHP is supporting projects that make a measurable difference to people’s lives. The LifeStraw Carbon For Water project relies on finance from offsetting to deliver safe water to 4 million people in Kenya. It was the first project to link water provision with carbon credits at scale and has been recognised by the United Nations. The Gyapa Stoves project supports local entrepreneurs to manufacture and distribute safe, efficient cookstoves to households in Ghana. Run on the ground by our partners Relief International, the Gyapa stove cuts charcoal use by up to 50%, saving families money and reducing harmful smoke emissions.

15

PharmaBOX High-performance box ensures temperature-controlled shipping

CUSTOMIZABLE AND SAFE!

Safe storage and temperature-controlled shipping throughout the medical and pharmaceutical supply chain is vital to the success of treatments.

This is why great care must be taken when it comes to replenishing the stocks of hospitals, physicians and pharmacies with healthcare and pharmaceutical products.

www.bito.com

WHAT ARE THE EUROPEAN STATEMENTS OF HOSPITAL PHARMACY? The European Statements of Hospital Pharmacy were formulated following an 18-month review process, which included two rounds of online Delphi consultations with EAHP’s member associations and an equal number of patient and other healthcare professional organisations.

Final agreement on the wording of the statements was reached at a European Summit on Hospital Pharmacy, held in Brussels in May 2014. Only those Statements where there was a high level of agreement between patient groups, doctors, nurses, and pharma- cists were accepted.

The primary purpose of the statements is to provide safer and more effective care where medicines are used in European hospitals. The Statements can also be used as a guide for safer and more effective use of medical devices as well, with the responsibility for medical devices being with Hospital Pharmacies in several of our member countries. The European Statements reflect the importance of the hospital pharmacist as a key stakeholder within the hospital teams for providing optimal and safe patient care. Therefore, the European Statements reflect what we believe every European health system should be aiming for when delivering hospital pharmacy services.

EAHP’s Policy and Advocacy

IMPLEMENTATION OF THE EUROPEAN STATEMENT OF HOSPITAL PHARMACY

The Statements are divided into 6 different sections: • Section 1 Introductory Statements and Governance • Section 2 Selection, Procurement and Distribution • Section 3 Production and Compounding • Section 4 Clinical Pharmacy Services • Section 5 Patient Safety and Quality Assurance • Section 6 Education and Research

ADOPTION OF A COMMENTED VERSION OF THE STATEMENTS In 2020, a review was conducted to assess the continued relevance of the Statements and that they effectively covered emerging issues. It was found that the document has remained remarkably resilient and a decision was made that the wording of the statements would not be changed, thereby staying true to the scientific principles used to develop and finalise them. What was agreed though, is that a small number of Statements would benefit from the addition of comments to further clarify their meaning.

The final version of the commented version of the Statements was approved by the EAHP General Assembly. The below are the Statements where comments were added: S 1.6 “Hospital pharmacists should take the lead in coordinating the activities of multidisciplinary, organisation-wide Drug & Therapeutics Committees or equivalent. They should have appropriate representation as full members of these Committees which should oversee and improve all medicines management policies”

17

EAHP’s Policy and Advocacy

COMMENT – Hospital management, taking account of national guidelines, determines what structures are in place to assure the efficacy, safety and cost-effective use of medicines.

S 2.2 “Hospital pharmacists should take the lead in developing, monitoring, reviewing and improving medicine use processes and the use of medicine related technologies. Responsibility for using these processes may rest with other health care professionals and may vary according to the medicine, the medicine related technology, the health care setting and the multidisciplinary team delivering care”.

COMMENT – Hospital pharmacists have a key role, working with others, in ensuring continuous quality improvement for medicines use processes, including where information technology is utilised S 3.5 “Hazardous medicines should be prepared under appropriate conditions to minimise the risk of contaminating the product and exposing hospital personnel, patients and the environment to harm” COMMENT – To achieve this there will need to be a multidisciplinary risk assessment of the hazardous medicines to determine where and how it is best pre- pared.

S 3.6 “ When the reconstitution or mixing of medicines takes place in a patient care area, a hospital pharmacist should approve written procedures that ensure staff involved in these procedures are appropriately trained” COMMENT – Among healthcare professionals the hospital pharmacist is in the best position, because of their expertise in formulation, to advise on reconstitution or mixing of medicines. It is critical that any healthcare professional undertaking these tasks is competent.

S 5.1 “ The “seven rights” (the right patient, right medicine, right dose, right route, right time, right information and right documentation) should be fulfilled in all medicines related activities in the hospital.

COMMENT – This is not an exhaustive list of ‘rights’ and with the increase in use of personalised medicines the ‘right patient’ has an additional meaning beyond just identification of the individual, it is also now whether the medicine is genetically appropriate for that individual patient

EAHP SELF-ASSESSMENT TOOL The EAHP Self-assessment tool allows hospital pharmacists to assess the level of implementation of the European Statements within their hospitals while providing tailored actions plans. EAHP is kindly asking all hospital pharmacies in Europe to assess their hospitals with the self-assessment tool to help us better understand gaps on implementation within Europe.

You can access the tool here: https://sat.eahp.eu/en/home

18

The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the “Oath to Society” that acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day. The Oath to Society is the promise that the members of EAHP and ESCP make to patients and the public they serve, the healthcare professionals they interact with and the health systems they work in. The Oath functions as a compass for pharmacists to adhere to the highest standards of ethics, integrity and professionalism, as they provide service to the community over the course of their careers. Touching on trust and respect, different aspects of the patient care pathway, the multidisciplinary care team, disease prevention and health promotion, education and the future development of pharmacy practice, the Oath to Society is all-encompassing.

The Oaths to Society can be found here: https://www.eahp.eu/hp-practice/oathtosociety

EAHP-ESCP

EAHP’s Policy and Advocacy

OATHS TO SOCIETY

Oath to Society

Photo: Dutch Association of Hospital Pharmacists (NVZA)

As a pharmacist, I vow to ser

ve by

with respect treating all equally, fairly and protecting all personal al standards, respecting and working to the highest of ethic me to d uste entr and health information of the multidisciplinary care skills and experience, as part • applying my knowledge, eve optimal person-centred achi and nt, tme trea ible team, to ensure the best poss

• •

• • • • • • • •

care adoption of healthy n of disease, promoting the contributing to early detectio tives initia th public heal behaviours and engaging in multi-disciplinary care givers and members of the educating patients, their care adverse effects and g agin man use, re optimal team about medication to ensu responding to questions in continuous dards of care and engaging following evidence-based stan learning long lifeand ent lopm professional deve d harm and overseeing , preventing medication-relate ness and ensuring continuity of care mise their safety, effective opti to s esse proc use on and improving medicati cost-effectiveness to individual needs onalised medication tailored providing compounded pers research and education in tice, prac of s dard stan of supporting the advancement pharmacy macy workforce and training of the future phar contributing to the education th care heal ngst amo tice prac y the pharmac promoting the interests of

19

EAHP’s Policy and Advocacy 20

implementation of the

european statements of hospital pharmacy

EAHP POLICY PRIORITIES

CONTINOUS EDUCATION

COMMON TRAINING FRAMEWORK

Fostering the continuous education of hospital pharmacists and the advancement of the profession

Creating a Common Training Framework and enabling the implementation of a common competency framework for hospital pharmacy in Europe

ACTIONS AGAINST MEDICINES SHORTAGES

COMBATTING INFECTIONS

Securing EU level action on the pan European health threat of medicines shortages

Leveraging the role of the hospital pharmacist in combatting infections and participating in vaccination programmes

EQUAL ACCESS FOR PATIENTS

ENSURING SAFE THERAPIES

Providing equal access for all patients to medicines

Ensuring safe and appropriate use of medicinal therapies

General Information

CALL FOR ABSTRACTS – 2023 LISBON

ABSTRACT SUBMISSION OPENS 1ST AUGUST 2022!

Original contributions from all fields of hospital pharmacy are encouraged and welcomed for poster presentation.

DEADLINE FOR SUBMISSION: 9TH OCTOBER 2022 During the review process, the award nominees will be selected, and the presenting author of the nominated abstracts will be invited to give an oral presentation after which the final judging will take place.

Please be sure to provide an email address which will not be blocked by spam servers so that EAHP may notify you for modifications and nominations.

(Abstracts may be submitted through the EAHP website’s online submission page.)

IMPORTANT NOTE: The online submission form does not recognise some symbols from certain keyboards. Therefore, please proof your abstract after it has been entered into the system and before your final submission.

Please visit the EAHP website at http://www.eahp.eu/congresses/abstract to view the guidelines and to submit abstracts for the Lisbon Congress 2023.

Abstracts must be entered into the system by section according to the guidelines.

There will be 5 sections: Background – Purpose – Material and methods – Results – Conclusion All abstracts must be linked to the European Statements on Hospital Pharmacy: Section 1: Introductory Statements and Governance Section 2: Selection, Procurement and Distribution Section 3: Production and Compounding Section 4: Clinical Pharmacy Services Section 5: Patient Safety and Quality Assurance Section 6: Education and Research

21

General Information

INFORMATION ABOUT ACPE ACCREDITATION The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE is the American agency for accreditation of professional degree programmes in pharmacy and providers of continuing pharmacy education, including certificate programmes in pharmacy. Accreditation is the public recognition granted to a professional degree programme in pharmacy or a provider of continuing pharmacy education, including certificate programmes in pharmacy that is judged to meet standards through periodic evaluations.

Note that only seminars and keynote presentations are accredited. Click on the ACPE logo to visit the website of the Accreditation Council for Pharmacy Education.

How can participants receive their ACPE certificates?

In order to receive your ACPE accreditation points, what you have learnt during this session will be assessed. At the beginning of their presentations, each presenter will ask 3 questions that will be answered in the content of their presentations. After the congress, you will receive an evaluation with the same questions, and this is when you will need to answer these questions in order to receive your accreditation certificates.

Please note that the ACPE certificate will not be sent automatically, but upon request only. EAHP will send you the certificate within 15 days after receiving your request.

More information on how to access the evaluation forms will be sent soon.

For licensed pharmacists and pharmacy technicians for the USA ACPE and the National Association of Boards of Pharmacy (NABP) are developing a continuing pharmacy education (CPE) tracking service, CPE Monitor, that will authenticate and store data for completed CPE units received by US-licensed pharmacists and pharmacy technicians from ACPE-accredited providers as the EAHP. This service will be particularly helpful to the growing number of pharmacists who are licensed in multiple states, and thus may need to meet the varied CPE requirements of different state boards of pharmacy. The CPE tracking system will create a direct link for sending CPE data from the EAHP to ACPE and then to NABP, ensuring that all reported CPE units are officially verified by the EAHP. To view and track these credits, you must first set up an NABP e-Profile (www.nabp.net), obtain your NABP e-Profile ID, and register for CPE Monitor.

So, for each licensed pharmacist from the United States of America who attends the congress, their NABP e-Profile ID and date of birth are requested to be sent out to congress@eahp.eu, in order to notify NABP and ACPE of the number of CPE units collected by each US participant during the congress on 2022. After CPE units are processed by ACPE and NABP, you will be able to access information about your completed CPE through your NABP e-profile (www.nabp.net).

AFTER THE CONGRESS YOU WILL RECEIVE AN EVALUATION FORM. PLEASE FILL IN THE EVALUATION FORMS OF THE SESSIONS YOU ATTENDED IN ORDER TO RECEIVE YOUR CERTIFICATE OF ATTENDANCE. Please note that the ACPE certificate will not be sent automatically, but upon request only. EAHP will send you the certificate within 15 days after receiving your request.

22

AUTOMATIC COMPOUNDING SYSTEM

A BATCH APPROACH FOR PATIENT SPECIFIC ONCOLOGY DRUGS High performance • Up to 35 preparations/h • Liquid and powder drugs managed

COMECER S.p.A. Via Maestri del Lavoro, 90 48014 - Castel Bolognese (RA) - Italy t: +39 0546 656375 - f: +39 0546 656353 marketing@comecer.com - www.comecer.com

Total flexibility • More than 300 drugs managed • Ready doses in all possible final containers

Comecer

booth #19

Significant savings • Zero drug residuals • Cost reduction

General Information

EAHP ACCREDITATION INITIATIVE The annual EAHP congress is recognised as a valid continuing pharmacy education by the below national association of hospital pharmacists.

ACCREDITATION FOR AUSTRIAN PARTICIPANTS The Weiterbildungskommission Krankenhausfachapotheker of the Austrian Chamber of Pharmacy, on request of the Austrian Association of Hospital Pharmacists (www.aahp.at), has accredited the 26th EAHP Congress. Austrian hospital pharmacists are therefore eligible to obtain continuing education points according to the Krankenhausfachapotheker-Weiterbildungsordnung 2015. Details on how to claim these points will be available in the member section of the Austrian Chamber of Pharmacists’ website (www.apotheker.or.at). ACPE certificate from participation of congress is needed. A total of max. 18 credits can be earned.

ACCREDITATION FOR BELGIAN PARTICIPANTS The Federal Public Service HEALTH, FOOD CHAIN SAFETY AND ENVIRONMENT has accredited the 26th EAHP Congress. Belgian hospital pharmacists are therefore eligible to obtain continuing education points.

ACPE certificate from participation of congress is needed. A total of max.

2 points per day (6 in total) in section can be earned.

ACCREDITATION FOR ESTONIAN PARTICIPANTS The 26th EAHP Congress is accredited by the Estonian Society of Hospital Pharmacists. Participants have to be present at forthcoming EAHP congress and submit copy of their certificate of participation to ESHP which includes name and all seminars/workshops attended.

1 accreditation point will be given for every 45 minutes of educational event participated. www.ehas.ee

ACCREDITATION FOR GERMAN PARTICIPANTS The German Society of Hospital Pharmacists (ADKA) acknowledges the high level and quality of scientific education provided by the EAHP annual congress. Therefore the EAHP annual congress is accredited by the German accreditation system of Zertifizierte Fortbildung Klinische Pharmazie der ADKA. ZeFoBi (ADKA) will accept the congress as a continuing education event and will give points on the basis of the ZeFoBi rules. https://www.adka.de

24

The 26th EAHP Congress has been accredited by the Norwegian Association of Pharmacists for continuing education points. In order to collect their accreditation points Norwegian participants must register their attendance directly on the website www.farmaceutene.no

ACCREDITATION FOR PORTUGUESE PARTICIPANTS To obtain continuing education points, please submit to Ordem dos Farmacêuticos the EAHP programme which is downloadable via the EAHP website along with your certificate of participation which is included with the name badges upon registration at the congress centre.

ACCREDITATION FOR SERBIAN PARTICIPANTS

General Information

ACCREDITATION FOR NORWEGIAN PARTICIPANTS

The 26th Congress is recognized as a valid form of continuing education (International Congress) by the Pharmaceutical Chamber of Serbia.

The following amount of credits will be awarded, in accordance with current regulations: invited lecturer – 15 points; oral presentation - 13 points; poster presentation - 11 points for the first author and 0.5 points for other co-authors; passive participation - 10 points.

ACCREDITATION FOR SLOVAK PARTICIPANTS The EAHP Annual Congresses have been accredited by Slovak Chamber of Pharmacists (SLeK) as a continuing education for pharmacists. The Section of Hospital Pharmacists of Slovak Chamber of Pharmacists acknowledges the high quality of scientific education provided by the EAHP annual congress. Participation will be evaluated according to the SLeK methodology depending on the number of hours spent on specific presentations and seminars within the congress. ACPE certificate of participation in congress is needed.

ACCREDITATION FOR SLOVENIAN PARTICIPANTS The Section of Slovenian Hospital Pharmacists at Slovenian Pharmaceutical Society acknowledges the high quality of scientific education provided by the EAHP annual congress.In order to collect accreditation points, Slovenian participants must fill in the form required by the Slovene Chamber of Pharmacy and pay the mandatory fee. A certificate of attendance and the program of the EAHP Congress must be submitted. Each individual professional development (such as the EAHP Congress) can be assessed with a maximum of 20 points.

ACCREDITATION FOR SWISS PARTICIPANTS The EAHP Congresses are accredited by the GSASA (Swiss Association of Public Health Administration and Hospital Pharmacists). Hospital Pharmacist Switzerland 50 FPH credit points per day and Clinical Pharmacist Switzerland 50 FPH credit points per day.

25

2022 EAHP Congress

ACPE Policy and Procedure 4.0 Monitoring Activity Announcements Checklist

Activity Announcements Required Items

CPE Activity A

A. Objectives: verbs must elicit or describe observable or measurable behaviours on the part of participants. (Avoid “understand”, “learn”, etc.)*

x

B. Type of activity, i.e. knowledge, application, practice*

x

C. Target audience(s) that may best benefit from participation in the activity

x

D. Faculty member(s) name, degree, and title/position*

x

E. Fees for the activity

x

F. Schedule of the educational activities

x

G. The amount of CPE credit, specified in contact hours or CEUs

x

H. The official ACPE logo, used in conjunction with the statements identifying the accredited provider sponsoring the activity:

x

General Information

INFORMATION ABOUT ACPE ACCREDITATION

• “The [name of accredited provider] is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

• (Optional: listing the ACPE – accredited or non-accredited co-sponsor – if applicable) I. The ACPE Universal Activity Number assigned to the activity

x

J. The appropriate target audience designation (‘P’ and/or ‘T’) in the activity UAN

x

K. A full description of all requirements established by the provider for successful completion of the CPE activity and subsequent awarding of credit.

x

• (e.g., passing a post-test at specified proficiency level, completing an activity evaluation form, participating in all sessions or certain combinations of sessions that have been designed as a track, etc.).

L. Acknowledgements of any organization(s) providing financial support for any component of the educational activity M. For home study activities: the initial release date and the expiration date

x N/A

27

General Information

INFORMATION ABOUT ACPE ACCREDITATION ADF Search Results

Accreditation Council for Pharmacy Education 135 S. LaSalle Street, Suite 4100 Chicago, IL 60603-4810 Phone (312) 664-3575 Fax (312) 664-7008 http://www.acpe-accredit.org Activity Title

Cosponsor

Release Date

Expiration Date

Hours (CEUs)

Status

Activity Type

0475-0000-22-001-L04-P

UAN

What are we paying for? - From productivity to value-based healthcare

No Joint Providership

03/23/2022

03/23/2025

0.75 (0.075)

Submitted

Knowledge

0475-0000-22-002-L04-P

What people want from their medicines Making shared decisions

No Joint Providership

03/24/2022

03/24/2025

0.75 (0.075)

Submitted

Knowledge

0475-0000-22-003-L04-P

The era of cell and gene therapies in oncology - Fiction, poetry, or science?

No Joint Providership

03/25/2022

03/25/2025

0.75 (0.075)

Submitted

Knowledge

0475-0000-22-004-L04-P

Better together! - Hospital pharmacists go collaborative

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-005-L04-P

How to survive with limited resources without letting the patients down

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-006-L04-P

The role of the hospital pharmacist in disaster management - Are we prepared?

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-007-L04-P

Gases, devices, diagnostics - Managing more than tablets

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-008-L04-P

The waste-reducing hospital pharmacy Let's get started!

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-009-L04-P

Opportunities and threats for hospital No Joint Providership pharmacy production in gene and cell therapy scenarios

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-010-L05-P

Side effects resulting in prescribing cascades

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-011-L04-P

The COVID-19 pandemic - Lessons learnt at the hospital pharmacy

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-012-L05-P

Medication with safety

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-013-L04-P

Teamwork in the hospital - Building relationships to optimise pharmacotherapy

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-014-L04-P

Hospital pharmacy practice research: why No Joint Providership and how to be more engaged and publish?

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-015-L04-P

How to work smarter not harder

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-016-L04-P

Work it out - Your idea to save health systems

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-017-L07-P

No Joint Providership 03/23/2022 03/23/2025 135 S. LaSalle Street, Suite 4100 Chicago, IL 60603-4810

Compounding for Paediatrics - A Survival No Joint Providership 03/23/2022 03/23/2025 Phone (312) 664-3575 Fax (312) 664-7008 http://www.acpe-accredit.org Guide through GMP

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-018-L01-P UAN

Pharmacotherapy session: Advances in heart failure Activity Titlepharmacotherapy

No Joint Providership Cosponsor

03/23/2022 Release Date

03/23/2025 Expiration Date

1.5 (0.15) Hours (CEUs)

Submitted Status

Knowledge Activity Type

0475-0000-22-019-L04-P

Contemporary ethical challenges in hospital pharmacy practice

No Joint Providership

03/23/2022

03/23/2025

2 (0.2)

Submitted

Application

Hazardous Medicinal Products: the European classification landscape

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Page 1 of 2 Knowledge

0475-0000-22-021-L04-P

Smooth operator - How to manage difficult situations

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Application

0475-0000-22-022-L04-P

Recognising the prescribing cascade

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Application

0475-0000-22-023-L04-P

Towards a more patient centered approach No Joint Providership to medication review

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Application

0475-0000-22-024-L04-P

Hospital pharmacist: learn to think global and act local

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Application

0475-0000-22-025-L04-P

From data to decision - Improve the use of EBM in clinical practice

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Application

0475-0000-22-026-L04-P

3D printed medical devices - The ultimate customization

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

0475-0000-22-027-L04-P

Bacteriophages - Back to the future

No Joint Providership

03/23/2022

03/23/2025

1.5 (0.15)

Submitted

Knowledge

Run Date: 02/14/2022 0475-0000-22-020-L03-P

Run Date: 02/14/2022

28

ADF Search Results No Joint Providership

Accreditation Council for Pharmacy Education

Page 2 of 2

27th EAHP CONGRESS 22-23-24 MARCH

FROM DRUG DESIGN TO TREATMENT SUCCESS WHAT REALLY MATTERS TO PATIENTS?

EAHP thanks the continued support of Silver Partner Clinigen Direct and Corporate Partner Omnicell #EAHP2023

The European Association of Hospital Pharmacists (EAHP) represents more than 23.000 hospital pharmacists in 35 European countries and is the only association of national organisations representing hospital pharmacists at European and international levels.

The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Experience the potential of Infinite Control in pharmacy automation Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.

Thanks to error-free mechatronics technology Deenova is the first company offering a fully automated closed loop solution for the management of both medications and medical devices (Implantable and Disposables), ensuring total traceability from prescription to administration to the bed side verification.

Complementary to Deenova D1 Series, the Deenova D8 Series manages hospital micrologistics and traceability of medical Supplies. In addition, Deenova D3 Series, for the automatic repackaging and dispensation of personalized therapies in unit doses, ensures simplified medications’ workflow to drive efficiency and traceability.

0% Reduction up to 0% of medications administration errors: with an estimated impact of 2.5Mn € save related to reduced patient stay1

-50% -50% Pharmacists time: supply of medications improved significantly2

15-25% Cost savings range between 15% and 25%3

1: Case Study Ospedale Papa Giovanni, Bergamo 2: OPTIMED-ID Feasibility Project: Evaluation of Impact of the System – Updated Report from Extension Period for Data Collection, S Ahlberg Pilfold, P Hourd and N Medcalf (Loughborough University) 3: 2014 JCI Quality Award – Winner Project, ASL Alessandria

DEENOVA HEADQUARTER Via Vittime della Strada, 2 29010 Gragnano Trebbiense (PC) Italy +39 0523 785311 info-it@deenova.com - www.deenova.com

1

THEME: HOSPITAL PHARMACISTS – CHANGING ROLES IN A CHANGING WORLD

KEYNOTES KEYNOTE 1 - What are we paying for? - From productivity to value-based healthcare ACPE UAN: 0475-0000-22-001-L04-P - A knowledge-based activity KEYNOTE 2 - What people want from their medicines - Making shared decisions ACPE UAN: 0475-0000-22-002-L04-P - A knowledge-based activity

Scientific Programme

SCIENTIFIC PROGRAMME

KEYNOTE 3 - The era of cell and gene therapies in oncology - Fiction, poetry or science?

ACPE UAN: 0475-0000-22-003-L04-P - A knowledge-based activity

SECTION 1: INTRODUCTORY STATEMENTS AND GOVERNANCE SEMINAR IG1 - Better together! – Hospital pharmacists go collaborative ACPE UAN: 0475-0000-22-004-L04-P - A knowledge-based activity SEMINAR IG2 - How to survive with limited resources without letting the patients down ACPE UAN: 0475-0000-22-005-L04-P - A knowledge-based activity SEMINAR IG3 - The role of the hospital pharmacist in disaster management - are we prepared?

ACPE UAN: 0475-0000-22-006-L04-P - A knowledge-based activity WORKSHOP 1 - Smooth operator - How to manage difficult situations ACPE UAN: 0475-0000-22-021-L04-P - An application-based activity

SECTION 2: SELECTION, PROCUREMENT AND DISTRIBUTION SEMINAR SPD1 - Gases, devices, diagnostics - Managing more than tablets ACPE UAN: 0475-0000-22-007-L04-P - A knowledge-based activity SEMINAR SPD2 - The waste-reducing hospital pharmacy – let’s get started!

ACPE UAN: 0475-0000-22-008-L04-P - A knowledge-based activity INTERACTIVE SESSION 1 - Work it out - Your idea to save health systems ACPE UAN: 0475-0000-22-016-L04-P - A knowledge-based activity

31

Scientific Programme

SECTION 3: PRODUCTION AND COMPOUNDING SEMINAR PC1 - Opportunities and threats for hospital pharmacy production in gene and cell therapy scenarios ACPE UAN: 0475-0000-22-009-L04-P - A knowledge-based activity SEMINAR PC2 - 3D printed medical devices – the ultimate customization ACPE UAN: 0475-0000-22-026-L04-P - A knowledge-based activity SEMINAR PC3 - Bacteriophages – Back to the future ACPE UAN: 0475-0000-22-027-L04-P - A knowledge-based activity INTERACTIVE SESSION 2 - Compounding for Paediatrics - A Survival Guide through GMP ACPE UAN: 0475-0000-22-017-L07-P - A knowledge-based activity

SECTION 4: CLINICAL PHARMACY SERVICES SEMINAR CPS1 - Side effects resulting in prescribing cascades ACPE UAN: 0475-0000-22-010-L05-P - A knowledge-based activity SEMINAR CPS2 - The COVID-19 pandemic - lessons learnt at the hospital pharmacy ACPE UAN: 0475-0000-22-011-L04-P - A knowledge-based activity WORKSHOP 2 - Recognising the prescribing cascade ACPE UAN: 0475-0000-22-022-L04-P - An application-based activity WORKSHOP 3 - Towards a more patient centered approach to medication review ACPE UAN: 0475-0000-22-023-L04-P - An application-based activity

SECTION 5: PATIENT SAFETY AND QUALITY ASSURANCE SEMINAR PSQ1 - Medication with safety ACPE UAN: 0475-0000-22-012-L05-P - A knowledge-based activity SEMINAR PSQ2 - Teamwork in the hospital – building relationships to optimise pharmacotherapy ACPE UAN: 0475-0000-22-013-L04-P - A knowledge-based activity WORKSHOP 4 - Hospital pharmacist: learn to think global and act local ACPE UAN: 0475-0000-22-024-L04-P - An application-based activity

SECTION 6: EDUCATION AND RESEARCH SEMINAR ER1 - Hospital pharmacy practice research: why and how to be more engaged and publish?

ACPE UAN: 0475-0000-22-014-L04-P - A knowledge-based activity

32

ACPE UAN: 0475-0000-22-015-L04-P - A knowledge-based activity WORKSHOP 5 - From data to decision – improve the use of EBM in clinical practice ACPE UAN: 0475-0000-22-025-L04-P - An application-based activity

OTHER SESSIONS STUDENT PROGRAMME - Contemporary ethical challenges in hospital pharmacy practice ACPE UAN: 0475-0000-22-019-L04-P - An application-based activity PHARMACOTHERAPY SESSION - Advances in heart failure pharmacotherapy ACPE UAN: 0475-0000-22-018-L01-P - A knowledge-based activity

Scientific Programme

SEMINAR ER2 - How to work smarter not harder?

Hazardous Medicinal Products: the European classification landscape ACPE UAN: 0475-0000-22-020-L03-P - A knowledge-based activity

INDUSTRY SPONSORED SATELLITES SIMPLIVIA - Novel Solutions and Advanced Technologies for Safe Handling of Hazardous Drugs in the Pharmacy OMNICELL - Future pharmacy – Transforming the patient experience EQUASHIELD - CSTD comparative studies & the future – Automated Compounding FRESENIUS KABI - A Fresh Perspective on the Role of Pharmacists in Biosimilars NOVARTIS - Close encounters between hospital pharmacists and gene therapies

AWARD NOMINEE ORAL PRESENTATIONS GOOD PRACTICE INITIATIVES ORAL PRESENTATIONS

FILL IN THE EVALUATION FORMS OF THE SESSIONS YOU ATTENDED IN ORDER TO RECEIVE YOUR ACPE ACCREDITATION CERTIFICATE AND CERTIFICATE OF ATTENDANCE. Please be reminded that you will only be able to download the certificates after the Congress. You will have 60 days from the date of the live activity to claim your ACPE accreditation points, the Certificate of attendance and your poster certificate (if applicable), through the EAHP congress portal! The personal logon code from your badge will be required to get the certificates.

33

From shelf to all-rounder Storage, preparation, work

Assemble exactly to your preferences

isomodulsystem.com/configurator

www.HHsystem.com H+H SYSTEM GmbH | Wolfgangerstrasse 32 | 5350 Strobl/Austria | Tel.: +43 6137 21793-0 | info@HHsystem.com

EAHP confirms that the Speakers and the Scientific Committee members responsible for the development of the Congress programme have signed and submitted the Conflict of Interest Disclosure forms. * Indicates speaker or SC member has stated a conflict of interest which has been reviewed and accepted. See speakers’ bios page for more information.

Tuesday, 22 March Time 12.00-17.00

Meetings/Events Registration opens (individuals, groups and exhibitors)

Room Foyer D

Scientific Programme

SCIENTIFIC PROGRAMME SCHEDULE

Wednesday, 23 March Time

Meetings/Events

Room Foyer D

07.00-17.00

Registration opens (individuals, groups and exhibitors)

08.30-10.15

Opening Ceremony & Keynote 1 – What are we paying for? From productivity to valuebased healthcare S. Simoens ACPE UAN: 0475-0000-22-001-L04-P A knowledge-based activity

Hall D

Exhibition opens

Hall X2

10.15-11.45

Coffee Break

Hall X2

10.30-12.00

Poster Award Nominees – Oral presentations

Hall G1

10.15

Section 3 – Production and Compounding 10.30 – VANCOMYCIN EYE DROPS AT 50 MG/ML: PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS Blandine Gouverneur 10.37 – INVESTIGATION OF LEACHABLE COMPOUNDS IN WATER FOR INJECTION USED IN HOSPITAL PHARMACY William Bello 10.44 – QUANTITATIVE AND QUALITATIVE EVALUATION OF MRNA VACCINES AFTER STERILE FILTRATION Rainer Trittler Section 4 – Clinical Pharmacy Services 10.51 – SELECTION OF CLINICAL RULES FOR THE SCREENING OF HIGH-RISK SITUATIONS IN PAEDIATRIC MEDICINE Christian Skalafouris 10.58 – EVALUATING PHARMACEUTICAL LOGISTICS AUTOMATED TECHNOLOGIES IN THE HOSPITAL SETTING: A HEALTH TECHNOLOGY ASSESSMENT (HTA) APPROACH Federica Asperti

35

Scientific Programme

11.05 – IMPLEMENTATION OF AN INTERPROFESSIONAL PREOPERATIVE MEDICATION MANAGEMENT PROGRAMME IN CARDIAC SURGERY: A PRE–POST QUALITY IMPROVEMENT STUDY Benedict Morath 11.12 – PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS Joan Ramon Roma Mora 11.19 – HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES

BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY Alberto Calvo García 11.26 – INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCERÚ Laura Elena Pineda Lancheros Section 5 – Patient Safety and Quality Assurance 11.33 – DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS Amir Reza Ashraf 11.40 – EERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING Alba Pau Parra 11.47 – POSITIVE IMPACT OF AN IMPLEMENTED WARD PHARMACIST IN A MULTIPROFESSIONAL CANCER CARE TEAM IN GERMANY Svenja Dierkes 10.30-12.00

Good Practice Initiatives – Oral presentations Section 1 – Introductory Statements and Governance 10.30 – WEB DIALOGUE: ONE MORE STEP IN TELEPHARMACY Beatriz Ardizone 10.40 – ASfarMA Project. HUMANIZATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH SEVERE ASTHMA Hilario Martinez Barros * Section 2 – Selection, Procurement and Distribution 10.50 – INTEGRATION OF A HOSPITAL PHARMACY PREPARER WITHIN A NEW INTERVENTIONAL TECHNICAL PLATFORM Morgane Houix Section 4 – Clinical Pharmacy Services 11.00 – CASE-STUDY: PHARMACEUTICAL TELECONSULTATION USING A MOBILE APPLICATION António Paulo Melo Gouveia Section 5 – Patient Safety and Quality Assurance 11.10 – DESIGN AND DISSEMINATION OF INFOGRAPHICS TO IMPROVE SAFETY IN DRUG HANDLING Paula Hernando Martinez 11.20 – IMPROVING MEDICATION BARCODE IDENTIFICATION ON THE SMALLEST UNIT OF USE: START-UP FIRST ePIL (ELECTRONIC LEAFLET) PROJECT FOR MEDICINES USED IN HOSPITALS IN SPAIN Ana Lopez de la Rica Section 6 – Education and Research 11.30 – IMPLEMENTATION OF A WORKSHOP ABOUT THE ROLE OF THE HOSPITAL PHARMACIST ROLE DURING THE CLINICAL CLERKSHIP IN MEDICAL TRAINING Guillaume Hache

36

Hall G2

Lunch

14.45-16.15

Seminars

14.45-16.15

Seminar IG3 – The role of the hospital pharmacist in disaster management – Are we prepared? N. Widmer & F. Buyle ACPE UAN: 0475-0000-22-006-L04-P A knowledge-based activity

Hall D

Seminar CPS1 – Side effects resulting in prescribing cascades L. McCarthy & A. Mohammad* ACPE UAN: 0475-0000-22-010-L05-P A knowledge-based activity

Hall K2

Seminar PC1 – Opportunities and threats for hospital pharmacy production in gene and cell therapy scenarios K. Green* & K. Chetouane ACPE UAN: 0475-0000-22-009-L04-P A knowledge-based activity

Hall G1

Pharmacotherapy Session – Advances in heart failure pharmacotherapy P. Forsyth* & M. Ledwidge* ACPE UAN: 0475-0000-22-018-L01-P A knowledge-based activity

Hall G2

Workshop 3 – Towards a more patient centered approach to medication review N. Barnett ACPE UAN: 0475-0000-22-023-L04-P An application-based activity

Rooms -2.32 & -2.33

Industry Sponsored Satellites – SIMPLIVIA Novel solutions and advanced technologies for safe handling of hazardous drugs in the pharmacy

14.45-16.45

Hall X2

Scientific Programme

13.30-14.45

Hall K1

Student Programme Student Programme – Contemporary ethical challenges in hospital pharmacy practice N. Miljkovic´ ACPE UAN: 0475-0000-22-019-L04-P An application-based activity

Room -2.31

16.15-17.15

Coffee Break

Hall X2

17.15-18.45

Seminars Seminar SPD2 – The waste-reducing hospital pharmacy – Let’s get started!

P. Oosterhof & C.F. Green ACPE UAN: 0475-0000-22-008-L04-P A knowledge-based activity

Hall D

Seminar ER2 – How to work smarter not harder A. Rieutord & P. Bonnabry ACPE UAN: 0475-0000-22-015-L04-P A knowledge-based activity

Hall K2

Seminar PSQ2 – Teamwork in the hospital - Building relationships to optimise pharmacotherapy K. Urbańczyk & J. Perez-Barcena ACPE UAN: 0475-0000-22-013-L04-P A knowledge-based activity

Hall G1

Seminar ER1 – Hospital pharmacy practice research: why and how to be more engaged and publish? P. P. H. Le Brun & I. Spriet ACPE UAN: 0475-0000-22-014-L04-P A knowledge-based activity

Hall G2

Workshop 1 – Smooth operator – How to manage difficult situations M. Beckmann* ACPE UAN: 0475-0000-22-021-L04-P An application-based activity

Rooms -2.32 & -2.33

37

Scientific Programme

Hazardous Medicinal Products: the European classification landscape J. Peppard & F. Schüllner ACPE UAN: 0475-0000-22-020-L03-P A knowledge-based activity 17.15-18.45

Room -2.31

Industry Sponsored Satellites – OMNICELL Future pharmacy – Transforming the patient experience

Hall K1

19.00-21.00

Get Together Reception

Hall X2

19.15-19.45

CLINIGEN presents: Love Your Pharmacist Ceremony 2022 > Exhibition stand #51

Hall X2

19.30-21.00

Poster Walk – Join the Scientific Committee during their evaluation of the abstract posters selected for the Poster Walk

Hall X1

Exhibition closes

Hall X2

20.00

Thursday, 24 March Time 08.00-17.00 08.00 09.00-10.30

09.00-10.30

10.30-11.00

38

Meetings/Events

Room

Registration opens (individuals, groups and exhibitors)

Foyer D

Exhibition opens

Hall X2

Seminars Seminar SPD2 – The waste-reducing hospital pharmacy – Let’s get started!

P. Oosterhof & C.F. Green ACPE UAN: 0475-0000-22-008-L04-P A knowledge-based activity

Hall D

Seminar PC2 – 3D printed medical devices – The ultimate customization C. Politis & J. Van den Broeck ACPE UAN: 0475-0000-22-026-L04-P A knowledge-based activity

Hall K2

Seminar PSQ2 – Teamwork in the hospital – Building relationships to optimise pharmacotherapy K. Urban´ czyk & J. Perez-Barcena ACPE UAN: 0475-0000-22-013-L04-P A knowledge-based activity

Hall G1

Pharmacotherapy Session – Advances in heart failure pharmacotherapy P. Forsyth* & M. Ledwidge* ACPE UAN: 0475-0000-22-018-L01-P A knowledge-based activity

Hall G2

Workshop 3 – Towards a more patient centered approach to medication review N. Barnett ACPE UAN: 0475-0000-22-023-L04-P An application-based activity

Rooms -2.32 & -2.33

Industry Sponsored Satellites – EQUASHIELD CSTD Comparative Studies and the Future of Automated Compounding

Hall K1

Coffee Break and attended posters. Have a cup of coffee with the authors and see the latest research from your peers!

Hall X1

Keynote 2 – What people want from their medicines – Making shared decisions S. Finnikin & S. Barnett-Cormack ACPE UAN: 0475-0000-22-002-L04-P A knowledge-based activity

12.00-13.30

Seminars

12.00-13.30

Hall D

Seminar IG1 – Better together! – Hospital pharmacists go collaborative G. Søndergård Nielsen & E. Fernández de Gamarra Martínez ACPE UAN: 0475-0000-22-004-L04-P A knowledge-based activity

Hall D

Seminar SPD1 – Gases, devices, diagnostics – Managing more than tablets N. Vink-van Kimmenade & K. Verbeke ACPE UAN: 475-0000-22-007-L04-P A knowledge-based activity

Hall K2

Seminar CPS2 – The COVID-19 pandemic – Lessons learned at the hospital pharmacy C. Dinsen-Andersen, J. Hanne Poulsen & L. De Waele ACPE UAN: 0475-0000-22-011-L04-P A knowledge-based activity

Hall G1

Interactive Session 2 – Compounding for paediatrics – A survival guide through GMP C. Tuleu* & F. Cosme ACPE UAN: 0475-0000-22-017-L07-P A knowledge-based activity

Hall G2

Workshop 2 – Recognising the prescribing cascade S. Byrne & K. Dalton ACPE UAN: 0475-0000-22-022-L04-P An application-based activity

Rooms -2.32 & -2.33

Industry Sponsored Satellites – FRESENIUS KABI A fresh perspective on the role of pharmacists in biosimilars

Hall K1

13.30-15.00

Lunch

Hall X2

15.00-16.30

Seminars

15.00-16.30

16.30-17.00 17.00

Scientific Programme

11.00-11.45

Seminar IG3 – The role of the hospital pharmacist in disaster management – Are we prepared? N. Widmer & F. Buyle ACPE UAN: 0475-0000-22-006-L04-P A knowledge-based activity

Hall D

Seminar ER2 – How to work smarter not harder A. Rieutord & P. Bonnabry ACPE UAN: 0475-0000-22-015-L04-P A knowledge-based activity

Hall K2

Seminar PC3 – Bacteriophages – Back to the future J.P. Pirnay & S.J.T. Vermeulen ACPE UAN: 0475-0000-22-027-L04-P A knowledge-based activity

Hall G1

Seminar PSQ1 – Medication with safety C. Lindén-Lahti & S. Kuitunen ACPE UAN: 0475-0000-22-012-L05-P A knowledge-based activity

Hall G2

Workshop 4 – Hospital pharmacist: learn to think global and act local C. Kirke ACPE UAN: 0475-0000-22-024-L04-P An application-based activity

Rooms -2.32 & -2.33

Industry Sponsored Satellites – NOVARTIS Close encounters between hospital pharmacists and gene therapies

Hall K1

Coffee Break

Hall X2

Exhibition closes

Hall X2

39

Scientific Programme

Friday, 25 March Time 08.00-11.00 09.00 09.00-10.30

Meetings/Events

Room

Registration opens (individuals, groups and exhibitors)

Foyer D

Exhibition opens

Hall X2

Seminars Seminar IG2 – How to survive with limited resources without letting the patients down A. Melo Gouveia & D. Mozgis ACPE UAN: 0475-0000-22-005-L04-P A knowledge-based activity

Hall D

Seminar PC2 – 3D printed medical devices – The ultimate customization C. Politis & J. Van den Broeck ACPE UAN: 0475-0000-22-026-L04-P A knowledge-based activity

Hall K2

Seminar PSQ1 – Medication with safety C. Lindén-Lahti & S. Kuitunen ACPE UAN: 0475-0000-22-012-L05-P A knowledge-based activity

Hall G2

Interactive Session 1 – Work it out – Your idea to save health systems R. Frontini & T. Hoppe-Tichy ACPE UAN: 0475-0000-22-016-L04-P A knowledge-based activity

Hall K1

Interactive Session 2 – Compounding for paediatrics – A survival guide through GMP C. Tuleu* & F. Cosme ACPE UAN: 0475-0000-22-017-L07-P A knowledge-based activity

Hall G1

Workshop 5 – From data to decision – Improve the use of EBM in clinical practice M. Balgård & F. Nagele ACPE UAN: 0475-0000-22-025-L04-P An application-based activity

Rooms -2.32 & -2.33

10.30-11.30

Coffee Break and attended posters. Have a cup of coffee with the authors and see the latest research from your peers!

Hall X1

11.30-13.00

Closing Ceremony & Keynote 3 – The era of cell and gene therapies in oncology – Fiction, poetry or science?

G. Ungerechts & T. Schöning ACPE UAN: 0475-0000-22-003-L04-P A knowledge-based activity

Hall D

Exhibition closes

Hall X2

12.00

The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

More information: https://www.eahp.eu/congresses/acpe

40

Connect Smarter.

Care Safer. ™

From preparation to administration, ICU Medical gives you access to innovative products designed to help safely, accurately, and efficiently deliver IV medications

Visit us at EAHP to learn how we can help enhance your IV medication safety

March 23–25 Stand 29

© 2022 ICU Medical Inc.

|

P22-5361

800.824.7890 | www.icumed.com

Better health.

Within reach.

Every day.

Hikma Pharma GmbH Lochhamer Str. 13 82152 Martinsried Germany www.hikma.com www.hikma.de Booth Nr. 60

ORAL PRESENTATIONS WEDNESDAY, 23 MARCH 2022 – FROM 10.30 TO 12.00, HALL G1 Section 3 - Production and Compounding 10.30 - VANCOMYCIN EYE DROPS AT 50 MG/ML: PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS Blandine Gouverneur 10.37 - INVESTIGATION OF LEACHABLE COMPOUNDS IN WATER FOR INJECTION USED IN HOSPITAL PHARMACY William Bello 10.44 - QUANTITATIVE AND QUALITATIVE EVALUATION OF MRNA VACCINES AFTER STERILE FILTRATION Rainer Trittler

Scientific Programme

POSTER AWARD NOMINEES

Section 4 - Clinical Pharmacy Services 10.51 - SELECTION OF CLINICAL RULES FOR THE SCREENING OF HIGH-RISK SITUATIONS IN PAEDIATRIC MEDICINE Christian Skalafouris 10.58 - EVALUATING PHARMACEUTICAL LOGISTICS AUTOMATED TECHNOLOGIES IN THE HOSPITAL SETTING: A HEALTH TECHNOLOGY ASSESSMENT (HTA) APPROACH Federica Asperti 11.05 - IMPLEMENTATION OF AN INTERPROFESSIONAL PREOPERATIVE MEDICATION MANAGEMENT PROGRAMME IN CARDIAC SURGERY: A PRE–POST QUALITY IMPROVEMENT STUDY Benedict Morath 11.12 - PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS Joan Ramon Roma Mora 11.19 - HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY Alberto Calvo García 11.26 - INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER Laura Elena Pineda Lancheros

Section 5 - Patient Safety and Quality Assurance 11.33 - DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS Amir Reza Ashraf 11.40 - ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING Alba Pau Parra 11.47 - POSITIVE IMPACT OF AN IMPLEMENTED WARD PHARMACIST IN A MULTIPROFESSIONAL CANCER CARE TEAM IN GERMANY Svenja Dierkes

43

SECURE DRUG DELIVERY INNOVATIVE PRODUCTS FOR THE COMPOUNDING PHARMACY

Since 1969, IMI has been devoted to the needs of the Compounding Pharmacist.

Their legacy of partnerships with compounding professionals from around the world enables IMI to respond to the voice of the customer with specialized products that meet the unique needs of the compounding industry.

• State of the art manufacturing • World-class customer service • Exclusive Focus • American-made, FDA Registered, • Specialized Products • Exceptional Quality

PREP-LOCK™

PREP-SEAL™

PREP-FILL™

Contact us for Free Evaluation Samples IMIWEB.COM | 1.800.344.2554

RX-VENT™

RX-TRACT™

MADE IN THE USA

OPENING CEREMONY & KEYNOTE 1 What are we paying for? – From productivity to value-based healthcare ACPE UAN: 0475-0000-22-001-L04-P – A knowledge-based activity Session:

Wednesday, 23 March 2022, from 08.30 to 10.15

Room:

Hall D

Facilitator:

Thomas De Rijdt

Presenter:

Steven Simoens

No conflict of interest declared. Please reference speakers’ biographies.

Scientific Programme

KEYNOTE PRESENTATIONS

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.3, 1.5

ABSTRACT The view on healthcare systems in Europe is moving from a productivity paradigm, which focuses on the amount of healthcare services provided, to a value-based healthcare paradigm, which focuses on patient health outcomes. In this paradigm shift, the healthcare system is rejecting a systemic “one-size-fits-all” approach, in order to apply a more patient-centered approach.

Traditionally, patient treatments were based on guidelines and other evidence-based treatment tools. In value-based healthcare, patient preferences in medical treatment are now fundamental to the way value is defined.

Value is no longer produced simply by delivering medical technology and medicines, in a valuebased healthcare paradigm, instead, value emerges when the perspectives of the healthcare system and patients fuse resulting in optimal patient experience as well as strong clinical outcomes. Factors such as new technology, availability of information and communication between patients and healthcare professionals (HCPs) enable the fusion.

To measure value-based healthcare, tools such as Quality Adjusted Life Years (QALY) and Patient Reported Outcome (PRO), may be implemented in the healthcare systems to support valuebased practice within limited healthcare budgets. This transition from productivity to value-based healthcare requires hospital pharmacies to reconsider their strategic thinking to remain a key player within healthcare.

LEARNING OBJECTIVES After the keynote, participants should be able to: • Describe the difference between value-based healthcare and productivity • List the key tools involved in achieving value-based healthcare • Explain measurement tools suitable for assessing value-based healthcare.

45

Scientific Programme

EDUCATIONAL NEED ADDRESSED Hospital pharmacists work in an ever-changing environment. To remain a key player in healthcare, it is essential for hospital pharmacists to understand and adapt to the way healthcare is viewed and measured in society.

KEYWORDS

Value-based healthcare, productivity, paradigm, QALY, PRO, technology, patient preferences.

Don’t forget to take a funny picture, visit EAHP at booth 67 46

What people want from their medicines – Making shared decisions ACPE UAN: 0475-0000-22-002-L04-P – A knowledge-based activity Session:

Thursday, 24 March 2022, from 11.00 to 11.45

Room:

Hall D

Facilitator:

Jonathan Underhill

Presenters: Samuel Finnikin, Sam Barnett-Cormack No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statement 1.1

Scientific Programme

KEYNOTE 2

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.6 Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.5

ABSTRACT

Shared decision making (SDM) is a process in which healthcare professionals and patients work together to make decisions on treatments jointly. When successful, SDM should result in decisions about a patient’s care that are aligned with both the best available evidence and the patient’s informed preferences and values. To do this requires healthcare professionals to engage effectively with people to determine what really matters to them about their disease or illness at this point in time and what a good outcome would look like for them.

SDM is appropriate in any healthcare setting whenever there is more than one treatment or management option available, including doing nothing. Having excellent communication and consultation skills is essential for hospital pharmacists to engage in the most appropriate way with the patient, to learn about their preferences, communicate to them the evidence-based information available and jointly agree on the decisions made.

In 2014, the Health Foundation found that a large majority of patients in the UK general practice wanted to be involved in decisions about their care. Subsequent evidence suggest that this is the case throughout the developed world. This does not mean that patients have to make the final decision, but that they wish to be involved in the process. As Melnikow and Kravitz put it, “Most patients want to see the road map, including alternative routes, even if they don’t want to take over the wheel.” The Montgomery ruling in the UK in 2015 provides a basis in law for the promotion of SDM; put simply, clinicians should not make decisions for patients, but with patients instead.

Current research suggests that SDM does not occur to the extent that it should. The UK’s Clinical Quality Commission (CQC) annual inpatient survey features the question “Were you involved as much as you wanted to be in decisions about your care and treatment?” The latest data from 2020 shows that less than half of patients were not involved as much as they wanted to be. Further survey data highlights that SDM is required in both primary and secondary care.

This keynote will address the barriers to making SDM routine by outlining the evidence base showing the benefits of SDM, while sharing practical, pragmatic experience of an academic general

47

Scientific Programme

practitioner from the UK who has made this a routine part of his work. A patient perspective will also be shared where real life examples and stories are used to demonstrate how SDM can help people cope better with their multimorbidity. Enabling hospital pharmacists to improve their knowledge and skills around evidence-informed decision making and consultation skills is essential if we are to achieve the aim of involving patients in their choices on which medicines to take. It will also enable them to take this back to their places of work to spread the message to others in their teams.

LEARNING OBJECTIVES

After the keynote, participants should be able to: • Describe the features of a patient-centred consultation • Discuss the different approaches to making decisions with patients • Describe the different techniques for exploring the values and preferences that a patient holds • Appraise the different approaches to risk communication • Recognise the affective and cognitive biases that could affect decision making.

EDUCATIONAL NEED ADDRESSED

This keynote addresses the skills needed by hospital pharmacists to effectively cooperate with the patient in the shared decision-making process.

KEYWORDS

Clinical decision support, communication, evidence-based medicine, health literacy, polypharmacy.

48

Scientific Programme

The widest range of elastomeric infusion pumps

Safe, reliable and trouble-free product Security

DOSI-FUSER® Hard Shell and clear labeling to minimize errors

Drug compatibility

An extensive drug stability table is available

Simplicity

Easy-to-fill. Compatible with Closed Systems Transfer Devices (CSTD) and robotic systems. Clear and simple filling guidance in the app dosi-fuser.com

Versatility

Comprehensive range DOSI-FUSER® covers a huge amount of therapies

49

100% Exposure Control

For a safer working environment

Paxxo AB • Bjurögatan 35, SE-211 24 Malmö, Sweden www.paxxo.com • Tel: +46 (0)40-18 60 25

The era of cell and gene therapies in oncology – Fiction, poetry or science?

ACPE UAN: 0475-0000-22-003-L04-P – A knowledge-based activity Session:

Friday, 25 March 2022, from 11.30 to 13.00

Room:

Hall D

Facilitator:

Torsten Hoppe-Tichy

Presenters: Guy Ungerechts, Tilman Schöning No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.2, 1.6, 1.7

Scientific Programme

CLOSING CEREMONY & KEYNOTE 3

Section 2 - Selection, Procurement and Distribution: Statements 2.1, 2.3, 2.6 Section 3 - Production and Compounding: Statements 3.2, 3.4, 3.5 Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.6 Section 6 - Education and Research: Statement 6.5

ABSTRACT

Personalised medicine, also known as precision medicine or individualised medicine increasingly involves molecular diagnostics, predictive (proactive) genetic testing, pharmacogenomics, and in-depth immuno-profiling. In immuno-oncology, multiple approaches of cell and gene therapy are on the threshold. i) genetically modified organisms (GMO) e.g. oncolytic viruses (OVs) as a platform technology to induce systemic immune responses against cancer; ii) mRNAtechniques to target neoepitopes which have to be identified through IT-based diagnostics of the patient´s tumor genome for development of patient individualized tumor vaccines; iii) cellbased therapies with the therapeutic use of adoptive cell therapy (ACT) including ACT of tumorinfiltrating lymphocytes (TIL), ACT with T cell receptor (TCR) gene therapy and ACT with chimeric antigen receptor (CAR) T-cells. These very heterogenic concepts also have a very suitable option for combination approaches among each other. They are subject of ongoing scientific efforts ultimately aiming for long-term therapeutic responses and broadening use for different tumor types.

In this keynote lecture the principles of the different techniques are explained as well as the potential but also the limitations so hospital pharmacist can assess the opportunities and challenges brought by gene and cell therapy.

LEARNING OBJECTIVES

After the keynote, participants should be able to: • Identify potential and limits of methodologies used in oncologic gene and cell therapy • Recognise the principles of OVs, mRNA-techniques and ACT • Assess opportunities and challenges for hospital pharmacy arising from those gene and cell therapy approaches.

51

Scientific Programme 52

EDUCATIONAL NEED ADDRESSED

Websites of pharmaceutical multinational researching enterprises reveal pipelines richly filled with products from cell and gene theranostic. Yet, it is still hardly feasible to derive a reliable foresight on upcoming new therapies and challenges as related to how hospital pharmacists can contribute to added values in cell and gene therapies. As a professional, each hospital pharmacist needs to be properly educated and fully equipped to actively support relevant trends of new therapeutic approaches.

KEYWORDS

Genetically modified organisms, oncolytic virus therapy, patient individualized tumor vaccination, adoptive cell therapy, gene therapy, immuno-oncology.

REDUCING RISK, REDUCING HARM NEOMED* pharmacy syringes and medicine accessories support drug safety practices with tamper evident caps and solutions designed to reduce human factor errors – compliant with ISO 80369-3

For more information, please visit https://avanos.co.uk/nicu-pharmacy

*Registered Trademark or Trademark of Avanos Medical, Inc., or its affiliates. ©2018 AVNS. All rights reserved. COPY-05805

QUALITY CONTROL IN SECONDS Verify the identity and concentration of compounded injectable medications, quickly and efficiently, with DrugLog® and PrepLog®.

VISIT US IN BOOTH 15 pharmacolog.com

SEMINAR IG1 Better together! – Hospital pharmacists go collaborative ACPE UAN: 0475-0000-22-004-L04-P – A knowledge-based activity Session:

Thursday, 24 March 2022, from 12.00 to 13.30

Room:

Hall D

Facilitator:

Ana Valladolid Walsh

Presenters: Gitte Søndergård Nielsen, Edurne Fernández de Gamarra Martínez No conflict of interest declared. Please reference speakers’ biographies.

Scientific Programme

SEMINARS

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.3

ABSTRACT

Hospital pharmacy encompasses numerous different activities that frequently require very specialized knowledge and it is not always possible to have enough human resources and time to perform these activities in the desired way.

Networking groups can be a solution to this problem, allowing added knowledge and efforts of the network members, and using time more efficiently.

On the other hand, working collaboratively can have a great impact on patients in the case of infrequent diseases with very personalized treatments that can be difficult to obtain or be useful to ensure the availability of drugs that are not used frequently. There are multiple examples of how benefits for patients or healthcare systems are obtained through collaboration. These collaborations can occur at many different levels (local, regional, national and international) among hospital pharmacists and with other pharmacists or different healthcare providers. In this seminar we will learn about experiences that have been proven to be beneficial for their participating members.

We hope that after attending this seminar you also believe that “Unity makes strength”!

LEARNING OBJECTIVES

After the session, participants should be able to: • Identify areas in which working in collaboration with other hospital pharmacists can be beneficial for patient’s health outcomes • List successful experiences of networking between hospital pharmacists.

EDUCATIONAL NEED ADDRESSED

Hospital pharmacists may have to deal with insufficient human resources to work on very specific and complex activities and can underestimate the value of networking as a solution for this problem. This seminar will show attendees the value of this approach focusing on the benefits for patients and healthcare systems.

KEYWORDS

Collaboration, networking and antidotes.

55

Scientific Programme

SEMINAR IG2 How to survive with limited resources without letting the patients down ACPE UAN: 0475-0000-22-005-L04-P – A knowledge-based activity Session:

Friday, 25 March 2022, from 09.00 to 10.30

Room:

Hall D

Facilitator:

Inese Sviestina

Presenters: Antonio Melo Gouveia, Dzintars Mozgis No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.3, 1.4, 1.5 Section 5 - Patient Safety and Quality Assurance: Statement 5.1

ABSTRACT

Although the economic crisis formally ended almost a decade ago, many countries in Europe still live under strict budgetary constraints and healthcare systems are deeply affected by these changes. Hospitals have also had to implement policies to manage tough budget constraints and hospital pharmacies are often at the back of the queue of all hospital needs.

What options are there to continue the development of hospital pharmacies and implement the European Statements of Hospital Pharmacy into daily life? How can hospital pharmacists improve patients’ treatment outcomes in these circumstances? Is it possible to balance limited resources and ethical aspects?

This seminar attempts to give answers to these questions by presenting different viewpoints from two different stakeholders in the health system: hospital pharmacist and hospital manager.

LEARNING OBJECTIVES

After the session, participants should be able to:

• Describe how limited resources could affect patient treatment outcomes • Identify how budgetary constraints affect hospital pharmacists’ work • Discuss how to develop services under these circumstances.

EDUCATIONAL NEED ADDRESSED

Hospital pharmacists regularly find themselves having to manage the impact of limited resources. There is, therefore, an educational need for being informed about these issues and then to set up processes inside and outside hospital pharmacy to find ways to solve these issues.

KEYWORDS

Hospital pharmacist, inequality, patient care, limited resources, collaboration with different stakeholder.

56

The role of the hospital pharmacist in disaster management – Are we prepared?

ACPE UAN: 0475-0000-22-006-L04-P – A knowledge-based activity Sessions:

Wednesday, 23 March 2022 – 14.45 to 16.15 Thursday, 24 March 2022 – 15.00 to 16.30

Room:

Hall D

Facilitator:

Stéphanie Deuster

Presenters: Nicolas Widmer, Franky Buyle No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Scientific Programme

SEMINAR IG3

Section 1 - Introductory Statements and Governance: Statement 1.5 Section 2 - Selection, Procurement and Distribution: Statements 2.5, 2.6 Section 5 - Patient Safety and Quality Assurance: Statements 5.6, 5.9

ABSTRACT

Emergency and disaster pharmacy serves to ensure the best possible pharmaceutical care for the population during major incidents and disasters, as well as in other exceptional situations. With all the expertise of pharmacists, emergency and disaster pharmacy plays a fundamental role in medical care. All over the world, pharmacists experienced disasters such as train accidents, earthquakes, flooding or other natural disasters, where hospitals were suddenly faced with large numbers of patients in these events of a mass casualty. Besides, hospital pharmacists have to be prepared for the treatment of patients in NBC emergencies (nuclear, biological or chemical hazards).

Competency of hospital pharmacists to dispense drugs and guarantee safe medication under normal conditions does not necessarily mean that they will be equally proficient in “mass dispensing” or other forms of medication supply that occur during emergencies, where existing supply chains are disrupted, information is limited, and key infrastructure may be compromised.

The preparedness for various sorts of emergencies justifies different concepts and several specific ranges of medicinal products to care for patients who suffered either severe injuries or harms from NBC emergencies.

The hospital pharmacists should be able to provide concepts and quality standards for the supply of medicines and medical supplies not only for their hospital, but also for rescue services. The main tasks usually are emergency drug supply and participation to crisis management at hospital level. Besides, the manufacturing capacity of a hospital pharmacy may play an important role. The support in the hospital emergency preparedness is vital. Many hospital pharmacies already have a disaster plan ready-to-go – but will it cover all aspects of the catastrophe we may face?

LEARNING OBJECTIVES

After the session, participants should be able to:

• Outline specialized knowledge on drugs and medical devices used in emergency and disaster • Identify the scope of activity in order to realize an emergency plan for their hospital pharmacy • Analyze complex pharmaceutical issues within unfamiliar contexts of emergencies.

EDUCATIONAL NEED ADDRESSED

Hospital pharmacists need to know the different therapies and drugs for the treatment of patients in the events of mass casualties and as well for NBC emergencies. They should organize their pharmacy to support the hospital in being optimally prepared for emergency situations.

KEYWORDS

Disaster, crisis management, emergency drug supply.

57

Scientific Programme

SEMINAR SPD1 Gases, devices, diagnostics – Managing more than tablets ACPE UAN: 0475-0000-22-007-L04-P – A knowledge-based activity Session:

Thursday, 24 March 2022, from 12.00 to 13.30

Room:

Hall K2

Facilitator:

Francesca Venturini

Presenters: Nicole Vink-van Kimmenade, Kristin Verbeke No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.4 Section 2 - Selection, Procurement and Distribution: Statements 2.1, 2.2 Section 5 - Patient Safety and Quality Assurance: Statement 5.2

ABSTRACT

A hospital pharmacy director is accountable for the management of medicinal products and all other health goods used in the hospital. While the pathway for medicines is very clear in terms of responsibility and tasks, this is not always the case for “borderline products” as, for example, medical devices (e.g., custom made), medical gases, disinfectants and diagnostics. A specific expertise needs to be implemented in the pharmacy staff, and specific interaction with other central offices need to be very clear in order to get a smooth management. Special expertise needs to be in place for procurement and vigilance on the safe use.

The seminar will focus on the management pathways of these products, providing information on the level of expertise needed, responsibilities of the hospital pharmacy, as well as models of management.

LEARNING OBJECTIVES

After the session, participants should be able to:

• Understand the characteristics of health goods other than medicines • Identify responsibilities of the hospital pharmacist on products other than medicines • Understand which organizational models of management could be put in place for these products.

EDUCATIONAL NEED ADDRESSED

University curricula often do not include products other than medicine. However, the hospital pharmacist in practice is responsible and involved in the management of such products. This seminar will provide information on this issue.

KEYWORDS

Medical gases, custom made medical devices, disinfectants, in vitro diagnostics, procurement, logistics, multidisciplinary management.

58

The waste-reducing hospital pharmacy – Let’s get started!

ACPE UAN: 0475-0000-22-008-L04-P – A knowledge-based activity Sessions:

Wednesday, 23 March 2022, from 17.15 to 18.45 Thursday, 24 March 2022, from 09.00 to 10.30

Room:

Hall D

Facilitators: Gunar Stemer on Wednesday, 23 March 2022, Jonathan Underhill on Thursday, 24 March 2022 Presenters: Piter Oosterhof, Christopher F. Green No conflict of interest declared. Please reference speakers’ biographies.

Scientific Programme

SEMINAR SPD2

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.3, 1.4 Section 2 - Selection, Procurement and Distribution: Statement 2.6

ABSTRACT

In its 2017 report, “Tackling wasteful spending on health”, the OECD systematically analysed and described how and why a considerable amount of health spending was deemed wasted. In this context, “wasteful” refers to first, services or processes that are either harmful or do not deliver benefits, and second, costs that could be avoided.

Examples of waste in health care are manifold and substantially occur in the three domains of clinical care (e.g. duplicating therapies, preventable clinical adverse events, overprescribing), operations (e.g. discarded medicines) and governance.

Not surprisingly, waste-reducing activities referring to medicines are in the focus of community and hospital pharmacists alike, as medication waste occurs at all stages of the pharmaceutical supply chain.

It is important to understand factors contributing to medication waste and learn about initiatives to address these sources of waste, in order to mitigate the financial and environmental impact of them.

While hospital pharmacists reduce waste in the above-mentioned meaning in clinical care by providing clinical pharmacy services and cost-efficient selection of medicines, other areas of hospital pharmacy practice contributing to waste are not that well explored.

This seminar will give an introduction in the concept of waste from a pharmacy viewpoint and then provide two different examples of how waste can be reduced, one in the original sense of “waste” and the second focused on waste in pharmacy and clinical pharmacy processes.

LEARNING OBJECTIVES

After the session, participants should be able to: • state various sources of waste generally in health care and specifically in hospital pharmacy • recall waste-reducing examples in the hospital pharmacy setting.

EDUCATIONAL NEED ADDRESSED

The ever-increasing awareness among health care professionals that resources being precious and often limited is driving the need for waste-reducing activities. Hospital pharmacists have to know how to contribute and save resources within their scope of practice.

KEYWORDS

Waste, supply chain, clinical pharmacy processes, lean management.

59

Scientific Programme

SEMINAR PC1 Opportunities and threats for hospital pharmacy production in gene and cell therapy scenarios ACPE UAN: 0475-0000-22-009-L04-P – A knowledge-based activity Session:

Wednesday, 23 March 2022, from 14.45 to 16.15

Room:

Hall G1

Facilitator:

Torsten Hoppe-Tichy

Presenters: Kim Green*, Kahina Chetouane No conflict of interest declared. Please reference speakers’ biographies. * Conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statement 1.1 Section 3 - Production and Compounding: Statements 3.2, 3.3, 3.4 Section 6 - Education and Research: Statement 6.4

ABSTRACT In the era of rising bacterial resistance, we are increasingly confronted with difficult to treat severe or chronic infections caused by multiresistant bacteria. Some of these infections are life-, organ- or limb-threatening, and in these situations (adjunctive) treatment with bacteriophages is sometimes considered.

Bacteriophages have widely been applied, already for many years, in Russia and Georgia, but did not found their entrance in (Western) Europe thus far due to the readily available antibiotics. However, as the antimicrobial pipeline is virtually dry, and as we are confronted with antimicrobial resistance, there is a clinical need to evaluate the place of bacteriophages in our current anti-infectious armamentarium.

Bacteriophages are often locally applied in chronic and debilitating infections, such as chronic osteomyelitis (as a last resort option in order to avoid amputation) and chronic upper respiratory infection, such as sinusitis (in order to avoid recurrent antibiotic courses). Next to this, bacteriophages are also sometimes systemically (intravenously) applied for severe acute infections, like severe sepsis or septic shock, caused by multiresistant bacteria.

Bacteriophages are not comparable from a development point of view to classic drugs, as targeted phages have to be identified and developed for the specific infecting pathogen, based on a ‘phagogram’. In Belgium, magistral preparations including phages for human applications are permitted since 2018. Furthermore, recent data on phage interactions with the immune system open new avenues for phage repurposing and their possible application in non-bacterial disorders.

In this session, a concise overview of different aspects related to the therapeutic use of bacteriophages will be provided. The session will be started by highlighting the history of bacteriophage use and previous experience with bacteriophages. he current clinical evidence, therapeutic indications and safety aspects will be discussed by an infectious diseases specialist. This will be followed by a discussion on the practical and regulatory aspects and the role of the pharmacist in compounding and dispensing.

Finally, research needs for the near future will be highlighted.

60

After the session, participants should be able to: • understand the therapeutic indications for bacteriophages • understand the differences in development (insights in efficacy and safety) with classic drugs • understand the pharmacy-related aspects of bacteriophage treatment (compounding and dispensing).

EDUCATIONAL NEED ADDRESSED

To learn and understand the history, current clinical evidence, therapeutic indications and safety aspects of bacteriophage use, practical and regulatory aspects and the role of the pharmacist in compounding and dispensing, research needs for the near future.

KEYWORDS

Bacteriophages, regulatory aspects, multiresistant bacteria, phagotherapy, efficacy, safety.

ww.eahp.eu nfo@eahp.eu 32 (0) 2/699.25.16

Scientific Programme

LEARNING OBJECTIVES

RT SI G - FIN AL RE PO

Special Interest Group on oducts Hazardous Medicinal Pr

SIG on Hazardous Medicinal Products: find out more on the Daily Dose to be released on 24th March 61

Methylene Blue

D

®

0,5%

> To see the invisible Marker for surgical visualization such as intraoperative seal tests, leakages visualization and delineation of the fistula tract

ProveDye® has a unique 0.5% concentration due to the high purity level of the European Pharmacopeia-compliant methylene blue ingredient1 INDICATIONS: Marker for surgical visualisation such as intra operative seal tests, leakage visualisation and delineation of the fistula tract. CONTRAINDICATIONS: Do not administer PROVEDYE®: In case of known hypersensitivity to the methylene blue or to any other thiazine dyes, in case of previous or ongoing treatment with Selective Serotonin Reuptake Inhibitors (SSRIs), bupropion, buspirone, clomipramine, mirtazapine and venlafaxine, in case of Glucose-6-Phosphate Dehydrogenase deficiency, in case of pregnancy or breastfeeding PROVEDYE® should be avoided. In case of moderate or severe renal disease patients must be closely monitored. METHOD OF ADMINISTRATION AND DOSAGE: The PROVEDYE® 0.5% Methylene Blue sterile solution can be administered: Undiluted in local injection, in local injection diluted in normal saline solution, in oral administration diluted in water. PROVEDYE® must be used immediately after opening or dilution. The PROVEDYE® dilution and volume to be administered depend on the destination of the coloration. PROVEDYE® could be diluted until 0.01%. For this, dilute 2 parts of PROVEDYE® 0.5% with 100 parts of normal saline solution or water. WARNINGS AND PRECAUTIONS: PROVEDYE® must be administered by a healthcare professional. A preoperative assessment is recommended before using PROVEDYE®. Protective measures against patient exposure to strong light, including that within instruments such as pulse oximeters should be taken, because there is a risk of cutaneous photosensitivity reaction. The wearing of gloves is recommended for users. Do not use a damaged ampoule of PROVEDYE®. Do not use PROVEDYE® if the solution is colourless.

PROVEDYE® must be used immediately after opening or dilution. Do not inject PROVEDYE® intravenously, subcutaneously, intrathecally, intra-amniotically or intraocularly. PROVEDYE® is for single use only: discard any remaining solution after opening. In case of re-use of PROVEDYE®, there is a risk to loss sterility due to potential contamination of the sterile solution (it is considered as a decrease of technical performance). PROVEDYE® should be disposed of in clinical waste. ADVERSE EFFECTS*: Selected adverse effects: nausea, abdominal and chest pain, headache, dizziness, tremors, anxiety, mental confusion, dyspnea, hypertension, the formation of methaemoglobinaemia and profuse sweating.

Reference: 1. European Pharmacopeia - Methylthioninium chloride monograph n°1132 Medical device CE-Marked - Class IIa

2797

For more information visit our booth number 62

Provepharm SAS, 22 rue Marc Donadille 13013 Marseille, France, Tel: +33 4 91 08 69 30 www.provepharm.com

DM/22/01-003/WW

*Additional information is provided in the Instructions for use.

3D printed medical devices – The ultimate customization ACPE UAN: 0475-0000-22-026-L04-P – A knowledge-based activity Sessions:

Thursday, 24 March 2022, from 09.00 to 10.30 Friday, 25 March 2022, from 9.00 to 10.30

Room:

Hall K2

Facilitator:

Thomas De Rijdt

Presenters: Constantinus Politis, Joyce Van den Broeck No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 3 - Production and Compounding: Statements 3.1, 3.2, 3.3, 3.4

Scientific Programme

SEMINAR PC2

Section 5 - Patient Safety and Quality Assurance: Statement 5.11

ABSTRACT

Nowadays, customized medical devices are becoming common practice in the operation rooms. The era where one size fits all lies far behind us, and printing of medical devices is a technology that gives a new dimension in personalized treatment of patients. Today’s applications include patient specific 3D printed cutting guides, 3D planning of complex surgery, printing of anatomical models of bone structures and organs and even printing of implantable devices. Also, bio-printing of tissues and organs is already explored in transplantation surgery.

As for the legislation, the Medical Device Regulation (MDR2017/745, applicable from May 2021) defines the requirements concerning customized devices and manufacturing of devices within the health institution. Specialized manufacturers have developed the expertise and knowhow of 3D printing, but with the growing quality and availability of printing equipment, printing of devices within the health institution could become common practice.

In this evolving technology, we can wonder if there is always a clear added value in the use of patient specific devices and if the sky is the limit in the clinical applications of 3D printing?

As the hospital pharmacist is responsible for quality and conformity of medical devices, there is definitely a responsibility that reaches further than control of the CE mark on the packaging. As the provider of patient therapy we will play a key role in managing just in time printing of high quality devices and assure the traceability.

LEARNING OBJECTIVES

After the session, participants should be able to: • Understand the possibilities and limitations of clinical application of 3D printed devices • Discuss the role of the hospital pharmacist according the current MDR2017/745.

EDUCATIONAL NEED ADDRESSED

3D printing is an evolving technology in manufacturing of medical devices. Hospital pharmacist must be aware of the possibilities and limitations of this technology, and their changing role in the responsibility in providing high quality medical devices.

KEYWORDS

3D-printing, implants, surgery, MDR, hospital exemption, manufacturing, medical device.

63

SINTECO HEALTHCARE

AUTOMATION FOR DRUG MANAGEMENT The robotic system from logistics to patient

SOLUTIONS FOR HEALTHCARE Designing complete solutions for automated and safe drug management

STAND N.43 Main Hall

Sinteco a Bucci Automations S.p.A. Division Zona Industriale Villanova, 32013 Longarone - Italy Phone: +39 0437 772146 | sinteco.it@bucci-industries.com healthcare.sintecorobotics.com

Bacteriophages – Back to the future ACPE UAN: 0475-0000-22-027-L04-P – A knowledge-based activity Session:

Thursday, 24 March 2022, from 15.00 to 16.30

Room:

Hall G1

Facilitator:

Juraj Sykora

Presenters: Jean-Paul Pirnay, Stephan J.T. Vermeulen No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.3

ABSTRACT

Scientific Programme

SEMINAR PC3

In the era of rising bacterial resistance, we are increasingly confronted with difficult to treat severe or chronic infections caused by multiresistant bacteria. Some of these infections are life-, organ- or limb-threatening, and in these situations (adjunctive) treatment with bacteriophages is sometimes considered.

Bacteriophages have widely been applied, already for many years, in Russia and Georgia, but did not found their entrance in (Western) Europe thus far due to the readily available antibiotics. However, as the antimicrobial pipeline is virtually dry, and as we are confronted with antimicrobial resistance, there is a clinical need to evaluate the place of bacteriophages in our current anti-infectious armamentarium.

Bacteriophages are often locally applied in chronic and debilitating infections, such as chronic osteomyelitis (as a last resort option in order to avoid amputation) and chronic upper respiratory infection, such as sinusitis (in order to avoid recurrent antibiotic courses). Next to this, bacteriophages are also sometimes systemically (intravenously) applied for severe acute infections, like severe sepsis or septic shock, caused by multiresistant bacteria.

Bacteriophages are not comparable from a development point of view to classic drugs, as targeted phages have to be identified and developed for the specific infecting pathogen, based on a ‘phagogram’. In Belgium, magistral preparations including phages for human applications are permitted since 2018. Furthermore, recent data on phage interactions with the immune system open new avenues for phage repurposing and their possible application in non-bacterial disorders.

In this session, a concise overview of different aspects related to the therapeutic use of bacteriophages will be provided. The session will be started by highlighting the history of bacteriophage use and previous experience with bacteriophages. The current clinical evidence, therapeutic indications and safety aspects will be discussed by an infectious diseases specialist. This will be followed by a discussion on the practical and regulatory aspects and the role of the pharmacist in compounding and dispensing. Finally, research needs for the near future will be highlighted.

LEARNING OBJECTIVES

After the session, participants should be able to:

• Understand the therapeutic indications for bacteriophages • Understand the differences in development (insights in efficacy and safety) with classic drugs • Understand the pharmacy-related aspects of bacteriophage treatment (compounding and dispensing).

EDUCATIONAL NEED ADDRESSED

To learn and understand the history, current clinical evidence, therapeutic indications and safety aspects of bacteriophage use, practical and regulatory aspects and the role of the pharmacist in compounding and dispensing, research needs for the near future.

KEYWORDS

Bacteriophages, regulatory aspects, multiresistant bacteria, phagotherapy, efficacy, safety.

65

Visit us at the EAHP Congress 2022 in Vienna at stand no. 23

CONSIS.ATP pouch packager.

Ultra-fast and reliable.

CONSIS Dose Systems are designed for filling unit-dose or multi-dose pouches with medication for individual patients, sorted by day and time of medication intake.

The CONSIS.ATP dispenses tablets at an impressive speed into pouches labelled individually for each patient on a small machine footprint.

For filling unit-dose and multidose pouches.

Ultra-fast dispensing speed (up to 3,600 pouches per hour) combined with extreme accuracy.

Can hold up to 480 canisters with different medicines at the same time (ATP2-480).

An unlimited number of Smart Canisters increases the possible number of automated medications exactly to your needs.

With a minimal footprint down to 0.89 m² the Consis.ATP is one of the smallest tablet packagers in its class.

www.willach.com

Side effects resulting in prescribing cascades ACPE UAN: 0475-0000-22-010-L05-P – A knowledge-based activity Session:

Wednesday, 23 March 2022, from 14.45 to 16.15

Room:

Hall K2

Facilitator:

Fatma Karapinar-Çarkit

Presenters: Lisa McCarthy, Atiya Mohammad* No conflict of interest declared. Please reference speakers’ biographies. * Conflict of interest declared. Please reference speaker’s biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statement 1.1

Scientific Programme

SEMINAR CPS1

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.2, 4.3, 4.4, 4.5, 4.8 Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.2, 5.5, 5.6, 5.8

ABSTRACT

The older population is increasing worldwide. This increases the number of patients with polypharmacy as well.

From scientific literature, it is known that the risk for adverse drug events increases with every medicine that is prescribed. Prescribing cascades occur when an adverse drug event is misinterpreted as a new medical condition, resulting in the prescription of a potentially unnecessary drug to treat this new condition. Especially, in the older population, the recognition of adverse drug events is difficult as ageing can mask drug-related adverse events, and causes of new conditions (e.g. falls or delirium) become increasingly difficult to attribute to a combination of medication.

The phenomena prescribing cascades was first described in the Lancet and British Medical journal over 20 years ago. In the scientific literature, over 30 different prescribing cascades are described, showing that prescribing cascades do not only result in the prescription of an additional drug to treat the adverse drug event, but even in the use of medical devices (e.g. a pacemaker to treat bradycardia). Prescribing cascades are an important public health problem because they lead to adverse outcomes and unnecessary costs for the healthcare system, that can be avoided.

Hospital pharmacist could help in mitigating strategies for prescribing cascades by recognizing them, prevent them and reverse them. This seminar will provide an overview of different prescribing cascades and will provide strategies for hospital pharmacists to prevent, detect and reverse prescribing cascades in daily practice

LEARNING OBJECTIVES

After the session, participants should be able to:

• Understand important prescribing cascades • Understand how pharmacists could help in reversing or preventing prescribing cascades.

EDUCATIONAL NEED ADDRESSED

Clinical pharmacists perform medication reconciliation and medication reviews. This seminar will focus on the recognition of prescribing cascades that pharmacists could include in their medication reconciliation and medication review activities.

KEYWORDS

Adverse drug reactions, counselling, drug use evaluation, interventions, medication safety.

67

Scientific Programme

SEMINAR CPS2 The COVID-19 pandemic – Lessons learnt at the hospital pharmacy ACPE UAN: 0475-0000-22-011-L04-P – A knowledge-based activity Session:

Thursday, 24 March 2022, from 12.00 to 13.30

Room:

Hall G1

Facilitator:

Lene Juel Kjeldsen

Presenters: Christine Dinsen-Andersen, Joo Hanne Poulsen, Lies De Waele No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory statements and governance: Statements 1.2, 1.3 Section 2 - Selection, Procurement and distribution: Statements 2.1, 2.5, 2.6 Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.2, 4.3 Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.5 Section 6 - Education and research: Statement 6.5

ABSTRACT

In early 2020, the world was introduced to a new viral outbreak. Worldwide the pandemic challenged the daily way of living since no prevention or sufficient treatment existed. The challenges were particularly serious for the hospitals, including hospital pharmacies, because the pandemic led to a swift increase in admitted patients pressuring the capacity of the hospitals throughout the world.

Various national initiatives were introduced, including physical distancing, hand hygiene, use of personal protection equipment, travel restrictions, digital communication and lab-testing in the hope of constraining the viral outbreak until effective vaccines and therapeutic agents could be developed. The initiatives were based on culture, political decisions, and the little available evidence, and (inter)national recommendations changed frequently as result of appearing evidence and changes in the outbreak epidemiology.

Authorities, researchers, pharma companies etc. mobilised resources to address this unknown land by developing vaccines and testing existing molecules for potential effect on the new virus. However, other problems appeared including increases in medication shortages, shortage of face masks and other personal, preventive agents.

The hospital pharmacist had an active role in many aspects of the pandemic, including providing alternatives to the unavailable medications and personal, preventive agents as well as participating in clinical trials, planning and monitoring. A plethora of solutions were introduced to minimise the risk of infection including provision of hospital medicines to patients at their homes.

In this session, we provide an overview of lessons learnt from the COVID-19 pandemic relevant for hospital pharmacists. These lessons will provide us with knowledge to be better prepared should a pandemic challenge our world once again.

LEARNING OBJECTIVES

After the session, participants should be able to:

• llustrate the essential role of the hospital pharmacist in an acute situation like the one caused by the COVID-19 pandemic • Discuss the effect of various initiatives implemented as a consequence of the COVID-19 pandemic • Analyse the implemented initiatives regarding patient safety.

68

KEYWORDS

COVID-19, pandemic, optimisation, vaccines, antiviral treatment, procedures.

Developed to advance ts to EAHP’s educational effor education support the continuing and of hospital pharmacists improve patient safety Programme dates

rch 2023 Congress | 22-23-24 Ma | April, May, September, Synergy Masterclass 3 October, November 202

Scientific Programme

EDUCATIONAL NEED ADDRESSED

The COVID-19 pandemic has provided a unique situation, where the health care systems throughout the world have been challenged on many aspects of routine tasks usually securing the best possible treatment of patients admitted to hospital. If a similar international situation should occur in the future, it is of great importance that hospital pharmacists can act rapidly based on the lessons learnt internationally.

Synergy programmes for 2023: ask further details to the EAHP team at booth 67

cists (EAHP) is ion of Hospital Pharma The European Associat rmacy Education Pha for ncil Cou n atio accredited by the Accredit n catio edu cy rma ng pha as a provider of continui

69

th

26 Congress of the EAHP Visit us at Stand 40

MediMix®

IMF GmbH is pleased to introduce the FIRST intelligent peristaltic pump able to facilitate everyday pharmacy production's tasks.

A Flexible, Efficient, Safe and Compact solution needed in every pharmacy, the MediMix vigo was designed with the aim to reduce pharmacy technician's workload without compromising precision and traceability.

The automatic pharmacy solution for liquid transfer:

Repeats and Repeats and Repeats… Ÿ High �lling speed up to 850 ml per minute Ÿ Simple and intuitive operation through integrated touch screen Ÿ Can be networked with common order entry management systems Flexible: Efficient: Safe: Compact:

Ideal for drugs reconstitution, IV transfer & mixing, plus filling of bags, syringes, elastomeric devices, and oral syringes.

Aimed to reduce pharmacy technician's workload.

Allows full traceability to the pharmacist, uses barcode technology to read formulations and verify the right ingredient is used and can be integrated with a scale for an automatic weight control reading.

With its very small footprint, offers solution for any size laminar flow cabinets or isolators.

Medication with safety ACPE UAN: 0475-0000-22-012-L05-P – A knowledge-based activity Sessions:

Thursday, 24 March 2022, from 15.00 to 16.30 Friday, 25 March 2022, from 09.00 to 10.30

Room:

Hall G2

Facilitator:

Raisa Laaksonen

Presenters: Carita Lindén-Lahti, Sini Kuitunen No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 4 - Clinical Pharmacy Services: Statement 4.8

Scientific Programme

SEMINAR PSQ1

Section 5 - Patient Safety and Quality Assurance: Statements 5.2, 5.3, 5.5

ABSTRACT

Medication errors, such as administering a wrong medicine to a patient, are common worldwide. Tackling this problem requires seeking for systems-based risk management approaches in healthcare. These approaches promote proactive management of medication risks by improving every day medication practices and processes in hospitals. One of the strategies to improved safety is learning from identified medication errors and risk prone processes. Another important aspect is to learn from safe operation and situations in healthcare where we succeed and ‘things go right’.

Co-ordinating and promoting medication safety is an important part of a hospital pharmacist’s role. To achieve effective outcomes, it is important to implement evidence-based development activities and share good practices.

The process of medication use involves multiple stages and many healthcare professionals with different roles, knowledge and skills, which is why inter-professional co-operation is a key element for success. To put theory into practice, this session presents examples of medication safety activities at the Helsinki University Hospital, Finland.

The interactive part of the session focuses on sharing best practices and designing successful medication safety activities in the participants’ own organisation

LEARNING OBJECTIVES

After the session, participants should be able to:

• To understand the key approaches to modern medication risk management • To demonstrate how to develop medication safety in hospital settings • To identify risk management strategies that could be developed in the participants’ own working environments.

EDUCATIONAL NEED ADDRESSED

This session will introduce the principles of medication safety risk management in hospitals, and provides examples of risk management practices that could be implemented in European hospitals.

KEYWORDS

Patient safety, medication safety, risk management.

71

Booth 6

feed your database and make it bloom

The ADKA Drug Information Tool: never search twice!    

A simple and clear tool to document drug information Quick access to previously researched inquires Finally, no more documenting one query twice Document knowledge – and use it at any time

Teamwork in the hospital – Building relationships to optimise pharmacotherapy ACPE UAN: 0475-0000-22-013-L04-P – A knowledge-based activity Sessions:

Wednesday, 23 March 2022, from 17.15 to 18.45 Thursday, 24 March 2022, from 09.00 to 10.30

Room:

Hall G1

Facilitator:

Beata Horoskzo

Presenters: Kamila Urbańczyk, Juan Perez-Barcena No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Scientific Programme

SEMINAR PSQ2

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.2 Section 5 - Patient Safety and Quality Assurance: Statement 5.1

ABSTRACT

Building relationships in the hospital is not something that can be checked off a to-do list, but it should always have a place among our top priorities because it affects everything we do personally and professionally. Good relationships can create an effective teamwork.

Teamwork among the members of hospital can result in better patient care, if everyone remembers that the main goal is the same: optimizing the use of medicines. Optimising the use of medicines in hospitals is central to the delivery of high-quality patient care. This process can be defined as prescribing the right drug in sufficient dose for the adequate duration and suitable to the clinical requirements of the patients at lowest cost. Managing medicines safely, effectively and efficiently is central to the delivery of high-quality care that is focused on the patient and gives value for money. Optimal pharmacotherapy saves lives, confines undesired toxicity, adverse events and maximize on the benefits that can be imitative from best use of medications.

In delivering health care, an effective teamwork can immediately and positively affect patient safety and outcome. The need for effective teams is increasing due to increasing co-morbidities and increasing complexity of specialization of care.

Communication and collaboration between professionals are essential to the enhancement of rational use of medicines. It is essential to establish collaboration of physicians and pharmacists concerning accurate and competent drugs use and prescribing. Studies examining prescribing advice given by clinical/hospital pharmacists have shown high rates of acceptance from medical staff, demonstrating that the role is both valued and effective.

LEARNING OBJECTIVES

After the session, participants should be able to:

• Describe how to build relationships in the team and an effective teamwork • List examples of teamwork in rational use of medicines

• Describe practice examples concerning accurate and competent use of medicines in the hospital.

EDUCATIONAL NEED ADDRESSED

This seminar addresses the skills needed by clinical/hospital pharmacists and physicians as well, to build good relationships among team members, to collaborate with colleagues and manage the rational use of medicines.

KEYWORDS

Optimal pharmacotherapy, use of medicines, inappropriate prescribing, multimorbidity, polypharmacy, teamwork, communication, effective team, building relationships.

73

Scientific Programme

SEMINAR ER1 Hospital pharmacy practice research: why and how to be more engaged and publish?

ACPE UAN: 0475-0000-22-014-L04-P – A knowledge-based activity Session:

Wednesday, 23 March 2022, from 17.15 to 18.45

Room:

Hall G2

Facilitator:

Stéphanie Deuster

Presenters: Paul P.H. Le Brun, Isabel Spriet No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 6 - Education and Research: Statement 6.4

ABSTRACT

University pharmacy curriculum prepares future pharmacists for pharmacy practice in community and hospital pharmacy. However, most curricula have too little attention for pharmacists’ participation in (pharmacy practice) research. Hospital pharmacists should actively engage in and publish research, particularly on hospital pharmacy practice. In this seminar, participants will be able to identify topics to be published and barriers to being published. As an example the policy of the European Journal of Hospital Pharmacy will be discussed to inform how this journal decides on what to publish and what to reject.

Furthermore, what kind of papers are published, how are they composed including how the editors are willing to help (young) pharmacists with publications.

Pharmacy practice research will be defined in the arena of research in healthcare; key opportunities and challenges in pharmacy practice research will be addressed. To allow participants to get into action for research, two practical models will be detailed. A 1st example will be the presentation of Academic Pharma, a research section of the LUMC hospital pharmacy to facilitate the design of new medicines. The main goal is to support the development of innovative medicines from the academy and conducting scientific research for that purpose. A few research projects will be discussed.

The 2nd example will present pharmacy practice research conducted at the Pharmacy Dpt. of the University Hospitals Leuven, Belgium, which is affiliated to the Department of Pharmaceutical and Pharmacological Sciences of the University of Leuven. Thanks to this affiliation, relevant pharmacy practice research, predominantly conducted in the domain of clinical pharmacy services but also in other domains, such as compounding is carried out by hospital pharmacists with help and support by Master students. During the past years, the results of many pharmacy practice research projects were translated into scientific, international, peer-reviewed publications.

Relevant examples will be discussed to illustrate the trajectory from setting-up and outlining the project up to implementation and publication of the results.

LEARNING OBJECTIVES After the session, participants should be able to:

• Identify reasons to be published and barriers to being published • Define pharmacy practice research in the arena of research in healthcare, key opportunities and challenges in pharmacy practice research • Describe the set-up and outline of a research project up to implementation and publication of the results.

74

KEYWORDS

Research, evaluative research, knowledge transfer, pharmacy practice.

Scientific Programme

EDUCATIONAL NEED ADDRESSED

University pharmacy curriculum prepares future pharmacists for pharmacy practice in community and hospital pharmacy but very little for pharmacists’ participation in pharmacy practice research. With these presentations, participants will be able to better understand why it’s important to publish and what pharmacy practice research is and how they can put themselves into action to contribute to the evaluation of professional practice.

eahpofficial

eahpofficial W elcome to the 26 th EAHP Congres Vienna, Austria! s in Celebrating with us the 50th EAHP Anniversary!!”. #EAHP2022 #H PCARE4U

Visit EAHP at booth 67 and impress your friends with the only one “real” social picture!

75

ALBIOX TAILORED STERILE SOLUTIONS High quality consumables for sterile cleanrooms and medical use.

Tailor-made sterile cleanroom products.

Component packing, assembling, bagging services and pouch sealing.

Sterilization services.

https://albiox.com | +358 400 241 990 | Info@albiox.com

How to work smarter not harder ACPE UAN: 0475-0000-22-015-L04-P – A knowledge-based activity Sessions:

Wednesday, 23 March 2022, from 17.15 to 18.45 Thursday, 24 March 2022, from 15.00 to 16.30

Room:

Hall K2

Facilitator:

Branislava Miljković

Presenters: André Rieutord, Pascal Bonnabry No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 6 - Education and Research: Statements 6.1, 6.2, 6.3

Scientific Programme

SEMINAR ER2

ABSTRACT Efficiency and effectiveness are both commonly used terms in a workflow. Efficiency refers to doing things in a right manner and focuses on the process and getting the maximum output with minimum outsources. Therefore, the efficacy increases productivity and saves both time and money.

On the other hand, effectiveness refers to doing the right things and focuses on the desired results. Therefore, the effectiveness should have a priority, since efficiency without effectiveness is a waste of resources.

Technological advances and increasing demands in healthcare create challenges in ensuring adequate education and training regarding the needs for achieving effectiveness and efficacy in the health system.

Various strategies have been developed to improve the efficacy and effectiveness of healthcare workflow and the Lean thinking concept, being one of them, encourages hospital pharmacists to think about complete healthcare process rather than a series of disconnected steps. Since the early times where Lean thinking was presented as the new “magic tool” for the healthcare managers, many health settings have experienced this approach. Although the first steps are often exciting by the implementation of the first actions, the acculturation of an entire pharmacy team is rather a challenge.

This seminar with two European pharmacists who developed this approach for about a decade, aims to present the keys to success in introducing and disseminating lean from operators to managers.

Recognizing the importance of training in Lean thinking concept is a critical component for making effective and efficient healthcare workflow.

LEARNING OBJECTIVES After the session, participants should be able to:

• Understand the difference in efficiency and effectiveness in workflow • Understand the principles and tools in the Lean concept.

EDUCATIONAL NEED ADDRESSED Achieving better efficiency and effectiveness in a workflow of healthcare requires education and training of hospital pharmacists.

KEYWORDS

Efficiency, effectiveness, Lean concept, training.

77

Visit us on booth

46

WORKSHOP 1 Smooth operator – How to manage difficult situations ACPE UAN: 0475-0000-22-021-L04-P – An application-based activity Session:

Wednesday, 23 March 2022, from 17.15 to 18.45

Room:

Rooms -2.32 & -2.33

Facilitator:

Lene Juel Kjeldsen

Presenter:

Matthias Beckmann*

* Conflict of interest declared. Please reference speaker’s biographies.

Scientific Programme

WORKSHOPS

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.1, 1.3, 1.5

ABSTRACT

The media are continuously covering stories of patients, who do not seem to have received optimal treatment during their hospital admission. Working as a hospital pharmacist, the overarching aim is to provide the best possible conditions for optimal medication treatment, concurrently understanding that mistakes may result in patient harm and even mortality. The daily work may be unpredictable and influenced by factors beyond the control of the hospital pharmacist. Hence, delivering high quality services under time pressure and budget constrains in an unpredictable environment can at times cause stressful situations.

Difficult situations can appear in many settings and they often involve other individuals. It may be in the meeting with scared, stressed and dissatisfied patients, who might experience a traumatic situation being admitted to hospital. Other examples include misunderstandings and lacking insight in the tasks and workflow of colleagues, ward staff, external collaborators or managers. Finally, difficult situations may also appear in stressful working environments and disruptive situations.

In the workshop, examples of difficult situations will be discussed and possible beneficial ways of managing and preventing them will be presented.

LEARNING OBJECTIVES

After the workshop, participants should be able to: • List potential predictors of difficult situations • Discuss management of difficult situations • Analyse prevention of difficult situations.

EDUCATIONAL NEED ADDRESSED

To be able to provide the best possible hospital pharmacy care, it is of great importance that hospital pharmacists understand how to deal with stressful situations caused by e.g. human factors such as suboptimal communication, mistakes, dealing with stressed out patients etc.

KEYWORDS

Management, difficult situations, patient safety, working environment.

79

Publishing practical and innovative hospital pharmacy research As the only official journal of the European Association of Hospital Pharmacists, the European Journal of Hospital Pharmacy advances the science, practice and profession of hospital pharmacy and aims to improve the standard of patient care in hospitals and related institutions worldwide.

Why read?

• Access high-quality, evidence-based research with practical application • View the full picture with articles on clinical practice, professional development and key issues affecting hospital pharmacy • Save time choosing the best content with our Editor’s Choices and Top 10 articles • Keep up to date with the latest hospital pharmacy developments in Europe and beyond

Join our online communities: @EJHP_BMJ /BMJPharmacy

Learn more today ejhp.bmj.com

Recognising the prescribing cascade ACPE UAN: 0475-0000-22-022-L04-P – An application-based activity Session:

Thursday, 24 March 2022, from 12.00 to 13.30

Room:

Rooms -2.32 & -2.33

Facilitator:

Virginia Silvari

Presenters: Stephen Byrne, Kieran Dalton No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.2 Section 5 - Patient Safety and Quality Assurance: Statement 5.1

Scientific Programme

WORKSHOP 2

ABSTRACT

Incremental prescribing, also known as a prescribing cascade, is the result of a prescriber misinterpreting an Adverse Drug Event (ADE) as a new medical condition. The physician being unaware that the patient’s new symptom is of iatrogenic origin prescribes additional medications to the patient. The resulting increase in the number of medications can cause even more side effects and trigger further propagation of the prescribing cascade. Prescribing cascades can happen to any patient, but they are more likely to happen in geriatric patients due to the higher number of medications they are on and the associated comorbidities. The identification and interruption of the prescribing cascade is essential to ensure medication safety in older people.

Although prescribing cascades are usually considered problematic and should be prevented or terminated, in certain clinical situations, they are considered therapeutically appropriate. On the basis of best available evidence, the prescribing cascades can be considered appropriate and intentional when the therapeutic benefit of the drug, that caused the ADE, outweigh the risk for the patient of having a new medication initiated to counteract the ADE. It is important for the hospital pharmacist to be able to recognize prescribing cascades and, if considered problematic, to advise the prescriber on medications changes needed to terminate and prevent future problematic incremental prescribing.

In this interactive workshop, through case studies, the HP will acquire the skills needed to identify prescribing cascades and the skills to manage such situations which could be either termination or acceptance of the prescribing cascade.

LEARNING OBJECTIVES

• After the workshop, participants should be able to: • Recognize prescribing cascades and distinguish between problematic and therapeutically appropriate cascades • Assess how the prevention and termination of problematic prescribing cascades enhances patient safety, with particular focus on elderly patients • Evaluate how patients can benefit from the acceptance of appropriate prescribing cascades.

EDUCATIONAL NEED ADDRESSED

This workshop addresses the skills needed by hospital pharmacists to recognize and manage prescribing cascade.

KEYWORDS

Adverse drug events, prescribing cascades, geriatrics.

81

Love Your Pharmacist Awards 2022

Awards Ceremony

Join us in celebrating the exceptional accomplishments of hospital pharmacists across Europe.

23rd March, 2022 7:15pm – 7:45pm Stand 51 in the Exhibition Area Our global online ordering platform helps healthcare professionals source unlicensed or unavailable medicines.

Hard to find medicines, delivered. www.clinigendirect.com

Towards a more patient centered approach to medication review ACPE UAN: 0475-0000-22-023-L04-P – An application-based activity Sessions:

Wednesday, 23 March 2022, from 14.45 to 16.15 Thursday, 24 March 2022, from 09.00 to 10.30

Room:

Rooms -2.32 & -2.33

Facilitator:

Kornelia Chrapkova

Presenter:

Nina Barnett

No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 4 - Clinical Pharmacy Services: Statements 4.6, 4.8

Scientific Programme

WORKSHOP 3

ABSTRACT

Medication review is defined as a structured evaluation of patient´s medicines with the aim of optimising medicine use, minimising the number of medication related problems, reducing waste and improving health outcomes.

Appropriate medicine use optimisation requires an individualised and patient-centered approach which takes patient´s preferences and experiences into account, and actively includes patients into decision making. Involving patients in deciding about their own therapy can lead to more positive outcomes, including better adherence to therapeutic regimen, increased medication safety, more educated lifestyle choices and better-informed persons.

Collaborative care of clinicians and patients offers an optimal combination of an evidence-based and patientcentered approach. What is important to the clinician does not necessarily mean it will be important to the patient and vice versa. Many tools such as deprescribing, STOP/START, Medstopper, Beers criteria etc… can be applied in the process of patient-centered medicine optimisation.

Patient-centered medication review offers a promising improvement in healthcare and implementation into daily clinical practice should be considered including pharmacists´ consultations.

LEARNING OBJECTIVES

After the workshop, participants should be able to:

• Define the benefits of patient-centered medication review • Identify the essential components for patient-centered medication review process • List tools which can be applied in the process of medicine optimisation.

EDUCATIONAL NEED ADDRESSED

Hospital pharmacists own an expertise in medication management and daily contact with patients place them in a valuable position in providing pharmaceutical care for patients. It´s important that patient-centered medication review is also adopted by pharmacists to maximize the benefits of pharmaceutical care.

KEYWORDS

Patient-centered, medication review, patient´s needs, shared decision making, tools pharmaceutical care, benefits.

83

Scientific Programme

WORKSHOP 4 Hospital pharmacist: learn to think global and act local ACPE UAN: 0475-0000-22-024-L04-P – An application-based activity Session:

Thursday, 24 March 2022, from 15.00 to 16.30

Room:

Rooms -2.32 & -2.33

Facilitator:

Despoina Makridaki

Presenter:

Ciara Kirke

No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.3, 1.7 Section 2 - Selection, Procurement and Distribution: Statements 2.1, 2.4, 2.5, 2.6 Section 4 - Clinical Pharmacy Services: Statements 4.3, 4.5 Section 5 - Patient Safety and Quality Assurance: Statements 5.3, 5.7

ABSTRACT Hospital pharmacists support health systems in multiple aspects from a clinical, scientific, leadership and managerial perspective. This role requires excellent communication skills, special experience based on hospital practice and advanced managerial competency.

“Think global, act local” is a concept originally used to urge people to consider the global environmental conditions and take action within their own communities. Nowadays, it expresses the broader message of considering the health of the entire planet and to take action locally.

This workshop equips hospital pharmacists to consider their alignment with global priorities including the UN Sustainable Development Goals, WHO Medication Without Harm Global Patient Safety Challenge and the FIP/WHO Good Pharmacy Practice guidance.

“Global thinking” and “local acting” can help hospital pharmacists deliver effective and efficient services, aligned with global policy and contributing to global knowledge and action against shared challenges. “Global Health” is the key-point for the future prosperity of mankind. The Covid-19 pandemic has given many examples of the concept “Think global, act local” and how its implementation can save human and essential material resources. In a parallel way, hospital pharmacists adapt global Good Pharmacy Practices (GPP), to their everyday practice.

This workshop is a training session to help pharmacists consider the global challenges affecting us all, drawing on UN, FIP and WHO resources. The workshop will use examples where hospital pharmacists and teams have implemented initiatives in line with these global priorities. Workshop participants will share their experiences implementing initiatives where they have responded locally to a global challenge. Crisis management also comprises an important application of the “think global, act local” concept. We will also discuss how pharmacists can embed initiatives into standard work and accreditation, e.g. by integrating Good Pharmacy Practices into Standard Operating Procedures (SOPs) and to the internal or external accreditation programmes of their hospitals, to improve effectiveness of hospital pharmacy services and patient outcomes.

84

• Categorize most critical procedures in hospital pharmacy practice and prepare simple yet detailed algorithms of action in crisis • Categorise the global priorities where hospital pharmacy practice can have an impact • Detect GPPs most relevant to their everyday practice • Design and perform the transfer of a global GPP to their hospital pharmacy • Collaborate with other healthcare professionals to address global priorities locally, in a common work environment, as members of multi-disciplinary team.

EDUCATIONAL NEED ADDRESSED

All hospital pharmacists and managers, especially those employed or interested in quality improvement and quality assurance.

Scientific Programme

LEARNING OBJECTIVES

After the workshop, participants should be able to:

KEYWORDS

Global priorities, crisis management, local adaptation, good pharmacy practice, SOP, accreditation, quality improvement.

85

Discover what EAHP has achieved over

EAHP th y r a s r e v i n n A 50 History Walk

i n, Hall X2 bittio Exhib

P booth

H right opposite the EA

From data to decision – Improve the use of EBM in clinical practice ACPE UAN: 0475-0000-22-025-L04-P – An application-based activity Session:

Friday, 25 March 2022, from 09.00 to 10.30

Room:

Rooms -2.32 & -2.33

Facilitator:

Ulrika Gillespie

Presenters: Matts Balgård, Fiona Nagele No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.4, 4.6 Section 6 - Education and Research: Statements 6.2, 6.3

Scientific Programme

WORKSHOP 5

ABSTRACT

Clinical pharmacists are increasingly involved in decision making around patients’ pharmacotherapy and need to be able to find and use the most up-to-date evidence and guidelines when providing advice and recommendations.

Many clinical pharmacists are in the habit of relying on “old” knowledge and do what feels safe. There is often limited time for continuous education within pharmacotherapy, plus the pharmaceutical industry may work to influence decisions and introduce biased knowledge. They also need to be able to quality-assure the evidence and communicate their findings to physicians and patients in an appropriate manner. They also need to be aware of what patient data is necessary to have in order to be able to give recommendations in each situation; (medical history, vitals, lab data, patient preferences, geriatric assessment/frailty index, and abilities of the patient) and how to achieve this. Continuous education for clinical pharmacists, it is important to keep updated and not only rely on old text book knowledge. This workshop will be a training session that can be used in the participants’ home settings. We will be using authentic patient cases that include therapeutic areas with a lot of new development and knowledge so that the participants need to consult the literature and guidelines to ensure their recommendations are correct. In the workshop there will be practical advice on how to achieve this. It will also be discussed what patient data and factors that need to be available and considered. Then participants will practice how to communicate the evidence and the different treatment options with the physician and the patient. What are the risks and benefits? How does it correspond to the patient’s preferences and abilities?

LEARNING OBJECTIVES

After the workshop, participants should be able to:

• Understand the importance of using the most up-to-date evidence and guidelines when providing advice and recommendations • Demonstrate how EBM can be used in clinical practice • Demonstrate skills in communicating EBM to health-care professionals and patients.

EDUCATIONAL NEED ADDRESSED

This workshop addresses the skills needed by hospital pharmacists able to find, use and communicate the most up-to-date evidence and guidelines when providing advice and recommendations in patient care.

KEYWORDS

EBM, Continuous education, clinical pharmacy, decision making.

87

Unit Dose Re-packaging and Hospital Automation Present in 750+ hospitals in 21 countries.

Robotic unit dose preserving primary package. Automatically cuts the blisterpack.

Print barcodes, alerts and advices and also a color band on the packaging.

See details

Automatic labeling of ampoules and vials.

It loads the ampoules, prints and inserts a flag, identifying the medicine.

EV

T O TA L

Opuspac

R. Humberto Pela, 68 Louveira, São Paulo, Brazil

Opuspac BR035212-001

H E A L T H

Texas, USA

Hospital Automation

SaoPaulo,Brazil

Barcelona,Spain

www.opuspac.com

info@opuspac.com

See details

INTERACTIVE SESSION 1 Work it out – Your idea to save health systems ACPE UAN: 0475-0000-22-016-L04-P – A knowledge-based activity Session:

Friday, 25 March 2022, from 09.00 to 10.30

Room:

Hall K1

Facilitator:

Torsten Hoppe-Tichy

Presenters: Roberto Frontini, Torsten-Hoppe Tichy No conflict of interest declared. Please reference speakers’ biographies.

Scientific Programme

INTERACTIVE SESSIONS

LINKED TO EAHP STATEMENTS

Section 1 - Introductory Statements and Governance: Statements 1.3, 1.5 Section 2 - Selection, Procurement and Distribution: Statement 2.1

ABSTRACT

When we see new drugs or new therapeutic approaches reach the market we see them coming with extremely high costs. Some years ago, when the monoclonal antibodies were first used in therapy we had an immense increase in our budget. Today new advanced therapy medicinal products have much higher costs and sometimes give us the feeling that even in richer countries health systems will not survive the next decades or even years because they will implode regarding lack of budget.

Different health systems react in different ways. The “Bismarck” approach tries to react with individual single patient-based decisions, in contrast to the “Beveridge” approach where decisions were made on the basis of patient groups. In both cases we also see other measures to cope with the situation of high-cost medication and therapies. At the end of the day all of the measures did not succeed. Health systems are still going to bleed out from a financial perspective.

In the workshop, the audience should act as stakeholders. Come out with your ideas to rescue your health system.

Every idea will be a good one. It is just brainstorming: Work it out!

LEARNING OBJECTIVES

After the interactive session, participants should be able to:

• List some measures to be used to cope with the problem of high price medications • List the approaches of different health systems in Europe to secure the given budget • Discuss political challenges to finance the system by getting new and innovative therapies being used.

EDUCATIONAL NEED ADDRESSED

Pharmacists should have a deeper knowledge in pharmacoeconomics and different health systems. They should understand why different structures of health systems will have to invent different measures to deal with financial challenges. Pharmacists should have own ideas to cope with the budgetary problems of health systems.

KEYWORDS

Health system, budget, finances, high price medications

89

Scientific Programme

INTERACTIVE SESSION 2 Compounding for paediatrics – A survival guide through GMP ACPE UAN: 0475-0000-22-017-L07-P – A knowledge-based activity Sessions:

Thursday, 24 March 2022, from 12.00 to 13.30 Friday, 25 March 2022, from 09.00 to 10.30

Rooms:

Thursday, 24 March 2022: Hall G2 Friday, 25 March 2022: Hall G1

Facilitator:

Armando Alcobia

Presenters: Catherine Tuleu*, Filipa Cosme *Conflicts of interest declared. Please reference speakers’ biographies

LINKED TO EAHP STATEMENTS

Section 3 - Production and Compounding: Statements 3.1, 3.2, 3.3, 3.4, 3.5 Section 4 - Clinical Pharmacy Services: Statements 4.4, 4.2, 4.3, 4.6, 4.7, 4.8 Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.3, 5.9 Section 6 - Education and Research: Statement 6.4

ABSTRACT Paediatric patients are not mini-adults. This statement, although so often heard, is normally not fully explored.

Why are children so different? Weight, height, gastric emptying time, gastric pH, distribution volume, hepatic metabolism, renal clearance, and other features contribute to different needs comparing to adults. And those needs require paediatric formulations, with different doses, different pharmaceutical forms, suitable palatability and so on.

All paediatric pharmacists face the problem of not having the medicine in need, at the required dose, or on the proper pharmaceutical form. So, compounding is frequently mandatory.

In addition, there are substantial differences between paediatric formulations available in each country, which make this task even harder. Therefore, in this seminar, we will deliver a “survival guide” to recognize how to adapt the medicines we need to administrate to our patients without compromising its safety and effectiveness.

In fact, we intend to answer the following questions:

1. Do I have to compound this medicine? Is there another option on the market?

2. Do I have what it takes? - go through the GMP 3. Is there any other hospital or health centre doing the same thing? - create your network. Ask a partner.

4. Use suitable literature - we will review some of the platforms that can be used as well as books, articles, authors and so on.

5. Which is the best pharmaceutical form for my patient considering its age? - we will discuss the best options for paediatric patients.

6. What about the excipients - which to avoid?

7. Expiration date - how do I know?

8. Batch release - quality control: packaging and labelling will be discussed 9. After administration, how to evaluate the clinical efficacy? - ask the child, ask the parents, ask the physician, ask the nurse. Make sure your patient is happy.

Finally, some clinical examples of the daily practice will be discussed.

90

• Understand the need to adapt drugs to paediatric population • Understand the need to preserve the medicine´s efficacy with safety compounding • Recognize GMP compliance with the need to address concrete issues in clinical practice.

EDUCATIONAL NEED ADDRESSED

All hospital pharmacists contact with the necessity to use compounded drugs in their daily practice. Therefore, this synergy will address the need to use a safety compound technique, suitable to respond to our paediatric patients’ needs.

KEYWORDS

Paediatrics, compounded drugs, GMP, safety, therapeutic effectiveness.

Scientific Programme

LEARNING OBJECTIVES

After the interactive session, participants should be able to:

26th Congress of the EAHP 7

The EAHP

Wednesday 23 March 2022

Daily dose

Information that makes you feel good!

STUDENTS

Shaping the future of the hospital phar mac

P

harmacy students are vital for the future of the profession. Consequently, EAHP is closely interacting with students and young professionals and their representation through the European Pharmaceutica l Students’ Association (EPSA). The partnership between EAHP and EPSA exists for quite some time and has further manifested itself in the connection of professionals with future hospital pharmacists through the EAHP-EPSA Internship Platform and the fostering of research activities by students with the help of the EAHP-EPSA Students Science Award.

EAHP-EPSA STUDENTS SCIENCE AWARD

PRESIDENT’S NOTE

The EAHP-EPSA Students Science Award was created to encourage students to conduct research linked to hospital and clinical pharmacy. The winner of the award is not only provided with the opportunity to explore the different facets of the hospital pharmacy profession through conducting research but she/he also has the chance to interact with professionals from around the globe when attending the EAHP’s annual congress. So far, six students received this award.

To offer more guidance, the structure of the EAHP-EPSA Students Science Award was slightly adjusted to include a

Welcome message

D

ear Friends of European Hospital Pharmacy. It is with great pleasure and with humbling honour that I welcome you all in Vienna, for the 26th EAHP Congress.

webinar on: “How to write an abstract?”. In addition, EAHP’s Board members responsible for student affairs agreed to give feedback to students throughout the drafting process of their submissions. The additional support was very much welcomed by students and many engaged in the support possibilities for the 2022 edition of the award.

Testimonials of past participants and winners show how much the award engagement has boosted their research skills and their curiosity about the hospital pharmacy profession. If you want to follow in the footsteps of this year’s winner – who will be announced on Friday during the closing ceremony – you should regularly check EAHP’s website and social media accounts for the announcemen t of the next edition of the EAHP-EPSA Students Science Award 2023.

EAHP-EPSA INTERNSHIP PLATFORM For the past 10 years, the EAHP-EPSA Internship Platform has matched students interested in gathering experience in a hospital pharmacy with hospitals willing to share their knowledge. Despite the difficulties during the pandemic, the Platform has continued to provide students with the opportunity to intern in a hospital pharmacy in 2021.

y profession

Those that managed to go abroad were very thankful for the opportunity to expand their clinical knowledge and to improve their language skills. Last year’s interns were for instance able to shadow their supervisors in all hospital pharmacy areas, helped with providing clinical pharmacy services on the ward, participated in the production of sterile and non-sterile medicines, learned about quality control of pharmaceutical raw materials and practised medication review.

Due to the high interest of students, the EAHP-EPSA Internship Platform constantly feels the need to increase the number of hospitals and countries available to offer this experience to as many future pharmacists as possible.

If you are interested in hosting students and young professionals from all across Europe at your pharmacy, don’t hesitate to contact intern@eahp.eu. The EAHP-EPSA Internship Platform is always looking for new hospitals!

Stephanie Kohl – EAHP Policy & Advocacy Officer

A Congress scientific programme that will help ...win a free registration hospital pharmacists face the new challenges

hand-in-hand in order to provide high-tech medicine and technologies through the irreplaceable personal touch of th pharmaceutical care.

EAHP’s 50 anniversary crossword

for Lisbon 2023!

This Congress will cover the aspects of professional and that healthcare systems all Do you wantmethodological challenges to win a FREE REGISTRAT ION for Europe must face in order to find a solution in order to over Congress, theScientific next EAHP The whole EAHP team, the held from 22 to 24 evidence-based decisions and evidence-informed of- employ Marchto2023, Committee and the Board of Directors are delighted in Lisbon? when available retimelines within reasonable fer you this in-person event for which all our efforts have policies Additionally, this uncertain. often and It’s easy! sources You only festive haveare to limited complete the crossword (don’t been employed to make this an extraordinary and transpired through multiple dimenforget to includeuncertainty, your name)having opportunity for all participants. and leave it at the EAHP booth and healthcare prosystems sions of our society healthcare (#67) in the exhibition area.

The winner will levels of disbe announced unprecedented times fessionals, is confronted with We know all too well how these unparalleled at the closing ceremony, on Friday Patient 11.30 toeducation 13.00 (Halland disbelief.

D). pharmaceutical th have turned our world upside down, but our profession trust and care have never been in such dire need and yet, ironically, neverproblems Dohave you have has clearly prevailed and hospital pharmacists finding thedeliver. answers?

Find some tips calls for issue This rather complex been so hard to in order ceased to proactively adapt to a changing world at the EAHPtoHistory Walk in the exhibition area… from hospital pharmacists. and input a deep involvement continuously serve patients.

Still need some answers? you. worry, here is another tip: This meansDon’t walk around the exhibition area, talk with exhibitors and I firmly believe that Spring this year will not only be the that the Congress’ scientific programme will sure answers am and askLife applauds for someI tips for the crossword! season of awakening, a period when nature kindly symbol help all of us face these challenges and enable us to find with colourful diversity, but will also be a perfect Not all exhibitors have the answers resistance, ensurfor tackling to theantimicrobial crossword, so for all of us. As a symbol, this gathering provides a perfect valid answers management don’t give the continuity ingdon’t find themofoncare, yourpromoting first try. quality setting for cherishing the renewed possibility for usuptoif you and advancing our clinical presence, meet in-person again, as well as allow us to commemorate in compounding other pressing issues. the losses endured during the pandemic. This new dawn among will bring about a different era for the hospital pharmacy Furthermore, your time with us in Vienna is also going NAME:nature of profession, as we embrace the ever-changing Down ideal opportunity to meet your fellow colleagues, Across the world around us and build upon the vast scientific and to be an pro-which country was the first association to join the 2. From experiences and knowledge, and find new EAHP 1. Where did the first EAHP foundation seminar take place? practical knowledge gained, as well as the increased visi- exchange international Associate Membership? to foster fessional connections and friends. orderNAME: 6. The First EAHP Congress took place in… bility of our professional activities. All this inLAST 3. At the foundation of the association Philip Jacobs was the EAHP… X2 Hall the changing roles of our profession. bition Exhibition, 9.

The 35th member country to join the EAHP was…

4. First name of the first EAHP president Welcome to the 26th EAHP Congress! (#67) Name of the current EAHP president right opposite the EAHP booth 10.

Welcome to Vienna!

5. City where the General Assembly took place in 1973 I am certain that this shifting landscape has the potential 11. Last name of the EAHP president when 7. Name of the current EAHP Vice-President to fundamentally change the way how pharmacy services the Statement Implementation project started Dr. András Süle – EAHP President 8. Wim Moeys was the coordinator of the first EAHP… are delivered. Novel therapeutic areas, combined with our emerging competencies within frontline patient care, go

Discover what EAHPP has achieved over

EAHP 50 Anniversary History Walk

SOCIAL MEDIA Engage in the social media debate using the hashtag #EAHP2022

Stay updated with our Daily Dose magazine.

To be released during the congress on Wednesday 23 and Thursday 24 91

Riedl Phasys.

Wireless. Fast. Flexible.

Errors reduction and costs optimization with your new automated pharmacy.

Forget about your old shelves and choose the automated warehouse RIEDL Phasys.

RIEDL Phasys will make it possible to have a precise and fast management of your hospital pharmacy.

RIEDL Phasys is equipped with a wireless bidirectional gripping arm which moves at a speed of 5 m/sec. Each gripper can dispense more than 1000 packs/h, thus significantly reducing the processing of orders delivery.

Packs, including round items, are handled on both sides of the robot with no need for the gripper to rotate, thus avoiding the risk of packs falling down.

www.gpi.it

The RIEDL OCR innovative system automatically reads expiry dates and batch numbers while loading.

Thanks to its sophisticated simplicity, the maintenance of RIEDL Phasys won’t interfere with the pharmacy working process.

RIEDL Phasys is the automated dispensing system that can be designed according to the pharmacy functional needs.

Given the extremely low energy consumption, RIEDL Phasys is environment friendly and a high continuity is ensured in case of electricity breakdown.

Thanks to its modular design and wide range of delivery systems, RIEDL Phasys can have an unlimited length and perfectly fit in the available storage space, even on a different floor or room from the pharmacy.

Moreover, it can keep up with the required capacity and loading/unloading rates as well as with the number of workstations.

RIEDL Phasys, Sophisticated Simplicity in Automation.

Contemporary ethical challenges in hospital pharmacy practice ACPE UAN: 0475-0000-22-019-L04-P – An application-based activity.

Session:

Wednesday, 23 March 2022, from 14.45 to 16.45

Room:

Room -2.31

Facilitator:

Branislava Miljković

Presenter:

Nenad Miljković

No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 4 - Clinical Pharmacy Services: Statements 4.1, 4.6, 4.7

Scientific Programme

STUDENT PROGRAMME

Section 5 - Patient Safety and Quality Assurance: Statements 5.1, 5.5, 5.6, 5.9

ABSTRACT

Ethical issues arise in everyday practice of a hospital pharmacist. Fundamental ethical principles, such as respect of the patient’s autonomy, integrity, privacy and confidentiality reflect the right of a patient to accept or refuse treatment and responsibility of a hospital pharmacist as a healthcare professional to act in the patient’s best interests and do no harm while enacting ethical principles.

Optimal and rational use of medicines as part of patient-centred care relies on ethically driven decisions taken by a hospital pharmacist. Hospital pharmacists also play a vital role in providing to their patients with an insight into risks and benefits of participating in a clinical trial involving medicines, where a clear patient’s or career’s understanding is of essence when providing consent. Moreover, formulary management and conservative prescribing make decision-making even more complex in times of limited healthcare-associated resources and frequent medicine shortages. At the same time, a hospital pharmacist needs to protect the patient’s integrity and preferences as ethical considerations at an individual level and allow for population-level ethical aspects to be considered, which yields conflicts among healthcare providers, funding bodies and patients. Therefore, fear from rationing and limited access to medicines place an additional burden on hospital pharmacists, who needs to provide best care in times of shortages and overcome ethical challenges.

Mitigating medicine shortages within multidisciplinary teams, in accordance with ethical principles, provides foundation on how to properly substitute a medicine and to whom to provide the alternative first. Therefore, it is necessary to have a process in place defining an alternative’s approval and ethical considerations for a substitute’s allocation that has already been established prior to a shortage occurring.

LEARNING OBJECTIVES

After the student programme, participants should be able to:

• Differentiate individual and population-level ethical aspects in delivering pharmaceutical care • Describe ethical considerations in pharmaceutical decision-making process • Describe ethical considerations in managing medicine shortages.

EDUCATIONAL NEED ADDRESSED

Hospital pharmacists provide their services in complex environment where ethical principles are challenged by scarcity of resources and patient’s and healthcare professional preferences. In order to overcome these challenges hospital pharmacists need to understand how to balance between individual and population-level ethical aspects and at the same time provide best pharmaceutical care to their patients.

KEYWORDS

Ethical principles, pharmacy practice, decision making, medicine shortages.

93

Visit Grifols Booth during the EAHP 2022.

Visit grifols-inclusiv.com to learn more.

AT-INCP-2200001

Product registration and availability vary by country.

For more information, please contact your Grifols’ representative.

Advances in heart failure pharmacotherapy ACPE UAN: 0475-0000-22-018-L01-P – A knowledge-based activity Sessions:

Wednesday, 23 March 2022, from 14.45 to 16.15 Thursday, 24 March 2022, from 09.00 to 10.30

Room:

Hall G2

Facilitator:

Virginia Silvari

Presenters: Paul Forsyth*, Mark Ledwidge* *Conflicts of interest declared. Please reference speakers’ biographies

LINKED TO EAHP STATEMENTS

Scientific Programme

PHARMACOTHERAPY SESSION

Section 4 - Clinical Pharmacy Services: Statement 1

ABSTRACT

Heart failure (HF) is a complex clinical syndrome where the efficiency of the heart is impaired and it is unable to meet the demands of the body. HF is a major healthcare concern as it is associated with high mortality, morbidity, and substantial economic burden to the health systems.

In patients with HF, the treatment goals are to reduce mortality, improve clinical status and quality of life (QoL), and prevent hospital admissions. HF treatments depend on the type of HF the patient has, which, as defined by the 2021 European Society of Cardiology (ESC) guidelines, can be: HF with reduced ejection fraction (HFrEF) if EF<40%, mildly reduced (HFmrEF) if EF 41-49% and preserved (HFpEF) if EF >50%.

Pharmacotherapy for HF management continues to advance due to the development in recent years of new drugs such as sacubitril-valsartan, dapagliflozin and empagliflozin. Sacubitril-valsartan is the first-in-class angiotensin receptor neprilysin inhibitor which has demonstrated a significant mortality benefit in HFrEF patients. Dapagliflozin or emplagliflozin are sodium-glucose cotransporter 2 inhibitors (SGLT2s) originally developed as antihyperglycemic agents, but which have proved to have beneficial effects in HF. ARNI or Angiotensin-Converting enzyme Inhibitors (ACEi) (or angiotensin-receptor blockers (ARB) in ACEi-intolerant patients), β- blockers (BB), mineralocorticoid receptor antagonists (MRAs) and SGLT2s combine to form the Guideline-Directed Medical Therapy (GDMT) for HF. GDMT has proven to help in reducing hospitalization and mortality of HFrEF patients and the same treatment can be considered in patients with HFmrEF. No therapy has convincingly shown to give a mortality benefit in patients with HFpEF. This seminar will focus on the pharmacological options currently available for the treatment of HF.

LEARNING OBJECTIVES

After the session, participants should be able to:

• Recognise pharmacological treatments for HF • Explain the mechanism of action of new medications used in HF • Discuss the importance of optimal use of GDMT for HF.

EDUCATIONAL NEED ADDRESSED

This seminar addresses the advances in pharmacotherapy made in recent years to reduce mortality, improve clinical status and QoL, and prevent hospital admissions of patients with HF.

KEYWORDS

Heart failure, medication therapy management, cardiovascular disease.

95

Hazardous Medicinal Products: the European classification landscape ACPE UAN: 0475-0000-22-020-L03-P – An knowledge-based activity.

Session:

Wednesday, 23 March 2022, from 17.15 to 18.45

Room:

Room -2.31

Facilitator:

Ana Valladolid Walsh

Presenters: Joan Peppard, Falko Schüllner No conflict of interest declared. Please reference speakers’ biographies.

LINKED TO EAHP STATEMENTS

Section 3 – Production and Compounding: Statements 3.3, 3.4, 3.5, 3.6

Scientific Programme

SIG LAUNCH

Section 5 – Patient Safety and Quality Assurance: Statements 5.6, 5.9

ABSTRACT

Hospital pharmacists and members of the multidisciplinary team – such as nurses, pharmacy technicians and others – are dealing with hazardous medicinal products in their daily work. Their safe handling is of uttermost importance for the safety of healthcare professionals and patients treated with these medicines. Their classification plays an essential role in determining suitable handling procedures. However, unlike the United States, Europe does not have one single body similar to the National Institute for Occupational Safety and Health (NIOSH) that addresses all questions linked to the classification of hazardous medicinal products.

To better understand the classification landscape for hazardous medicinal products in Europe, the European Association of Hospital Pharmacists (EAHP) has established a Special Interest Group (SIG). EAHP’s SIG on Hazardous Medicinal Products discussed and gathered information on the current status of hazardous medicinal product classification in European countries as well as their similarities and differences, put together a definition of the term ‘hazardous medicinal product’ for Europe and reflected on the protection of healthcare professionals and patients from exposure to hazardous medicinal products. Specific focus was put on the NIOSH model which is used by many European countries and the Dutch model (Risico instrument Farmaceutische Stoffen (RiFaS) – Pharmaceutical Substances Risk Assessment).

‘Hazardous medicinal products’ were addressed in a wide sense including but not limited to carcinogenic, mutagenic or toxic to reproduction (CMR) drugs, some of the immunomodulators and biological substances. Based on their findings and discussion outcomes the SIG developed recommendations and guidance to support hospital pharmacists and their advocacy work linked to protocols around classification, storage, and handling of potentially hazardous medicinal products. This session will be dedicated to sharing the results of the work carried out by EAHP’s SIG on Hazardous Medicinal Products throughout 2021, including the European-developed classification model recommended by the SIG.

LEARNING OBJECTIVES

After the session, participants should be able to: • Recognise different classification models for hazardous medicinal products identified by the SIG (e.g. NIOSH, the Dutch model), including their strengths and weaknesses • Identify hazardous medicinal products with the help of a proposed European definition and the Europeandeveloped classification model recommended by the SIG • Discuss protocols around the classification, storage, and handling of potentially hazardous medicinal products.

EDUCATIONAL NEED ADDRESSED

The classification of hazardous medicinal products is largely influenced by NIOSH. EAHP’s SIG has closed gaps by identifying classification systems around Europe and creating a European model a definition of the term ‘hazardous medicinal products’ applicable to the European treatment landscape.

KEYWORDS

Hazardous medicinal products, occupational exposure, personnel, pharmaceutical preparations.

97

CUSTOMIZED SOLUTIONS FOR ASEPTIC PROCESS Please come and visit us on our STAND N°2

Applications in Hospital Pharmacy JCE Customized Solutions and Systems with more than 29 years’ experience Several countries have already trusted us: Belgium, Switzerland, Austria, Poland, Italy, China, Vietnam ...

Range of isolators with specific applications in hospital pharmacy : • • • • •

- Bio-decontamination with peracetic acid or hydrogen peroxide

Reconstitution cytotoxic drugs monoclonal antibodies Reconstitution of of cytotoxic drugs or or monoclonal antibodies Preparation parental nutrition Preparation Preparation forms Preparation of of parental nutrition of of drydry forms Weighing and dosing Clinical Clinical trials Weighing and dosing trials Hematology and Immunology Bacteriology Bacteriology and Virology Hematology and Immunology and Virology Secure RTP Transfer Systems Secure RTP Transfer Systems

- Physical and bacteriological validation & system qualification - Large range of accessories and

disposables

Secure Transfer of potentially Infections and related Medical Waste, including Sharp Items and Toxic Waste

• Patented Patented RTP RTP connection connection system system • Secure Secure transfer transfer door door • Introduction Introduction diameter diameter : : • 150 150 mm mm • Made Made outout of of 316 316 L stainless L stainless steel steel or or PVC PVC • Max. Max. airair pressure pressure • allowed allowed > 500 > 500 Pa.Pa. • Suitable Suitable with with all all types types of of isolators isolators

CTR 150 050 ® Waste Container • • • • • • • • •

Rigid HDPE Container Rigid HDPE Container Real Capacity : 55 Real Capacity : 55 L L kGy gamma irradiated 2525 kGy gamma irradiated Suitable incineration Suitable forfor incineration Complies with Complies with thethe standards governing standards governing Transfer potentially thethe Transfer of of potentially Infectious and related Infectious and related Medical Waste, including Sharp Medical Waste, including Sharp Items Items • Complies Complies with X 30-511 / UN with NFNF X 30-511 / UN 3249 / UN 3291 3249 / UN 3291 • Easy Easy use to to use

ZA Bioparc - Rue Michel Renaud - 03270 Hauterive - France Tél. : 33 (0) 470 595 140 - Fax : +33 (0) 470 595 141 contact@jcebiotechnology.com

jcebiotechnology

.com

JCE BIOTECHNOLOGY

www.

JCE Multiway System ® MWS A 150® Transfer Door

Balgård, Matts WORKSHOP 5 - From data to decision - Improve the use of EBM in clinical practice Affiliation:

Uppsala University Hospital, Department of Geriatrics

Country:

Sweden

CURRENT STATUS, POSITION Matts Balgård is currently a senior clinical pharmacist at Uppsala University Hospital. He is also an associated teacher in pharmacotherapy and clinical pharmacy at Uppsala University School of Pharmacy.

EDUCATION Matts Balgård studied pharmacy at Uppsala University and became licensed to practice in 1999. He obtained a MSc in Clinical Pharmacy from Strathclyde University in Glasgow, UK 2007 and he also holds a Swedish post graduate specialization degree in hospital pharmacy.

Speakers’ biographies

SPEAKER’S BIOGRAPHIES

RESEARCH AREA Matts Balgård’s professional areas of interest are geriatrics, teaching, clinical tutoring and professional development.

Conflict of interest: No conflict of interest declared.

Barnett, Nina WORKSHOP 3 – Towards a more patient centered approach to medication review Affiliation:

Tardis Consultants UK Limited / Northwick Park Hospital

Country:

United Kingdom

CURRENT STATUS, POSITION Prof. Dr. Nina Barnett is currently a Consultant Pharmacist based in North West London, UK. She is responsible for supporting pharmacy professionals with care of older people and developing personcentred communication. She is the promotes managing polypharmacy, supporting medicines adherence and deprescribing and shared decision making with the Medicines Use and Safety Team, NHS Specialist Pharmacy Service. Prof Dr. Nina Barnett is a visiting professor at Kingston University, London, UK.

EDUCATION Prof. Dr. Nina Barnett studied Pharmacy at the Kings College, University of London and registered as a pharmacist in 1987. She obtained an MSc in 1998 and, in 2018 she obtained a PhD in pharmacy at Kingston University, London, for her work on developing a person-centred approach to pharmacy practice.

RESEARCH AREA Prof. Dr. Nina Barnett’s current research interests include developing new strategies to embed a personcentred approach, including shared decision making. This supports medication adherence, optimising polypharmacy and safe deprescribing using a health coaching approach in primary and secondary care. She is looking at ways to incorporate professional and personal development into clinical case review, using learning from the certificate in therapeutic counselling skills and studies which she recently completed.

Conflict of interest: No conflict of interest declared.

99

Comprehensive Solutions for Sterile Compounding & IV Infusion

TPN Compounding System

Fluid Dispensing Pump

www.kapsamsaglik.com.tr

IV Chemotherapy Compounding System

KEYNOTE 2 - What people want from their medicines - Making shared decisions Affiliation:

Independent Expert Patient

Country:

United Kingdom

CURRENT STATUS, POSITION Drawing on extensive personal and community experience, Sam Barnett-Cormack is available as an expert patient wherever such input is desired, in research, policy making, professional development, or any other area.

EDUCATION Although both undergraduate and postgraduate degrees suffered interference from his complicated medical life, Sam completed a first degree in Mathematics and Computer Science (Lancaster, 2007), and masters degrees in Advanced Computer Science (Lancaster, 2008) and Educational Research (Lancaster, 2014). He has put skills from these qualifications, and those developed independently, to a wide range of uses, including in service to the wider community of those with long-term health conditions.

Scientific Programme

Barnett-Cormack, Sam

RESEARCH AREA As an expert patient, Sam has provided a patient voice at professional development events, conferences, to research steering groups, and worked as a member of England’s National Institute of Health and Care Excellent Guideline Development Group regarding adults with multiple health conditions. Sam’s particular areas of expertise include mental health, sleep disorders, and the impact of health conditions and treatment on daily life.

Conflict of interest: No conflict of interest declared.

Beckmann, Matthias WORKSHOP 1 - Smooth operator - How to manage difficult situations Affiliation:

Sprachraum eG

Country:

Germany

CURRENT STATUS, POSITION Since 2008 Matthias Beckmann has been working for “Sprachraum” as a trainer and systemic coach. In addition to rhetoric, presentation design and trainer training, his topics include in particular communication in challenging situations at work and in everyday life. He conveys these topics in lectures, workshops and trainings to a wide variety of target groups throughout Germany and Switzerland. He has also worked for years as a copywriter and speechwriter for the automotive industry.

EDUCATION Matthias Beckmann studied psycholinguistics/speech science, psychology and education at the LMU Munich from 2003 to 2008. In 2006 he co-founded “Sprachraum - the institute for individual further education and personal development in Munich” with some of his fellow students.

Conflict of interest: Matthias Beckmann is the co-founder and Trainer of Sprachraum eG.

101

Keep Life Flowing PLASMA

BIOPHARMA

LIFE

We extract plasma and ensure quality.

We develop and produce plasma products.

We improve and save lives!

All that Really Matters.

SEMINAR ER2 – How to work smarter not harder Affiliation:

Hôpitaux Universitaires de Genève

Country:

Switzerland

CURRENT STATUS, POSITION Prof. Pascal Bonnabry is head of pharmacy at the Geneva University Hospitals, Switzerland. He is also associate professor at the School of Pharmaceutical Sciences of the University of Geneva.

EDUCATION Prof. Pascal Bonnabry studied at the Geneva university and obtained his pharmacy degree in 1992. He specialised himself in clinical pharmacology and became PhD in 1996. Since 1996, he is active in hospital pharmacy. He has specialization titles in clinical pharmacology and hospital pharmacy.

RESEARCH AREA

Speakers’ biographies

Bonnabry, Pascal

Prof. Pascal Bonnabry main research interests are in the fields of risk management, the optimization of processes, the evaluation of information technologies and new pedagogic approaches.

Conflict of interest: No conflict of interest declared.

Buyle, Franky SEMINAR IG3 – The role of the hospital pharmacist in disaster management – Are we prepared?

Affiliation:

Ghent University Hospital

Country:

Belgium

CURRENT STATUS, POSITION Dr. Franky Buyle is currently a hospital pharmacist at the Ghent University Hospital. He is involved in the clinical activities of the pharmacy with special expertise in the use of antimicrobial agents. He is also involved with the disaster policy within the hospital pharmacy.

EDUCATION Dr. Franky Buyle studied Pharmacy at the Ghent University in Belgium and became licensed pharmacist in 2006 and licensed hospital pharmacist in 1997. In 2015, he obtained a PhD in medical sciences at the Ghent University on quality indicators for antimicrobial stewardship programs.

RESEARCH AREA Dr. Franky Buyle research focuses on antimicrobial stewardship activities in a hospital setting.

Conflict of interest: No conflict of interest declared.

103

Speakers’ biographies

Byrne, Stephen Workshop 2 – Recognising the prescribing cascade Affiliation:

University College Cork, School of Pharmacy

Country:

Ireland

CURRENT STATUS, POSITION Prof. Stephen Byrne has been appointed Interim Registrar of University College Cork and will commence in the role from the 1st November 2020. Stephen joined UCC in 2004 and was subsequently appointed to the Chair of Clinical Pharmacy Practice and Head of the School of Pharmacy in October 2013. For the last two-years Stephen has held the position of Dean of Undergraduate Studies, UCC and has co lead Priorities 2 and 5 of UCC’s Academic Strategy, amongst being an active member of several University Committees including Academic Council, Academic Board, ACRIC and AC Learning and Teaching.

EDUCATION: Prof. Stephen Byrne graduated from the University of Sunderland (UK) in 1996 with a 1st class Honours Degree in Pharmacy, before embarking on his clinical training in Scotland, Dublin and Limerick. In 2002 he graduated from the School of Pharmacy, Trinity College Dublin having completed his PhD in the area of artificial intelligence and its role in the management of oral anticoagulant therapy.

RESEARCH AREA Prof. Stephen Byrne has published over 100 peer review papers and has supervised 20 PhD students during his time in UCC. He has been a co-investigator in three EU funded research projects and as developed a wide network of international collaborators. Among his many research achievements, he is part of a UCC team that developed the STOPP/START criteria which has been endorsed internationally and adapted into treatment pathways for older persons worldwide. His research team have also worked in the field of antimicrobial usage patterns and he was part of a multidisciplinary team to publish the first set of national antimicrobial guidelines for use in primary care in 2011. Stephen has co-chaired a National Guideline development group, he has acted has conference host/chairperson for international conferences and has actively participated in national meetings and policy development groups.

Conflict of interest: No conflict of interest declared.

104

SEMINAR PC1 - Opportunities and threats for hospital pharmacy production in gene and cell therapy scenarios Affiliation:

Dr. Gustave Roussy Hospital

Country:

France

CURRENT STATUS, POSITION Dr. Kahina Chetouane is currently a hospital pharmacist at Gustave Roussy (Specialised Cancer Treatment Center in Paris, France). She is responsible of clinical trials and advanced therapy medicinal products.

EDUCATION Dr. Kahina Chetouane studied Pharmacy at the University of Marsillia and completed her residency Hospital Pharmacy at the Paris Public Hospitals Association (APHP).

In 2018, she obtained her university degree in the management of advanced therapy medicinal products.

RESEARCH AREA

Speakers’ biographies

Chetouane, Kahina

Dr. Kahina Chetouane’s research focuses on advanced medicinal product and on various clinical pharmacy aspects in clinical trials.

Conflict of interest: No conflict of interest declared.

Cosme, Filipa INTERACTIVE SESSION 2 – Compounding for Paediatrics – A Survival Guide through GMP Affiliation:

Santa Maria´s Hospital - University Hospital Center of North Lisbon

Country:

Portugal

CURRENT STATUS, POSITION Dr.ª Filipa Cosme is currently a hospital pharmacist at Santa Maria´s Hospital in Lisbon. She is responsible for the clinical pharmacy paediatric activities. Also, she is an investigator at iMed Research- Lisbon University. Her main field is in paediatric formulations.

EDUCATION Dr.ª Filipa Cosme studied at the University of Lisbon and became a licensed pharmacist in 2011. In 2015 she obtained her second MSc in Pharmacotherapy and Pharmacoepidemiology also in University of Lisbon. In 2017 she became a Hospital Pharmacist specialist. In 2021 she is starting her PhD in pharmacy at University of Lisbon.

RESEARCH AREA Dr.ª Filipa Cosme research focuses on non-sterile paediatric formulations, medication adherence, and clinical pharmacy mainly in intensive paediatric and neonatal care.

Conflict of interest: No conflict of interest declared.

105

MIX -MIX FILL - -LABEL - USE - FILL LABEL - USE Syringe filling & Syringe labelling made easy!

Praxi Label ™

Praxi Fill ™

Semi-automated syringe labeller

Automated syringe filler

intended to increase productivity of the

Fast, accurate, repeatable filling and capping.

syringe filling process by eliminating the

Increase productivity

PraxiFill™ is an automated syringe filler

tedious manual task of aspirating solution into the syringe and capping the filled syringe.

PraxiFill™ is designed to be used with MedXL pre-capped sterile syringes for increased efficiency and productivity.

increase labeling productivity as it eliminates the work related injuries due to frequent hand and wrist

Easy to control with touch screen pad

The labels are pre-graduated and may be printed on any heat transfer label printer.

Small footprint

are available.

MEDXL EUROPE BV T +31 464395153 medxl-europe.com

tabletop syringe labeler intended to

Filling speed is up to 8 syringes/minute depending on syringe size.

5cc, 10cc, 20cc and 50cc syringes

FILL YOUR NEEDS

PraxiLabel™ is a semi-automatic

movements involved in the syringe labeling operation.

Simple and fast change over between different sizes Small footprint

PraxiFill ™

Praxi Label ™

praximedsystem.com

WORKSHOP 2 – Recognising the prescribing cascade Affiliation:

University College Cork, School of Pharmacy

Country:

Ireland

CURRENT STATUS, POSITION Dr. Kieran Dalton is a lecturer in clinical practice at the School of Pharmacy, University College Cork.

EDUCATION Dr. Kieran Dalton graduated with a Bachelor of Pharmacy (BPharm) degree from University College Cork in 2013 and completed a Master of Pharmacy (MPharm) degree from the Royal College of Surgeons in Ireland in 2014.

After his registration, Kieran worked as a hospital pharmacist before pursuing a PhD in clinical pharmacy in University College Cork, which he completed in 2019.

RESEARCH AREA

Speakers’ biographies

Dalton, Kieran

Dr. Kieran Dalton’s PhD investigated the factors affecting the optimisation of medication appropriateness in hospitalised older adults. Whilst he continues to focus on this topic, Kieran is also conducting research into pharmacist prescribing in hospitals and the emerging role of pharmacists in general practice.

Conflict of interest: No conflict of interest declared.

De Waele, Lies SEMINAR CPS2 – The COVID-19 pandemic - Lessons learnt at the hospital pharmacy Affiliation:

UZ Leuven, Hospital Pharmacy

Country:

Belgium

CURRENT STATUS, POSITION Mrs. Lies De Waele is currently a hospital pharmacist at UZ Leuven. She is head of the distribution department of the hospital pharmacy.

EDUCATION Lies De Waele studied Pharmacy at the University of Leuven and became licensed pharmacist in 2010. Afterwards she specialised in hospital pharmacy and started working in Jessa hospital in 2012. In 2018 she became head of the distribution department in the hospital pharmacy of UZ Leuven.

RESEARCH AREA Lies De Waele is interested in supply chain management, automatisation of medication distribution, centralized and decentralized distribution, warehouse management, quality systems and patient safety.

Conflict of interest: No conflict of interest declared.

107

Speakers’ biographies

Dinsen-Andersen, Christine SEMINAR CPS2 – The COVID-19 pandemic - Lessons learnt at the hospital pharmacy Affiliation:

Hospital Pharmacy of the Capital Region of Denmark

Country:

Denmark

CURRENT STATUS, POSITION Christine Dinsen-Andersen is currently a senior hospital pharmacist in the Medicines Information Centre at the hospital pharmacy in the Capital Region of Denmark.

EDUCATION Christine Dinsen-Andersen studied Pharmacy at the University of Copenhagen, School of Pharmaceutical Sciences and became a licensed pharmacist in 1996. After 9 years in the primary care sector, she was employed in Frederiksborg amts Hospital as clinical pharmacist. In 2010, she started working in the Medicines Information Centre.

RESEARCH AREA Christine Dinsen-Andersen specialises among others in the management of medicines shortages at regional and local level in the hospitals and on a national level as the Chairman of the National Task Force for critical medicines shortages.

Conflict of interest: No conflict of interest declared.

Fernández de Gamarra Martínez, Edurne SEMINAR IG1 – Better together! - Hospital pharmacists go collaborative Affiliation:

Hospital Santa Creu I Sant Pau

Country:

Spain

CURRENT STATUS, POSITION Ms. Edurne Fernández de Gamarra Martínez is currently a clinical pharmacist at Hospital Santa Creu i Sant Pau (Barcelona). She is focused on critical care, paediatrics, infectious diseases, pharmacokinetics and drug safety. She is also residents’ preceptor at her Pharmacy Department and the delegate from Catalunya at the Board of the Spanish Society of Hospital Pharmacy. She develops teaching activities at Universitat Ramon Llull-Blanquerna.

EDUCATION Ms. Edurne Fernández de Gamarra Martínez studied Pharmacy at the Complutense University of Madrid and became licensed pharmacist in 2002. From 2004 to 2008 she followed the Residency Training Program and obtained the tittle of Hospital Pharmacist Specialist in 2008.

She also has a Diploma in International Public Health from the National Health School (Spain), a Master Degree in Antimicrobial Therapy (Autonomous University in Barcelona) and in 2013 she became a Board Certified Pharmacotherapy Specialist (by the Board of Pharmacy Specialties from the US).

RESEARCH AREA Ms. Edurne Fernández de Gamarra Martínez’s research focuses on pharmacokinetics and on pharmaceutical care in paediatrics and critical care.

Conflict of interest: No conflict of interest declared.

108

KEYNOTE 2 - What people want from their medicines - Making shared decisions Affiliation:

University of Birmingham, Institute of Applied Health Research

Country:

United Kingdom

CURRENT STATUS, POSITION Dr. Sam Finnikin is a general practitioner at Sutton Coldfield Group Practice in the West Midlands (England). He works for NHS England and NHS Improvement as a National Clinical Specialty Advisor in Personalised Care and Cardiovascular Disease and is a Research Fellow at the University of Birmingham.

EDUCATION Dr. Sam Finnikin completed his postgraduate medical degree at the University of Birmingham in 2007. He gained his Certificate of Completion of Training in general practice in 2015 and an MSc in Primary Care and Clinical Sciences in the same year.

RESEARCH AREA

Speakers’ biographies

Finnikin, Samuel

Dr. Sam Finnikin’s research focuses on shared decision making and the use of risk scoring and risk communication in clinical consultations. Much of his research has focused on the use of statins for the primary prevention of cardiovascular disease.

Conflict of interest: No conflict of interest declared.

Forsyth, Paul* PHARMACOTHERAPY SESSION -Advances in heart failure pharmacotherapy Affiliation:

NHS Greater Glasgow & Clyde

Country:

United Kingdom

CURRENT STATUS, POSITION Paul is currently Lead Pharmacist for Clinical Cardiology in NHS Greater Glasgow & Clyde. He is nationally credentialed as a Consultant Pharmacist by the Royal Pharmaceutical Society (RPS). He also co-chairs the United Kingdom Clinical Pharmacy Association (UKCPA) Heart Failure group.

EDUCATION Paul studied Pharmacy at Strathclyde University and registered as a pharmacist in 2002. He qualified as an Independent Prescriber in 2007. In 2015 he obtained a MSc in Primary Care from Glasgow University.

RESEARCH AREA Paul’s research focuses on heart failure, cardiology and advanced pharmacist practice.

Conflict of interest: Mr Paul Forsyth was Advisor for: • Astra Zeneca • Novartis • Servier • Vifor No financial relationship in any amount in the last 12 months with the manufacturers of the products or providers of the services

109

Speakers’ biographies

Frontini, Roberto INTERACTIVE SESSION 1 - Work it out - Your idea to save health systems Affiliation:

Retired Hospital Pharmacist from University Hospital of Leipzig

Country:

Germany

CURRENT STATUS, POSITION Dr. Roberto Frontini retired from the position of Director of Pharmacy at the University Hospital Leipzig (Germany) 2017 and he is since 2019 alternate member of PRAC (Pharmacovigilance Risk Assessment Committee) at European Medicine Agency (EMA).

EDUCATION Dr. Roberto Frontini studied pharmacy at the University of Hamburg and became licensed pharmacist in 1988.

In 1993, he obtained the PhD (Dr.rer.nat.) and worked at the hospital of the University of Lübeck until 1995.

In 1996, he obtained specialisation degree in Hospital Pharmacy and become Head of the Pharmacy of the St. Franziskus-Hospital in Cologne. From 2001 to 2017 he was Director of Pharmacy at the University Hospital of Leipzig. He was from 2011 to 2017 Qualified Person of the Production Unit for Investigational Medicinal Products of the same pharmacy. He retired in 2018 and is since 2019 alternate member of PRAC.

RESEARCH AREA: Dr. Frontini research and activity focus is on patient safety and automation in hospital.

Conflict of interest: No conflict of interest declared.

Green, Christopher F. SEMINAR SPD2 - The waste-reducing hospital pharmacy – Let’s get started!

Affiliation:

Countess of Chester Hospital NHS Foundation Trust, Pharmacy

Country:

United Kingdom

CURRENT STATUS, POSITION Dr. Christopher F. Green is currently Director of Pharmacy and Medicines Management.

EDUCATION Dr. Green studied Pharmacy at Liverpool John Moores University, and became a registered pharmacist in 1993.

In 1996, he obtained a Postgraduate Diploma in Clinical Pharmacy and in 2004, he registered as a Pharmacist Prescriber. In 2000, he obtained a PhD in pharmacy practice at Liverpool John Moores University for his work on hospital pharmacists and their role in adverse drug reaction reporting. In 2017, he obtained a Master’s Degree in Leadership and Quality Improvement from Ashridge Business School.

RESEARCH AREA Dr. Green’s research interests focus on pharmacy practice, quality improvement and adverse drug reactions.

Conflict of interest: No conflict of interest declared.

110

SEMINAR PC1 - Opportunities and threats for hospital pharmacy production in gene and cell therapy scenarios Affiliation:

University Hospital Heidelberg

Country:

Germany

CURRENT STATUS, POSITION Kim Green is currently a hospital pharmacist at the University Hospital of Heidelberg. He is responsible for providing drug information to the local HCP. He is also responsible for the task force ATMP.

EDUCATION Kim Green studied pharmacy at the University Erlangen-Nürnber and became a licensed pharmacist in 2011.

In 2015 he finished his specialisation for Clinical Pharmacy (Fachapotheker für Klinische Pharmazie). In 2019, he became first VicePpresident of the German Hospital Pharmacist Association (ADKA).

Speakers’ biographies

Green, Kim*

RESEARCH AREA Kim Green’s main research focus is patient empowerment and its influence on adherence and QoL.

Conflict of interest: Mr Kim Green is Advisory for • Roche • Leopharma

Hanne Poulsen, Joo SEMINAR CPS2 – The COVID-19 pandemic - Lessons learnt at the hospital pharmacy Affiliation:

Hospital Pharmacy, Capital Region of Denmark

Country:

Denmark

CURRENT STATUS, POSITION Dr. Joo Hanne Poulsen is currently in a post doc position at the Medicines Information Center at the Hospital Pharmacy in the Capital Region of Denmark.

EDUCATION Dr. Joo Hanne Poulsen graduated as pharmacist in 2010 from the University of Copenhagen, followed by a Master of Public Health degree in 2016 and a PhD degree in 2021. Dr. Hanne Poulsen has been employed as a pharmacist at a community pharmacy and a psychiatric center at Bispebjerg Hospital. Since 2021 she has been in a post doc position at the Medicines Information Center at the Hospital Pharmacy in the Capital Region of Denmark.

RESEARCH AREA Dr. Joo Hanne Poulsen’s research focuses on patient safety in the medication process in the secondary healthcare sector. Her work has focused on risk analysis and patient safety aspects related to drug changes and shortages at a national, regional and local level. Her PhD covered both the organizational and the practical perspectives of drug changes due to critical drug shortages.

Conflict of interest: No conflict of interest declared.

111

INTERACTIVE SESSION 1 - Work it out - Your idea to save health systems Affiliation:

Heidelberg University Hospital

Country:

Germany

CURRENT STATUS, POSITION Dr. Torsten Hoppe-Tichy is a Chief Pharmacist at Heidelberg University Hospital for more than 25 years. He is also a Lecturer at School of Pharmacy of Ruprecht-Karls-University of Heidelberg teaching Pharmacoeconomics and Clinical Pharmacy.

EDUCATION Dr. Hoppe-Tichy studied Pharmacy at the School of Pharmacy at Technical University of Braunschweig. He became a licensed pharmacist in 1984. In 1989, he finished his PhD in pharmaceutical chemistry. He holds a specialisation in Clinical Pharmacy and in Pharmaceutical Analytics. He is an honorary member of the German Association of Hospital Pharmacists (ADKA).

Speakers’ biographies

Hoppe-Tichy, Torsten

RESEARCH AREA Dr. Hoppe-Tichy’s research focuses on antimicrobial therapy, pharmacokinetics and pharmacoeconomics.

Conflict of interest: No conflict of interest declared.

Kirke, Ciara Workshop 4 - Hospital pharmacist: learn to think global and act local Affiliation:

Health Service Executive, Quality and Patient Safety Department, National Medication Safety Programme

Country:

Ireland

CURRENT STATUS, POSITION Ms. Ciara Kirke is Clinical Lead of the National Medication Safety Programme in Ireland. She is responsible for leading initiatives to reduce medication-related harm and harm with venous thromboembolism in the public health system. She acts as a medication error expert for the European Medicines Agency and the World Health Organisation.

EDUCATION Ms. Kirke studied Pharmacy at Trinity College Dublin and completed her MSc in Clinical Pharmacy at Queen’s University Belfast. She has completed multiple post-graduate diplomas in leadership, management, risk management, quality and is an IHI improvement advisor.

RESEARCH AREA Ms. Kirke collaborates with researchers in all aspects of medication safety and venous thromboembolism.

Conflict of interest: No conflict of interest declared.

113

STAND

11

Trusted, evidence-based medicines information to support decision-making MedicinesComplete from Pharmaceutical Press, the Royal Pharmaceutical Society’s knowledge business, makes it easy for health professionals to access essential medicines information at the point of care.

BNF for Children

Stockley’s Drug Interactions

Stockley’s Interactions Checker

Martindale: The Complete Drug Reference

Martindale’s ADR Checker

Critical Illness

Clarity’s Diagnosis and Treatment Guidance

Palliative Care Formulary

N EW

British National Formulary (BNF)

Drug Monitoring Checker

Scan the QR code to request a complimentary trial

about.medicinescomplete.com

SEMINAR PSQ1 - Medication with safety Affiliation:

Helsinki University Hospital (HUS)

Country:

Finland

CURRENT STATUS, POSITION Ms. Sini Kuitunen is currently a Clinic Senior Pharmacist at New Children’s Hospital, which is a part of Helsinki University Hospital (HUS). She is responsible of paediatric medication safety and medication use-process.

EDUCATION Ms. Kuitunen studied Pharmacy in the University of Helsinki and became a licenced BSc (Pharm) in 2011 and MSc (Pharm) in 2015. Ms Kuitunen is a PhD student at the University of Helsinki.

RESEARCH AREA Ms. Kuitunen’s research focuses on medication safety, with a special interest in paadiatrics, intravenous drug administration and closed loop medication management systems.

Speakers’ biographies

Kuitunen, Sini

Conflict of interest: No conflict of interest declared.

115

Speakers’ biographies

Le Brun, Paul P.H. SEMINAR ER1 - Hospital pharmacy practice research: why and how to be more engaged and publish?

Affiliation:

Leiden University Medical Center

Country:

The Netherlands

CURRENT STATUS, POSITION Dr. Paul P.H. Le Brun is currently hospital Pharmacist-clinical pharmacologist. As head QA/QP responsible for the quality of production and trials medication. As associate-professor teaching students in production and quality at university of Leiden.

EDUCATION Dr. Paul PH Le Brun obtained his degree in pharmacy from the Groningen University in 1982. He started his career at the Dutch Laboratory of Pharmacists (LNA), department of the Royal Dutch Association of Pharmacists (KNMP) from 1982 until 1985. The LNA supports Dutch local and hospital pharmacists with the preparation of medicines.

From 1985 until1988 he was trained and worked as a hospital pharmacist in the Central Hospital Pharmacy of The Hague.

He joined Merck Sharp & Dohme as production pharmacist from 1989 to 1992. GMP implementation, troubleshooting, training of personnel and product and process validation were his main responsibilities.

From 1992 until 2017 he was director of production of the Central Hospital Pharmacy in The Hague, where he was responsible for all production activities, including management, product development, product and process validation and renovation of premises. This position was combined with clinical tasks in Bronovo and Haga teaching hospital, respectively.

January 2017 he was appointed as head QA and Qualified Person at the department clinical pharmacology and toxicology of the Leiden University Medical Centre where he is also associate professor GMP. In 2001 he obtained his Ph.D on the improvement and development of antibiotic inhalation for CF patients. The title of his thesis reads: “Optimization of antibiotic inhalation therapy in Cystic Fibrosis. Studies on nebulized tobramycin. Development of colistin dry powder inhaler system”. In 2001 he also received the innovation award of the Royal Dutch Society of Pharmacists for his research. He further specialized as clinical pharmacologist in 2002.

From 2007 until 2012, he was a member of the board of the Dutch Society of Hospital Pharmacists (NVZA) with the area of attention: production, QC and QA policy regarding hospital pharmacy in the Netherlands. To date he is one of the Dutch delegates for the General Assembly of the European Association of Hospital Pharmacists.

In 2009 he was one of the editors of Recepteerkunde, a Dutch standard textbook on pharmacy products and preparations and also of the follow up, the international equivalent ‘Practical Pharmaceutics’, which came available in 2015. Paul is chief editor of the second edition which will come available in 2022.

RESEARCH AREA Main Research Themes: Aseptic preparation parenteral drugs Medicinal product development

THESES Supervision of PhD project: Sterility assurance of aseptic handling in hospital pharmacies. Frits Boom. To be finalised in 2022 Local, National and International Research Collaborations: Academic Pharma LUMC GERPAC (France) Microbiological Shelf-life for Hospital Pharmacy Aseptic Preparations

Conflict of interest: No conflict of interest declared.

116

PHARMACOTHERAPY SESSION - Advances in heart failure pharmacotherapy Affiliation:

St Vincents University Healthcare Group, School of Medicine, University College, Dublin

Country:

Ireland

CURRENT STATUS, POSITION Mark Ledwidge is currently Research Director of the STOP-HF Unit in St Vincent’s University Healthcare Group, Dublin and UCD Professor (Adjunct) the School of Medicine, University College, Dublin.

EDUCATION Mark studied pharmacy in Aberdeen, obtained a PhD in Pharmaceutics from Trinity College in 1997 and has worked as a pharmacist in community, hospital, industry and academia for almost 30 years.

RESEARCH AREA

Speakers’ biographies

Ledwidge, Mark*

Major areas of interest include prevention of heart failure, heart failure therapeutics and pharmacogenomic strategies in heart failure.

Conflict of interest: Prof. Mark Ledwidge is: • Funder, Researcher of Abbott Diagnostics, Co-founder of Solvatrin Therapeutics Funded Researcher for: • Novartis AG, Bayer, Hypercell

Lindén-Lahti, Carita SEMINAR PSQ1 - Medication with safety Affiliation:

Helsinki University Hospital (HUS)

Country:

Finland

CURRENT STATUS, POSITION Mrs Carita Lindén-Lahti is currently a Medication Safety Officer at Helsinki University Hospital (HUS). She is responsible of coordinating and developing medication safety in HUS. She is also doing her PhD studies in the University of Helsinki.

EDUCATION Mrs Lindén-Lahti studied Pharmacy at the University of Helsinki and became MSc (Pharm.) in 2008. In 2020 she obtained ASHP/ISMP Medication Safety Certificate.

RESEARCH AREA Mrs Lindén-Lahti’s research focuses on medication safety interventions and severe medication errors.

Conflict of interest: No conflict of interest declared.

117

SEMINAR CPS1 - Side effects resulting in prescribing cascades Affiliation:

University of Toronto and Trillium Health Partners

Country:

Canada

CURRENT STATUS, POSITION Dr. Lisa McCarthy is a Clinician Scientist with the Institute for Better Health and Pharmacy Department at Trillium Health Partners, a large community-based academic hospital in Canada. Her clinical practice is with Seniors Services. She is also an Associate Professor with the University of Toronto’s Leslie Dan Faculty of Pharmacy and Temerty Faculty of Medicine.

EDUCATION Dr. Lisa McCarthy completed her pharmacy studies at the University of Toronto (BScPhm 2002; PharmD 2005) and an ambulatory care specialty residency program (2003). She also undertook a post-PharmD research fellowship and obtained an MSc in Health Research Methodology (2010) from McMaster University.

Speakers’ biographies

McCarthy, Lisa

RESEARCH AREA Dr. Lisa McCarthy leads research that aims to optimize medication experiences for people and to reduce medication-related harm for people, organizations, and health systems. She is a recognized expert in the fields of problematic polypharmacy, with particular expertise in deprescribing and prescribing cascades, and care transitions.

Conflict of interest: No conflict of interest declared.

119

Speakers’ biographies

Melo Gouveia, Antonio SEMINAR IG2 – How to survive with limited resources without letting the patients down Affiliation:

Instituto Portugues de Oncologia (Portuguese Institute of Oncology)

Country:

Portugal

CURRENT STATUS, POSITION Dr. Antonio Melo Gouveia is currently chief pharmacist at IPO Lisboa, one of the major cancer centers in Portugal. He is involved in management, purchasing and decisions concerning drugs used in the hospital. He is also vice-president of the Portuguese health technology assessment committee (CATS) in INFARMED, the Portuguese medicines agency.

EDUCATION Degree in pharmaceutical sciences with specialisation in clinical analysis and in hospital and community pharmacy. Post graduate studies in general management and in management and administration of health institutions. Started career as military pharmacist in 1989, worked in Portuguese Medicines Agency (INFARMED) from 1997 to 2001, as head of the area of drug assessment. Been chief pharmacist in oncology hospital since 2002. Has been a member of the drug assessment committee of INFARMED (CAM) since 1991, was a member of the national ethics committee for clinical trials (CEIC) from 2009 to 2011, and is VP of CATS since 2016. Was member and president of the college of hospital pharmacists of the Order of Pharmacist (regulatory body of the pharmaceutical profession) from 2010 to 2019.

RESEARCH AREA Oncology drugs, health technology assessment, pharmacy practice in oncology, management

Conflict of interest: No conflict of interest declared.

120

STUDENT PROGRAMME - Contemporary ethical challenges in hospital pharmacy practice Affiliation:

(1) Institute of orthopaedics Banjica - Head of Hospital Pharmacy Services (2) EAHP Board Member

Country:

Serbia

CURRENT STATUS, POSITION Dr. Nenad Miljković is currently the Head of Hospital Pharmacy Services at the Institute of Orthopaedics Banjica in Belgrade, Serbia and the President of Hospital Pharmacy Section at the Pharmaceutical Association of Serbia.

He is also Director of Finances at European Association of Hospital Pharmacists (EAHP).

EDUCATION Dr. Nenad Miljković studied Pharmacy at the University of Belgrade, where he specialised in clinical pharmacy in 2014. In 2012, he obtained a dual Master degree in European Public Health at the University of Sheffield, School of Health and Related Research (ScHARR) and at the University Sorbonne Paris Cité, French School of Public Health (EHESP). In 2021, Nenad obtained a PhD in clinical pharmacy at the University of Belgrade for health risk assessment in medicine shortages under the COST Action 15105 and in cooperation with KU Leuven.

Speakers’ biographies

Miljković, Nenad

RESEARCH AREA Dr. Nenad Miljković’s research focuses on health risk and patient clinical needs assessment, medicine shortages mitigation strategies analysis, including therapeutic substitution and prospective risk evaluation.

Conflict of interest: No conflict of interest declared.

121

SEMINAR CPS1 - Side effects resulting in prescribing cascades Affiliation:

OLVG Hospital

Country:

The Netherlands

CURRENT STATUS, POSITION Ms. Mohammad is currently a researcher at the OLVG Hospital. She is currently performing a systematic review on prescribing cascades and a research on the quantification of prescribing cascades in the Netherlands.

She is also affiliated with a research on the method of the prescription sequence symmetry analysis (PSSA).

EDUCATION Ms. Mohammad studied Pharmacy at the University of Utrecht and became a licensed pharmacist in 2020.

RESEARCH AREA Ms. Mohammad’s research focuses on prescribing cascades, whether they are problematic and possible interventions to prevent them.

Speakers’ biographies

Mohammad, Atiya*

Conflict of interest: Ms Atiya Mohammad still has a professional relationship with Ncontrol which provided data from community pharmacies.

Mozgis, Dzintars SEMINAR IG2 – How to survive with limited resources without letting the patients down Affiliation:

Centre for Disease Prevention and Control - Republic of Latvia

Country:

Latvia

CURRENT STATUS, POSITION Assoc. Prof. Dzintars Mozgis MD., PhD. is currently a Deputy Director of the Center for Diseases Prevention and Control, Latvia and he also works in the public health and epidemiology department at Riga Stradins University.

He is responsible for prevention and control mostly of noncommunicable diseases, health promotion and health care management.

EDUCATION Assoc. Prof. Mozgis studied at Medical Institute in Riga and became a paediatrician in 1982. In 1987, he obtained specialty – paediatric surgery, but in 2004. a PhD in paediatric surgery at Riga Stradins University for his work in research of anorectal malformations. From 1995 until 2010,. he served as CEO at University Children Hospital in Riga.

RESEARCH AREA Assoc. Prof. Mozgis’ research focuses on health care management, history of medicine, paediatric surgery, public health and comparative trends in the consumption of drugs.

Conflict of interest: No conflict of interest declared.

123

Close the loop.

Bridge the gap with automation: Support your hospital pharmacy with Unit Dose, inventory optimization or point of care solutions.

Find your missing piece at booth n°25 hall X2

swisslog-healthcare.com

WORKSHOP 5 - From data to decision - Improve the use of EBM in clinical practice Affiliation:

University Hospital Vienna, Hospital Pharmacy

Country:

Austria

CURRENT STATUS, POSITION Fiona Nagele currently works as a clinical pharmacist at the University Hospital Vienna. She is the responsible ward pharmacist for the departments of cardiology, angiology and vascular surgery.

EDUCATION Fiona Nagele studied Pharmacy at the Karl-Franzens University Graz and became licensed pharmacist in 2015.

In 2018, she obtained a postgraduate MSc in Clinical Pharmacy, International Practice and Policy at UCL London.

RESEARCH AREA Fiona Nagele’s areas of expertise include antithrombotic stewardship, drug interactions and cardiovascular risk management.

Speakers’ biographies

Nagele, Fiona

Conflict of interest: No conflict of interest declared.

125

Speakers’ biographies

Oosterhof, Piter SEMINAR SPD2 - The waste-reducing hospital pharmacy – Let’s get started!

Affiliation:

(1) OLVG (2) Radboudumc

Country:

The Netherlands

CURRENT STATUS, POSITION Piter Oosterhof is currently a hospital pharmacist in training in OLVG. He is responsible for logistics and focuses on infectious diseases. In addition, he is an outpatient pharmacist at OLVG and researcher at Radboudumc.

EDUCATION Piter Oosterhof studied Pharmacy at the University of Groningen and became licensed pharmacist in 2012.

RESEARCH AREA Piter Oosterhof research focuses on effective use of antiretroviral agents.

Conflict of interest: No conflict of interest declared.

Peppard, Joan Hazardous Medicinal Products: the European classification landscape Affiliation:

Midland Regional Hospital Tullamore

Country:

Ireland

CURRENT STATUS, POSITION Joan Peppard is currently Chief Pharmacist and head of department in the Midland Regional Hospital Tullamore Co Offaly. With a keen interest in the growth and development of hospital pharmacy and a strong commitment to excellence in patient care, Ms Peppard served in a leadership capacity on a number of key committees in Ireland at local, regional and national level including Presidency of the Hospital Pharmacists Association Ireland from 2004 - 2006 and 2011 - 2012. As President of the EAHP since 2015 she is involved in numerous issues focused on improvement in patient care through implementation of the European Statements of Hospital Pharmacy, development of a common training framework for recognition of hospital pharmacy as a specialisation, and annual surveys of European Hospital Pharmacy practice in conjunction with hospital pharmacy self-assessment to measure progress in these areas.

EDUCATION Joan studied pharmacy at University College Dublin and became a licensed pharmacist in 1980. In 1996 she undertook a Diploma in Business Studies and obtained a BA in Healthcare Management in 2000. Joan undertook a Leadership course for Health Systems Managers with the Office of Health Management/ University of Limerick and obtained an MA (Ethics) from Dublin City University, Mater Dei Institute of Education in 2012.

Joan has worked in hospital pharmacy in Ireland since 1984. and her current role is Chief Pharmacist in Midland Regional Hospital Tullamore, Co Offaly. She was President of the European Association of Hospital Pharmacists 2015 - 2018 and President of the Hospital Pharmacists Association Ireland from 2004 - 2006 and 2011 - 2012.

RESEARCH AREA Joan is currently Chair of the EAHP Special Interest Group on Hazardous Medicinal Products. Her previous research interests included Clinical Ethic Committees, Research Ethics Committees and Medicine Shortages.

Conflict of interest: No conflict of interest declared.

126

SEMINAR PSQ2 - Teamwork in the hospital – Building relationships to optimise pharmacotherapy Affiliation:

Hospital Son Espase – Intensive Care

Country:

Spain

CURRENT STATUS, POSITION Dr. Perez-Barcena is currently an intensive care doctor in Mallorca (Spain). He is responsible of the Neurocritical Care Unit.

EDUCATION Dr. Perez-Barcena studied medicine at the Universidad de Navarra (Spain). In 2008 he obtained a PhD at Universidad Autonoma de Barcelona.

He was also partially trained at Jackson Memorial Hospital, University of Miami, USA.

Speakers’ biographies

Perez-Barcena, Juan

RESEARCH AREA Dr. Perez Barcena’s research focuses on traumatic brain injured patients and neurocritical care patients.

Conflict of interest: No conflict of interest declared.

127

www.temasinergie.com

CLF-IS

COMPACT LAMINAR FLOW ISOLATOR SYSTEM SMALL SCALE, FULL COMPLIANCE

THE PERFECT ALLY FOR YOUR HOSPITAL PHARMACY THE COMPACT LAMINAR FLOW ISOLATOR SYSTEM IS A MODULAR CGMP CLASS A/ISO 5 ISOLATOR SYSTEM SPECIFICALLY DESIGNED FOR SAFE HANDLING OF HAZARDOUS COMPOUNDS (CHEMOTHERAPY, ONCOLOGICAL APPLICATIONS) IN HOSPITAL PHARMACIES. IT CAN NOW BE INTEGRATED WITH OUR BRAND NEW VPHP GENERATOR FOR A TOTALLY RELIABLE 6-LOG BIO-DECONTAMINATION PROCESS Established in 1985, Tema Sinergie has become a world leader in the design and manufacture of shielded isolators for the Nuclear Medicine market.

The company enhances its position on the international market and promotes internal growth by efficiently responding to existing needs and anticipating industry demands with innovative ideas.

Presently, the main focus is on the pharmaceutical and chemical sectors, for which Tema Sinergie manufactures customized high-quality stainless steel barrier isolator systems for containment and aseptic processes.

VISIT US AT BOOTH 38 of EAHP!

GUARANTEED ASEPSIS MODULAR BASED CONFIGURATION AUTOMATIC LEAK TEST EASE OF MAINTENANCE ERGONOMIC DESIGN GLOVE INTEGRITY TESTING MAXIMUM SAFETY

SEMINAR PC3 – Bacteriophages – Back to the future Affiliation:

Queen Astrid Military Hospital, Head of the Laboratory for Molecular and Cellular Technology (LabMCT)

Country:

Belgium

CURRENT STATUS, POSITION Dr. Jean-Paul Pirnay is Senior Scientist and currently Head of the Laboratory for Molecular and Cellular Technology (LabMCT) in Queen Astrid Military Hospital.

EDUCATION Dr. Jean-Paul Pirnay graduated as Industrial Engineer in Biochemistry and Biotechnology in 1990. He performed his military service in 1993 and served since then as a researcher in the Queen Astrid Military Hospital (QAMH) in Brussels. He contributed to the development of the human cell and tissue banks and to the introduction of molecular microbiology and phage therapy in the QAMH. In 2003, he received a PhD in Medical Sciences for the study of the molecular eco-epidemiology of Pseudomonas aeruginosa. He is currently Research Coordinator of the QAMH and head of the Laboratory for Molecular and Cellular Technology (LabMCT), which harbors the human cell and tissue banks of the QAMH, a phage research laboratory and a cleanroom production facility.

Speakers’ biographies

Pirnay, Jean-Paul

RESEARCH AREA Research projects include the development of living skin equivalents, the study of the molecular epidemiology (including antibiotic resistance) of bacterial pathogens, and the development and application of therapeutic phage preparations.

Conflict of Interest: No conflict of interest declared

129

Speakers’ biographies

Politis, Constantinus SEMINAR PC2 - 3D printed medical devices – The ultimate customization Affiliation:

KULeuven - Leuven University Hospitals

Country:

Belgium

CURRENT STATUS, POSITION Prof. Dr. Constantinus Politis is currently Head of the Department of Oral and Maxillofacial surgery at Leuven University Hospitals and Head of the Research Group OMFS-IMPATH at KULeuven.

EDUCATION Prof. Dr. Constantinus Politis graduated at the Catholic University of Leuven in medicine (MD, summa cum laude), in dentistry (DDS, magna cum laude). He specialized in oral and maxillofacial surgery at the Catholic University of Leuven. Postgraduate training was additionally followed in Arnhem (Stoelinga), Aachen (Koberg), Copenhagen (Pindborg), Göteborg (Bränemark) and San Francisco (Marx). He also holds a master degree in management (MM) from the Applied Economic Sciences at the University of Hasselt and a master degree in Hospital Management (MHM) from the Catholic University of Leuven. He became a recognition as medical specialist in management of health care data.

RESEARCH AREA His professional field of interest is in orthognathic and orthodontic surgery and trigeminal nerve dysfunction.

Clinical research projects include prevention and repair of iatrogenic trigeminal nerve injury, transplantation of teeth and orthognathic surgery. He has been granted membership of the Belgian Royal Academy of Medicine.

Conflict of interest: No conflict of interest declared.

Rieutord, André SEMINAR ER2 – How to work smarter not harder Affiliation:

Gustave Roussy Cancer Campus – Département Pharmacie Clinique

Country:

France

CURRENT STATUS, POSITION Dr. André Rieutord is currently the Chief Pharmacist at Gustave Roussy Cancer Campus.

EDUCATION Dr. André Rieutord studied Pharmacy at the University of Grenoble and was graduated as an Hospital Pharmacist at The University of Paris in 1992. He completed his PhD in Analytical Chemistry in 2002 and obtained his “Habilitation à Diriger des Recherches” in 2005.

RESEARCH AREA Healthcare Management Clinical Pharmacy Education

Conflict of interest: No conflict of interest declared.

130

Abacus Medicine supplies European original medicine

The world and the role of hospital pharmacists is changing rapidly, but one thing remains the same: Throughout Europe, hospital pharmacists rely on Abacus Medicine as their supplier of original, prescription medicine.

Together, we work to provide optimal patient care and keep healthcare affordable.

Assured quality

Simple ordering

Reach us at: Tel. :+43 1 26 50 642 Fax: +43 1 26 50 642 99 E-Mail: meinservice@abacusmedicine.at www.abacusmedicine.at

Fast availability

Attractive conditions

Authentic design

The Smartest Medication Solution Closing the gap of the last 50 meters to the patient’s bedside

Up to 25 minutes time saving per nurse per shift

Highly improved medication safety www.amissolution.com

Continuously secured medication

KEYNOTE 3 - The era of cell and gene therapies in oncology Fiction, poetry or science?

Affiliation:

Heidelberg University Hospital

Country:

Germany

CURRENT STATUS, POSITION Dr. Tilman Schöning is currently Deputy Head of Pharmacy at Heidelberg University Hospital and Head of Oncology Pharmacy unit at the Pharmacy.

EDUCATION Dr. Tilman Schöning studied Pharmacy at the University of Heidelberg and became a licensed pharmacist in 2020. In 2004 he became specialist in hospital pharmacy. In 2009 he obtained a PhD in medical microbiology for his work on B streptococci.

Speakers’ biographies

Schöning, Tilman

RESEARCH AREA Dr. Tilman Schöning focusses on oncology pharmacy in general and on automation in preparation, biosimilar monoclonal antibodies and ATMP in oncology.

Conflict of interest: No conflict of interest declared.

133

See us at EAHP Stand #42

Optimize Your Pharmacy’s Workflow Capsa Healthcare is your partner for solutions that optimize your pharmacy’s workflow and ensure accuracy in medication dispensing, administration, and secure control in any healthcare environment.

• Custom central filling automation from RoboPharma • Automated Medication Dispensing Solutions • Mobile Medication Management Talk to Capsa Healthcare today about our latest product innovations and technology solutions.

NexsysADC™

MedLink™

CapsaHealthcare.com

RoboPharma.com

+1.614.864.9966

+31416347172

Trio™

Hazardous Medicinal Products: the European classification landscape Affiliation:

Tirol Kliniken Hospital Pharmacy

Country:

Austria

CURRENT STATUS, POSITION Dr. Falko Schüllner is currently a hospital pharmacist at Tirol Kliniken Hospital Pharmacy in Innsbruck (AT). He is the representative director of the Tirol Kliniken Hospital Pharmacy, Qualified Person and Responsible Person for GDP. He is in authority over the department Quality Assurance in the Hospital Pharmacy.

EDUCATION Dr. Falko Schüllner studied Pharmacy at the University of Innsbruck and became licensed pharmacist in 2000. In 2002 he obtained a PhD in pharmaceutical chemistry at the University of Innsbruck for his work on Synthesis on biological evaluation of 14-Alkoxymorphinanes.

From 2007 until 2009 he completed an additional education as an approved Hospital Pharmacist (aHPh).

Speakers’ biographies

Schüllner, Falco

In 2015 he became the Representative Director of the Tirol Kliniken Hospital Pharmacy and Responsible Person for GDP. In 2019 he got the confirmation to perform the task as a Qualified Person.

RESEARCH AREA Dr. Falko Schüllner’s research focuses on quality assurance topics in connection with the activities of the Tirol Kliniken Hospital Pharmacy. He is also collaborating with internal departments and external institutions on the field of hazardous medicinal products.

Conflict of interest: No conflict of interest declared.

135

Speakers’ biographies

Simoens, Steven KEYNOTE 1 - What are we paying for? - From productivity to value-based healthcare Affiliation:

KU Leuven

Country:

Belgium

CURRENT STATUS, POSITION Prof. Dr. Steven Simoens is a Professor of Health Economics.

EDUCATION Prof. Dr. Steven Simoens is a Commercial Engineer (KU Leuven, 1997), who later specialised in health economics and obtained a MSc in Health Economics (University of York, 1998) and a PhD in Economics (University of Aberdeen, 2001).

RESEARCH AREA The research interests of Steven Simoens focus on health economic aspects of medicinal products. Steven has carried out numerous cost(-of-illness) analyses, economic evaluations and budget impact analyses of medicinal products. He has also worked extensively in the area of policy relating to market access of medicinal products, with a particular interest in oncology medicinal products, orphan medicinal products, cell and gene therapies, antibiotics, vaccines, generic and biosimilar medicinal products.

Conflict of interest: No conflict of interest declared.

136

SEMINAR ER1 - Hospital pharmacy practice research: why and how to be more engaged and publish?

Affiliation:

University Hospitals Leuven - University of Leuven

Country:

Belgium

CURRENT STATUS, POSITION Prof. Isabel Spriet is the Head of the clinical pharmacy department in the Pharmacy Department of the University Hospitals Leuven. She is also appointed as Associate professor at the Department of the Pharmaceutical and Pharmacological Sciences and works in the Clinical Pharmacology and Pharmacotherapy group.

EDUCATION Prof. Isabel Spriet studied Pharmaceutical Sciences at the University of Ghent, and became licensed pharmacist in 2002. In 2003, she obtained the degree of hospital pharmacist, and she completed a Fellowship in Clinical Pharmacy in 2004. In 2011, she obtained a PhD in Pharmaceutical Sciences and was appointed as Associate Professor at the Department of Pharmacological and Pharmaceutical Sciences.

Speakers’ biographies

Spriet, Isabel

RESEARCH AREA The research of Isabel Spriet focuses on the organization of clinical pharmacy in the Belgian context and on the optimization of antimicrobial dosing in special patient populations.

Conflict of interest: No conflict of interest declared.

137

More security through Ready-to-Use products for Intensive Care

Meet our experienced team at stand 53

Reduce risks in infusion preparation Specialised in providing high quality injectables and Ready-to-Use solutions, hameln pharma fulfil the needs of hospital specialists through its range of medication with innovative packaging and labelling design aimed at reducing the incidence of medication errors.

The already fully diluted medicines in practical 50 ml vials offer decisive advantages in the care of patients.

With Integrated Syringe Label®

By using hameln pharma Ready-to-Use solutions with Integrated Syringe Labels® healthcare professionals can: ● Reduce the risk of medication errors and increase patient safety ● Deliver the right drug in the right concentration and volume ● Reduce the risk of contamination ● Reduce workload and release time for patient care ● Simplify the labeling of the syringe

Examples of products from hameln pharma‘s Ready-to-Use infusion product range.

Not all products are registered in all countries.

hameln pharma gmbh | Inselstraße 1 | 31787 Hameln | Tel: +49 (0) 51 51 / 80 50 245 | www.hameln-pharma.com

SEMINAR IG1 – Better together! - Hospital pharmacists go collaborative Affiliation:

The North Denmark Region

Country:

Denmark

CURRENT STATUS, POSITION Mrs. Gitte Søndergård Nielsen is the Hospital Pharmacy Manager (CEO) at the Hospital Pharmacy in The North Denmark region, which is one of five regions in Denmark. The region has 3 hospitals on 11 sites with 1,800 beds.

The Hospital Pharmacy has 225 employees.

Mrs. Søndergård Nielsen is also the chairman of SAK - the collaboration between the hospital pharmacies in the five regions and Amgros. Amgros is owned by the Regions. SAK work with efficient operation and development of new initiatives within procurement and tendering procedures, manufacture, clinical pharmacy and development of competences.

EDUCATION

Speakers’ biographies

Søndergård Nielsen, Gitte

Mrs. Gitte Søndergård Nielsen studied Pharmacy at the University of Copenhagen and graduated in 1995. Gitte Søndergård Nielsen started as Hospital Pharmacy Manager in 2008 and was elected as chairman of SAK in 2017.

Conflict of interest: No conflict of interest declared.

139

Speakers’ biographies

Tuleu, Catherine* INTERACTIVE SESSION 2 – Compounding for Paediatrics - A Survival Guide through GMP Affiliation:

UCL - School of pharmacy

Country:

UK

CURRENT STATUS, POSITION Since 2017, Dr. Catherine Tuleu is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. Her recently founded spin out company [senCeuTics Ltd] is focused on preclinical taste evaluation and paediatric formulation development.

EDUCATION Prof. Dr. Catherine Tuleu is a UK-qualified French pharmacist. She graduated from Universite Paris V and obtained her PhD with distinction from Universite Paris XI.

RESEARCH AREA Working closely with paediatric hospitals and pharmaceutical companies, Dr. Tuleu’s work underpinning ethos is to ensure that paediatric formulations are effective, safe and of quality, bringing science into practice.

Her research is inherently translational, ranges from formulation, process and methodology development to clinical implementation, integrating the following themes: children centric excipient research; reformulation and repurposing for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s) and sensory pharmaceutics (acceptability and in vitro/in vivo taste assessment).

Conflict of interest: Prof. Dr. Catherine Tuleu has been: • Advisory Board at RB (Reckitt Benckiser) • Paediatrics Global Advisory Board at ViiV • Advisory Board at Bayer She is no longer a professional relationship with the above companies.

140

Quick Easy Safe Made in France since 1972

TURNKEY SOLUTIONS FOR PATIENT SAFETY Discover our IV bag ranges for safe pharmacy compounding, with possible customization by our dedicated R&D team, according to your specifications and needs.

All bag ranges are produced in strictly controlled clean-room environnement to avoid microbiological contamination, and are supplied sterilized.

INERTA®

Ready-to-Use single-chamber bags range for drug reconstitution.

DUAL-MIX®

Ready-to-Use double-chamber bags range for lyophilized or powder drug and its diluent.

READYMIX®

Ready-to-Use multi-chamber bags range for drug concentrate and its diluent, or nutrition.

pending Z.A. de Bassilour 64210 BIDART France - +33 (0)5 59 54 66 56 - www.technoflex.net - info@technoflex.net

KEYNOTE 3 - The era of cell and gene therapies in oncology - Fiction, poetry or science?

Affiliation:

National Center for Tumor Diseases (NCT) Heidelberg

Country:

Germany

CURRENT STATUS, POSITION Guy Ungerechts MD, PhD is Deputy Director of the Medical Oncology Department at the National Center for Tumor Diseases (NCT) Heidelberg, and heads the Clinical Cooperation Unit Virotherapy at DKFZ.

EDUCATION Guy Ungerechts MD, PhD is a medical oncologist trained in the field of oncolytic viruses at Mayo Clinic, Rochester, USA and at the Ottawa Hospital Research Institute (OHRI), Ottawa, Canada. His clinical focus is GI oncology with particular interests in translational medicine and early clinical trials of immuno(viro)therapy.

Speakers’ biographies

Ungerechts, Guy

RESEARCH AREA Guy has been responsible for the development and conduction of several Phase I/II and III trials with oncolytic viruses derived from different platforms including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T cell engager (BITEs) for enhanced immune(viro)therapy. Between 2015 and 2020 he was holding an Ontario Institute for Cancer Research (OICR) sponsored clinician-scientist position in Ottawa, Canada. As a staff medical oncologist, he was member of the GI cancer group at The Ottawa Hospital (TOH) between 2015 and 2017. He is adjunct professor at the University of Ottawa and affiliated investigator at the OHRI in Dr. John Bell´s research program.

Conflict of interest: No conflict of interest declared.

143

YOUR PARTNER FOR TRANSFER SYSTEMS Visit our stand to learn how our devices can help enhance drug mixing and transfer

West Vial Adapters, MixJect and Mix2Vial are 510(k) cleared by the United States Food and Drug Administration and carry the CE mark (0344). The Vial2Bag Advanced™ 20mm Admixture Device is 510(k) cleared by the United States Food and Drug Administration. Products are shown for INFORMATION purposes only and may not be approved for marketing in specific regions. Please contact your West Pharmaceutical Services, inc. (West) representative for product availability.

Vial2Bag™, Mix2Vial® and MixJect® are trademarks or registered trademarks of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc. West and the diamond logo is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. ©2022 West Pharmaceutical Services, Inc.

SEMINAR PSQ2 - Teamwork in the hospital – Building relationships to optimise pharmacotherapy Affiliation:

The Regional Specialist Hospital in Wrocław

Country:

Poland

CURRENT STATUS, POSITION Ms. Kamila Urbańczyk is currently a clinical pharmacist at The Regional Specialist Hospital in Wroclaw. She is responsible for developing clinical pharmacy services with main focus on vascular and general surgery. Miss Urbańczyk is also a Vice-President of Polish Society of Clinical Pharmacy and lecturer at the Department of Clinical Pharmacology at Wrocław Medical University.

EDUCATION Ms. Urbańczyk studied Pharmacy at the Wrocław Medical University and became licensed pharmacist in 2017.

In 2020 she graduated Advanced Clinical Pharmacy Practice from Queen’s University Belfast.

Speakers’ biographies

Urbańczyk, Kamila

RESEARCH AREA Ms. Urbańczyk focuses on different aspects of clinical pharmacy service development and drug-related problems.

Conflict of interest: No conflict of interest declared.

145

Isolators performances for all your applications

Powders Clinical Trials

Cytotoxics Monoclonal Antibodies

Sterility Testing Sterile Compounding

Total Parenteral Nutrition

Visit us — Booth 47 Our specialized ressources Design & Production

Qualifications & Trainings

Maintenance & Assistance

Engineering Research & Development Modelling Assembly

On-site installation IQ & OQ Cycle development User and technical trainings

Preventative maintenances Troubleshooting Hotline Remote maintenance

EuroBioConcept SAS ZA des Petits Carreaux · 4 Avenue des Coquelicots · 94380 Bonneuil-sur-Marne · France Tél. + 33 (0)146 58 75 85 · Fax : + 33 (0)146 58 76 46 contact@eurobioconcept.fr · www.eurobioconcept.fr

SEMINAR PC2 - 3D printed medical devices – The ultimate customization Affiliation:

Materialise

Country:

Belgium

CURRENT STATUS, POSITION Joyce Van den Broeck is currently Technical Product Manager at Materialise. She is responsible for the R&D activities for the personalized orthopaedic implants and instruments for corrective osteotomies.

EDUCATION Joyce Van den Broeck studied civil engineering at KU Leuven, master in Biomedical Technology. She obtained a PhD in 2009 for her work on computational modelling for the design of patient-specific instrumentation for orthopaedic surgery.

RESEARCH AREA

Speakers’ biographies

Van den Broeck, Joyce

Joyce Van den Broeck’s work focuses on the R&D, operational and regulatory activities required to bring personalized implants and instruments for orthopaedic surgery from 3D medical images to the OR.

Conflict of interest: No conflict of interest declared.

147

80th FIP World Congress of Pharmacy and Pharmaceutical Sciences Seville, Spain 18-22 September 2022

Pharmacy united in the recovering of health care At this critical time, when the challenges presented by the COVID-19 pandemic are still fresh in the minds of all healthcare professionals, we must create more comprehensive plans to better manage health crises that may appear on the horizon.

Several features of the pandemic serve as useful springboards to develop better plans for future emergencies and accelerate change in our healthcare systems.

It is our responsibility to review our shared experiences and search for solutions to advance the well-being of global communities.

Come to the 2022 FIP congress in Seville, Spain, where pharmacy practitioners, pharmaceutical scientists and educators from around the world will discuss how pharmacy, united together in “the new normal”, can contribute to the recovery of our healthcare systems by building on the developments and innovations of the past two years.

Three main subthemes A

Topic B

Topic C

Never waste a crisis — Learnings for future preparedness

Science and evidence supporting the response to COVID-19

Dealing with new and extraordinary ethical challenges

Although the COVID-19 pandemic is still active, within this track we will discuss how to implement post-pandemic changes to healthcare delivery based on lessons learnt during the global emergency of the past two years.

This track will focus on how scientific developments in responding to COVID-19 have been evolving in a parallel with the “infodemic” — intentional attempts to disseminate false information — and what should be done to prepare for the future.

COVID-19 has presented many ethical issues both in itself and in the methods used in its management. This track will look into ethical principles under which health care operates with regard to contextual, societal and cultural factors.

Topic

Find out more here: https://seville2022.fip.org

SEMINAR SPD1 - Gases, devices, diagnostics - Managing more than tablets Affiliation:

KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID)

Country:

Belgium

CURRENT STATUS, POSITION Prof. Kristin Verbeke is responsible for the 13C and H2-breath testing within the University Hospitals Leuven.

These are functional diagnostic tests used in routine in clinical gastroenterology. Besides, Prof Verbeke is the head of a research laboratory within TARGID that uses amongst others, stable isotope techniques to quantify the colonic bacterial metabolism in humans and its implications for health.

EDUCATION Prof. Kristin Verbeke obtained the degree of Pharmacist from KU Leuven (Leuven, Belgium) in 1991 and subsequently a PhD in Pharmaceutical Sciences from the same university in 1995 for her work on radioactive labelling of proteins. In 2002, she was appointed at the faculty of medicine where she started working with stable isotopes.

Speakers’ biographies

Verbeke, Kristin

RESEARCH AREA The main research activities of Prof. Kristin Verbeke involve the elucidation of the colonic bacterial metabolism and its impact on host health.

Conflict of interest: No conflict of interest declared.

149

IPSA’s Solutions for drugs and medical devices storage and distribution.

To support the closed loop medication administration

IPSA is a manufacturer of innovative solutions for healthcare to optimize hospital logistics, particularly the storage and supply of drugs and medical devices.

High-tech Hardware & Software are integrated to improve patient safety and reduce hospital costs while supporting healthcare operators.

IPSA’s Smart Hospital solutions integrate innovative technologies to bring the logics of the “Internet of things (loT)” to hospitals: the objects used by the operators for the clinical & logistics processes in the wards and in operating rooms become “intelligent” and communicate in an integrated manner with the hospital software providing data and information useful to the government and process improvement.

Smart Hardware, a range of intelligent devices — Smart Carts, Smart Drawers and Smart Cabinets — with embedded software able to simplify the healthcare operators’ activities supporting them in the storage and distribution phases.

Smart Software, a complete suite of modular, scalable and secure solutions with features like the real-time inventory, the full traceability of products and consumption till the clinical & logistics management of the drugs distribution processes with a solution able to support the preparation, distribution and administration of drugs in hospital wards.

The software provides functionalities that can grow with the hospital digitalization process starting from the real-time inventory up to the complete traceability of the products’ consumption and to the clinical & logistics management of their distribution.

In the hospital wards, the system involves the use of smart trolleys, smart drawers and cabinets to support nurses in their storage and distribution activities. Healthcare operators can now concentrate on patient care.

-47% 760

:ME )QMPMS +EPPS 'LMZEWWS 8YVMR -8%0= 4L [[[ MTWE IY MRJS$MTWE IY

SEMINAR PC3 – Bacteriophages – Back to the future Affiliation:

University College Ghent

Country:

Belgium

CURRENT STATUS, POSITION Dr. Sc Stefan Vermeulen is currently a researcher in applied medical sciences in relation to phage therapy. As an educator, he translates this research directly to his students.

EDUCATION Dr. Sc Stefan Vermeulen studied chemistry and molecular biology at Ghent university and graduated in 1991. He became a doctor in medical sciences in 1997 on cancer invasion. Until 2004 he was doctoral assistant in the center of medical genetics in Ghent and thereafter he became a full lector in the University College of Ghent.

Speakers’ biographies

Vermeulen, Stefan J.T.

RESEARCH AREA Bio-informatics, Genetics, Phage therapy as an alternative to or in combination with antibiotics, Co-evolution of phages Conflict of interest: No conflict of interest declared.

151

AntiVirus® pneumatic tube meets robotics Automated box and unit dose transport

by Sumetzberger Would you like to learn more about innovative AntiVirus® pneumatic tube solutions?

Sumetzberger ultra-modern, computercontrolled pneumatic tube systems meets high tech box picking and unit dose machines.

Unit Dose

Innovative interface solutions for automated, controlled, documented and safe transport of medicines. Also approved for narcotics.

Contact us!

Box Picking

JUST IN TIME Medication delivery 24/7

Unit dose transport and tracking

Made-to-order medication for each patient.

Box picking, transport and tracking

Centralized, space -saving drug distribution.

Ing. Sumetzberger GmbH. | Leberstrasse 108-110 | 1110 Vienna |

+43 1 74035 0 |

pt.sales@sumetzberger.at

SEMINAR SPD1 - Gases, devices, diagnostics - Managing more than tablets Affiliation:

Radboud University Medical Centre

Country:

The Netherlands

CURRENT STATUS, POSITION Drs. Nicole Vink is currently a hospital pharmacist at the Radboud University Medical Center in Nijmegen, the Netherlands. She is responsible for the production department of the pharmacy and is project manager for the reconstitutions done at the wards. She is responsible for the quality of medicinal gases used in the hospital.

EDUCATION Drs. Nicole Vink studied Pharmacy at the University of Utrecht and became a pharmacist in 2000. She obtained the title of hospital pharmacist in 2006 in the Radboud University Medical Center in Nijmegen.

Speakers’ biographies

Vink-van Kimmenade, Nicole

RESEARCH AREA Drs. Nicole Vink is specialised in the production and reconstitution of medicines including medicinal gases and, in the preparation and use of parenteral nutrition.

Conflict of interest: No conflict of interest declared.

153

Meet us at Stand No. 41

Creating smarter drug content for better care With Lexicomp®, you have access – online and on mobile – to 20 drug databases, drug monographs, and many interactive tools and calculators including: • extensive view of adverse reactions • details on preparation and administration • off-label drug uses • IV compatibility tools • patient education • renal dosing, etc.

SEMINAR IG3 – The role of the hospital pharmacist in disaster management – Are we prepared?

Affiliation

Eastern Vaud Hospitals

Country:

Switzerland

CURRENT STATUS, POSITION Dr. Nicolas Widmer is currently chief pharmacist of the Pharmacy of the Eastern Vaud Hospitals, an interhospital pharmacy in the French-speaking part of Switzerland. Dr. Nicolas Widmer is also Privatdozent at the University of Geneva and operational director of its Specialised Centre for Emergency and Disaster Pharmacy. In the Swiss Armed Forces, he is also in charge of the specialised training of aspiring pharmacy officers.

EDUCATION Dr. Nicolas Widmer studied Pharmacy at the University of Lausanne in Switzerland and became pharmacist in 2000 and hospital pharmacist in 2005. In 2006 he obtained a PhD in Life sciences at the University of Lausanne for his work on the clinical pharmacokinetics of an anticancer agent. He then headed the Therapeutic Drug Monitoring unit at the Clinical Pharmacology Service of the Lausanne University Hospital until 2013, before joining the Pharmacy of the Eastern Vaud Hospitals. He also followed a military career and obtained the rank of lieutenant colonel in 2019.

Speakers’ biographies

Widmer, Nicolas

RESEARCH AREA Dr. Nicolas Widmer research focuses on the clinical pharmacokinetics of anticancer drugs, on therapeutic drug monitoring and, more recently, on emergency and disaster pharmacy.

Conflict of interest: No conflict of interest declared.

155

Globally supplying unlicensed medicines and speciality medicines We look forward to welcoming you at our EAHP stand no.

57

Our European hubs: • Chiasso (Switzerland & Italy) • Copenhagen (Nordics) • Vilnius (Baltics) • Lisbon (Iberia)

Discover more: www.farmamondo.com info@farmamondo.com

Wednesday, 23 March Time

Meetings/Events

Room

14.45-16.15 Industry Sponsored Satellites – SIMPLIVIA Novel Solutions and Advanced Technologies for Safe Handling of Hazardous Drugs in the Pharmacy

Hall K1

Industry Satellites

INDUSTRY SPONSORED SATELLITES

17.15-18.45 Industry Sponsored Satellites – OMNICELL Future pharmacy – Transforming the patient experience

Hall K1

Thursday, 24 March Time

Meetings/Events

Room

09.00-10.30 Industry Sponsored Satellites – EQUASHIELD CSTD Comparative Studies and the Future of Automated Compounding

Hall K1

12.00-13.30 Industry Sponsored Satellites – FRESENIUS KABI A Fresh Perspective on the Role of Pharmacists in Biosimilars

Hall K1

15.00-16.30 Industry Sponsored Satellites – NOVARTIS Close encounters between hospital pharmacists and gene therapies

Hall K1

157

There is an incredible number of health information systems in the healthcare ecosystem which generate vast amounts of data.

What if these systems could work together within and across organisations?

What if this data could be aggregated and accessed in near real-time and presented in a way that helps staff understand how they can improve pharmacy operations based on fact?

What if these insights resulted in better patient care and ensured the right patient received the right medication at the right time?

Omnicell invites you to attend the EAHP Satellite Symposia Session 2022:

Pharmacy Excellence: Working together now to achieve the vision for the future Wednesday, 23rd March 2022 5:15 pm - 6:45 pm Hall K1

26th Congress of the EAHP

Pharmacy Excellence: Working together now to achieve the vision for the future Pharmacy is one the largest and most essential parts of every healthcare system, which has its own unique challenges.

These challenges, compounded by error prone and manually intensive workflows, drive up cost and result in inefficiencies and inaccuracies. They also keep all caregivers from focusing on what matters most – patient care.

What if there were solutions available, that clinicians could derive data from and gain insights that lead to pro-active steps to improve patient care?

For last 30 years, Omnicell has been laser focused on medication management innovation and supporting hospitals all around world to take first step on their automation journey towards pharmacy excellence. We’re committed to supporting clinicians with connected, intelligent solutions and integrated systems to access detailed information and easy-to-understand data insights.

Omnicell are working with hospitals, side-by-side in a progressive partnership to support a smooth transition to new technology, ensuring full buy in and adoption by staff. Industry experts will spend time on hospital sites understanding different workflows in various departments and providing guidance on how technology can best be used to overcome persuasive challenges and make significant time and cost savings, quickly.

Pharmacists, clinicians and caregivers will be able to work to the top of their profession with a vision of zero errors, zero paper and zero waste, so they can focus on safe, patent care.

Our aim is to provide solutions with outcomes – not products.

81% 81%

of pharmacists asked said they would recommend medication management automation to other Trusts. of pharmacists asked felt that interoperability of digital medication management solutions was essential.

Results from UK market Interoperability Survey 2021.

have often dreamt of a system of care “ We with medicines which is provided through integrated digital systems using data and where patient safety is paramount.

This is interoperability. So, this is a journey in modernisation, in replacing manual processes with automated systems.

It’s about a partnership between those working in the healthcare setting with those who specialise in technology and its application. Ultimately, it’s about improving patient care through the safe and secure use of medicines in our hospitals using efficient processes to save time.”

A Professor Liz Kay, Clinical Pharmacist

and Retired Clinical Director of Medicines Optimisation

Join the conversation at Omnicell’s symposium to hear from those who are already on their autonomous pharmacy journey and discover: • the journey so far with interoperability • the integration and partnership between those working in healthcare with technology experts • the power of data • a vision for the long-term future.

A new frontier for CSTD automated compounding technologies Utilizes the EQUASHIELD® CSTD to ensure healthcare safety

70

Doses per hour, Utilizing CSTDs

8

Simultaneous work stations

Equashield’s CSTD & Pro, the Perfect Pair for Safe & Automated Compounding of Hazardous Drugs.

EQUASHIELD® Pro redefines automated workflow, optimizing throughput. Unlike traditional robots’ reliance on robotic arms that mimic human motion by using a needle and a syringe, EQUASHIELD® Pro uses a multi-station compounding approach to minimize the motion and time it takes to prepare a dose. EQUASHIELD® Pro offers hazardous drug protection and reduces medication errors. With a highly versatile design, EQUASHIELD®, together with EQUASHIELD® Pro, offers high throughput and a small footprint for a cost effective CSTD hazardous drug IV compounding system.

www.equashield.com

EQUASHIELD

Unprecedented Technology for Handling Hazardous Drugs We are pleased to invite you to the symposium session: CSTD Comparative Studies and the Future of Automated Compounding

Thursday / 24.3.2022 / Hall K1 09:30 - 10:00 The Efficiency of Closed System Transfer Devices: A Comparative Study Dr. Elena Khanonkin and Dr. Tikhon Filippov, Faculty of Chemistry, Technion – Israel Institute of Technology

10:00 - 11:00 The future of CSTD – Automated Compounding Dr Marie-Laure Brandely, Cochin Hospital, Paris

Visit us at booth #37

www.equashield.com

EAHP 2022 CONGRESS

Gene Therapies

Close encounters between hospital pharmacists and gene therapies Join us to hear from experts and take part in the Q&A sessions

Thursday 24th March 2022

15.00–15.30 Fundamentals of gene therapy to pharmacists Dr. Doris Haider (Chair)

15.00–16.30

15.30–16.00 Treating SMA with a gene therapy: Experience with ZOLGENSMA (onasemnogene abeparvovec) in SMA Types 1 & 2 Prim. Univ. Prof. Günther Bernert, MD

Hall K1

16.00–16.30 Role and responsibilities of pharmacists with ZOLGENSMA in SMA Dr. Bertrand Pourroy

SMA, spinal muscular atrophy.

Faculty

Satellite

SYMPOSIUM

Dr. Doris Haider (Chair) Head of Pharmacy, KFN (Klinik Favoriten) Austria

Pharmacists play a critical role in accelerating and improving patient treatment when managing gene therapies like ZOLGENSMA. Building knowledge and confidence by sharing experiences and best practice in the use of such innovative treatments is vital

Prim. Univ. Prof. Günther Bernert, MD Head of the Department of Pediatric Medicine, Klinik Favoriten, Vienna President of the Austrian Muscle Research Foundation

The goal of this symposium is to provide an update on the use of gene therapy, with a specific focus on the treatment of SMA and the patient journey from a pharmacist’s perspective

Dr. Bertrand Pourroy Head of Oncopharmacy and ATMP Department, AP-HM France

Our expert panel will discuss common challenges faced by pharmacists involved in the treatment of patients with gene therapies, strategies to overcome them, real-world experiences treating SMA with ZOLGENSMA, and practical, clinical considerations to ensure pharmacy readiness, today and for the future

Thursday 24th March 2022 15.00–16.30 Hall K1

This medicinal product is subject to additional monitoring. This enables quick identification of new safety information. Health professionals are encouraged to report suspected side effects. For information on reporting side effects, see section 4.8 of local Summary of Product Characteristics.

Name of the medicinal product: ZOLGENSMA 2 x 1013 vector genomes/mL solution for infusion.

General description: Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor neuron (SMN) protein. It is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) based vector containing the cDNA of the human SMN gene under the control of the cytomegalovirus enhancer/chicken-β-actin-hybrid promoter. Onasemnogene abeparvovec is produced in human embryonic kidney cells by recombinant DNA technology. Qualitative and quantitative composition: Each mL contains onasemnogene abeparvovec with a nominal concentration of 2 × 1013 vector genomes (vg).

Vials will contain an extractable volume of not less than

either 5.5 mL or 8.3 mL. The total number of vials and combination of fill volumes in each finished pack will be customised to meet dosing requirements for individual patients depending on their weight. Excipient with known effect: This medicinal product contains 0.2 mmol sodium per mL. List of excipients: Tromethamine, Magnesium chloride, Sodium chloride, Poloxamer 188, Hydrochloric acid (for pH adjustment), Water for injections.

Therapeutic indications: ZOLGENSMA is indicated for the treatment of: patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. Contraindications: Hypersensitivity to the active substance or to any of the

This information material is intended for distribution and use at the 2022 EAHP Congress only

excipients. Pharmacotherapeutic group: Other drugs for disorders of the musculo-skeletal system, ATC code: M09AX09. Marketing authorization holder: Novartis Gene Therapies EU Limited, Block B, The Crescent Building, Northwood, Santry, Dublin 9, D09 C6X8, Ireland. Prescription status/Conditions regarding supply: Medicinal product subject to restricted medical prescription, supply through pharmacies only. For further information to the sections Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction, Undesirable effects and possible Tolerance as well as to Fertility, pregnancy and lactation please refer to the published Summary of Product Characteristics. Date of revision of the text: May 2021 ALL-ZOL-21-0155 | March 2022

Visit Omnicell on stand 31

Do you want your pharmacy team to be equipped with the right, advanced technology so they can focus on patient care?

Join Omnicell at EAHP Congress and discover a range of intelligent and connected technology and how these solutions can fulfil a vision of:

zero errors

zero paper

zero waste

And most importantly, transform the delivery of patient care.

The road to pharmacy excellence starts here.

automationsalesuk@omnicell.com www.omnicell.com

ORAL PRESENTATIONS BY GPIs NOMINEES WEDNESDAY, 23 MARCH – FROM 10.30 TO 12.00, HALL G2 Section 1 - Introductory Statements and Governance 10.30 - WEB DIALOGUE: ONE MORE STEP IN TELEPHARMACY Beatriz Ardizone 10.40 - ASfarMA Project. HUMANIZATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH SEVERE ASTHMA Hilario Martinez Barros*

Section 2 - Selection, Procurement and Distribution

Scientific Programme

GOOD PRACTICE INITIATIVES

10.50 - INTEGRATION OF A HOSPITAL PHARMACY PREPARER WITHIN A NEW INTERVENTIONAL TECHNICAL PLATFORM Morgane Houix

Section 4 - Clinical Pharmacy Services 11.00 - CASE-STUDY: PHARMACEUTICAL TELECONSULTATION USING A MOBILE APPLICATION António Paulo Melo Gouveia

Section 5 - Patient Safety and Quality Assurance 11.10 - DESIGN AND DISSEMINATION OF INFOGRAPHICS TO IMPROVE SAFETY IN DRUG HANDLING Paula Hernando Martinez 11.20 - IMPROVING MEDICATION BARCODE IDENTIFICATION ON THE SMALLEST UNIT OF USE: START-UP FIRST ePIL (ELECTRONIC LEAFLET) PROJECT FOR MEDICINES USED IN HOSPITALS IN SPAIN Ana Herranz Alonso

Section 6 - Education and Research 11.30 - IMPLEMENTATION OF A WORKSHOP ABOUT THE ROLE OF THE HOSPITAL PHARMACIST ROLE DURING THE CLINICAL CLERKSHIP IN MEDICAL TRAINING Guillaume Hache

169

Floor Plan 170

EXHIBITOR STAND LIST COMPANY NAME

STAND NUMBER

COMPANY NAME

STAND NUMBER

Abacus Medicine

9

Hikma

60

Accord Added Pharma Albiox

8 45 55

ICU Medical IMI Impromediform GmbH

29 48 40

AMiS Solutions

24

IPSA

35

APD ARxIUM Avanos Medical B. Braun Baxter BITO BIQ HS BMJ Group/EJHP Capsa Healthcare Clinigen Comecer Computer Engineering

17 7 61 5 44 14 46 26 42 51 19 2

2 16 1 3 54 21 12 31 65 15 27 62

Deenova

30

EAHP / EPSA Equashield Eurobioconcept

67 37 47

JCE Biotechnology Kedrion Biopharma KEENTURTLE Kapsam Health Products Leventon NuboMed MedXL Europe Omnicell Paxxo Pharmacolog Pfizer Provepharm MedicinesComplete (pharmaceutical press) Simplivia Healthcare Sinteco Stockart

Farmamondo

57

Sumetzberger

46

Fresenius Kabi German Society of Hospital Pharmacists (ADKA) - Drug Information Tool GPI SPA

28

Swisslog Healthcare

25

6

TECHNOFLEX

63

34

38

GRIFOLS

49

H+H Systems

13

Tema Sinergie The Compounding Company West Pharmaceuticals

hameln

53

Willach Pharmacy Solutions

23

Hemedis

18

Wolters Kluwer Health

41

11 22 43 20

64 56

KEENTURTLE

1

Hemedis Comecer

18

19 20

17

Computer Engineering & JCE 2

Catering Point

16 NuboMed

STOCKART

21

14

15

22

Farmamondo

57

MAIN ENTRANCE

30

31

BITO

13 H+H Systems Willach

23

12

AMiS Solutions

24

Catering Point

Catering Point

28

Deenova

Accord

8

Swisslog Healthcare

25

48

43

45

46

Albiox

55

54

47

BMJ/ EJHP

26

Catering Point 67

Clinigen

51

Love Your Pharmacist Ceremony 2022

Catering Point

49

Catering Point

Leventon Avanos

61

27

53

GRIFOLS

Eurobioconcept

Pfizer

Hameln

IMI

Added Pharma

42

60 Hikma

11

TOILETS

Sinteco 44

40

Catering Point

Point

9

Fresenius Kabi

Baxter

Tema

Impromediform

41

7

Poster area

29

BIQ HS Wolters Capsa Kluwer Healthcare Sumetzberger

37

6

Catering Point

Omnicell

Catering Point

ADKA ARxIUM Abacus Catering

MedXL Europe Pharmaceutical Press

ICU

Equashield

West Pharma

B. Braun Melsungen AG

Catering Point

38

56

5

Simplivia

34

35

3

Kedrion Pharmacolog Biopharma

APD

GPI

IPSA

Kapsam

Floor Plan

EXHIBITION MAP

TECHNOFLEX

62

Provepharm

63

64

Paxxo

EAHP 50th Anniversary History Walk

68

65

The Compounding Company

171

KEENTURTLE SETS NEW STANDARDS IN MEDICATION SAFETY saving lives by securing drug management for patients wherever they are

Our mission: to systematically detect and reduce the risks related to real-life drug prescribing

Patients and healthcare professionals at the heart of our solutions

the first decision support system to provide detection and personalised and contextualised alerts truly relevant as well as risk prioritisation among your patients.

Eight years of research and development and three core areas of expertise in synergy for effective drug risk prevention Data intelligence, tailored use and health science

Mastering the very small to see health in the big picture and help you to secure the patient's medication in real time throughout their care pathway

= Real-time, relevant, personalised and contextualised Alerts www.keenturtle.com

43

Hospitals Up to 10'000 beds

300 000 hospital stay secured

Thousands

of serious problems avoided

Floor Plan

CONGRESS CENTRE FLOOR PLAN

173

Unit Dose Re-packaging and Hospital Automation Present in 750+ hospitals in 21 countries.

Robotic unit dose preserving primary package. Automatically cuts the blisterpack.

Print barcodes, alerts and advices and also a color band on the packaging.

See details

Automatic labeling of ampoules and vials.

It loads the ampoules, prints and inserts a flag, identifying the medicine.

EV

T O TA L

Opuspac

R. Humberto Pela, 68 Louveira, São Paulo, Brazil

Opuspac BR035212-001

H E A L T H

Texas, USA

Hospital Automation

SaoPaulo,Brazil

Barcelona,Spain

www.opuspac.com

info@opuspac.com

See details